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Campylobacter jejuni is the most prevalent cause of bacterial diarrhoea worldwide and 
is frequently associated with severe post-infectious complications such as the Guillain- 
Barre  syndrome.  Despite  the  serious health burden  caused  by  the  bacterium  disease 
pathogenesis  remains  ill  defined.  Human  (3-defensins  (hBDs),  a  family  of epithelial 
antimicrobial  peptides,  are  a  major  component  of host  innate  defence  at  mucosal 
surfaces.  In  the  present  study  we  investigated  the  effect  of C.  jejuni  on  intestinal 
epithelial innate responses. Up-regulation of IL-8, hBD-2 and hBD-3 gene and peptide 
expression was observed in Caco-2 and HT-29 cell-lines in response to C. jejuni strains 
11168H  and  81-176.  Furthermore,  recombinant  hBDs  were  found  to  exhibit  potent 
bactericidal  activity  against  C. jejuni  suggesting  a  major  role  for  these  peptides  in 
disease pathogenesis.
Secondly,  we aimed to  identify host receptor(s)  involved in  sensing of C. jejuni and 
initiating  innate  defence.  Given the  invasive nature  of infection,  we  investigated the 
potential  role  of  cytoplasmic  nucleotide-binding  oligomerisation  domain  (NOD) 
proteins. Using small interfering (si) RNA targeting NODI  and transfection of NOD2 
overexpression plasmids, we identified NODI  as a major pattern recognition receptor 
involved in mediating innate host defence to C. jejuni while NOD2 was found to play a 
minor role. Additionally, reduced NODI  expression resulted in an increased number of 
intracellular C. jejuni thus highlighting a critical role for NODI mediated antimicrobial 
defence in limiting infection.
In  the  final  part  of the  study  an  ex-vivo  model  of C. jejuni  infection  using  human 
intestinal  biopsies  was  developed.  Additionally,  a vertical  diffusion  chamber  system 
was utilised to improve culture conditions in C. jejuni infection models.
2ABSTRACT
In conclusion, this study highlights the important role of intestinal innate host defence 
to  C.  jejuni.  The  development  of new  and  improved  models  of infections  has  the 
potential  to  provide  previously  unavailable  opportunities  to  study  C.  jejuni  disease 
pathogenesis.
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1.1  Campylobacter jejuni
1.1.1  Background
Campylobacter  was  first  identified  in  1906,  when  two  British  veterinary  surgeons 
reported the presence of “large numbers of a peculiar organism” in the uterine mucous 
of pregnant sheep (McFadyean and Stockman, 1913; Skirrow, 2006). This was part of a 
major investigation into epizootic abortion in cattle and sheep initiated by the British 
government. The organism described was most likely Campylobacter fetus (subspecies 
fetus), a common cause of veterinary disease. Although uncommon in humans, C. fetus 
can cause septic disease in immunodeficient patients (Sauerwein et al.,  1993). In 1947, 
Vinzent and colleagues isolated this organism from the blood of three pregnant women 
admitted  to  hospital  with  sepsis,  two  of whom  later  aborted  (Vincent  et  al,  1947). 
Campylobacter were initially classified as Vibrio spp.  due to spiral morphologies and it 
was not until  1963  that  Sebald and Veron postulated the  new genus  Campylobacter 
(Sebald and Veron,  1963).  The first report on Campylobacter enteritis dates back to 
1938 when a milk-borne outbreak of diarrhoea was reported, now regarded as the first 
documented  instance  of  human  Campylobacter  enteritis  (Levy,  1946).  Inability  to 
culture the organism delayed identification of Campylobacter jejuni as a major cause of 
bacterial diarrhoea until the  1970s (Butzler et al.,  1973). Although significant progress 
has been made in the diagnosis and treatment of Campylobacter-reldled disease(s), the 
continuous problem  of colonization of live-stock combined with antibiotic  resistance 
adds  certain  urgency  for  a  need  to  further  our  understanding  of how this  organism 
causes the observed clinical spectrum.
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1.1.2  Taxonomy, typing methods and diversity
The group of Campylobacteriaceae include the genera Campylobacter and Arcobacter. 
Together  with  the  closely  related  group  of Helicobacteriaceae  {Helicobacter  and 
Wolinella)  they  form  the  delta-epsilon  subdivision  of  the  Proteobacteria  (purple 
bacteria)  (Gupta,  2000).  Interestingly,  many  of  these  species  are  host-associated 
{Helicobacter,  Campylobacter,  Wolinella) and represent important human and animal 
pathogens  (Eppinger  et  al,  2004).  Out  of  the  known  Campylobacter  species, 
Campylobacter jejuni  (C.  jejuni)  and  Campylobacter  coli  (C.  coli)  are  the  most 
important human pathogens (Ketley,  1997). In addition, Campylobacter upsaliensis is 
being  increasingly  accepted  as  causative agent for  diarrhoeal  disease,  particularly  in 
children  (Jimenez  et  al.,  1999).  In  contrast,  Campylobacter  fetus  spp.  and 
Campylobacter venerealis are mainly associated with disease in animals (Bawa et al, 
1991).  Diversity  of C. jejuni  strains  is  striking  with  regards  to  both  genotypic  and 
phenotypic features. One possible explanation may be that C. jejuni cells are naturally 
able  to  take  up  DNA  (Wang  and  Taylor,  1990;  Wassenaar  et  al,  1995)  leading  to 
significant genetic exchange when different C. jejuni strains are present. Various typing 
methods  have  allowed  identification  and  further  classification  of  different  strains. 
Serotyping detects soluble heat-stable or heat-labile antigens which are exposed on the 
bacterial cell surface. The heat-labile typing scheme developed by Lior et al. recognizes 
over 100 different serotypes of C. jejuni, C. coli and C.  lari (Lior et al., 1982). Another 
serotyping scheme developed by Penner and colleagues was further modified by Frost 
et al., and involves detection of heat-stable antigens by hemagglutination (Penner and 
Hennessy,  1980;  Frost et al.,  1998).  The heat-stabile antigen detected was originally 
thought  to  be  a  long  chain  lipopolysaccharide  (LPS),  however  increasing  evidence 
supported  by  genetic  studies  suggests  that  the  serodeterminant  antigen  relates  to 
structures  within  the  capsular  polysaccharide  of C. jejuni  (Karlyshev  et  al.,  2000).
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Another phenotypic typing method developed for Campylobacter characterises isolates 
using bacteriophages. Phage-typing is currently used for surveillance in the UK (Frost et 
al.,  1999).  Combination  of  serotype  and  phage  type  allows  a  greater  level  of 
discrimination  of isolates.  In  addition to  these phenotypic  typing  schemes  there  are 
multiple ways to demonstrate the genotypic diversity of C. jejuni strains. These include 
molecular-based  approaches  such  as  Polymerase  Chain  Reaction  (PCR)- 
Deoxyribonucleic  Acid  (DNA)  fingerprinting,  DNA-DNA  hybridization,  multilocus 
sequence typing (MLST) and PCR-restriction fragment length polymorphism (RFLP) 
analysis (Johnsen et al., 2006; Price et al., 2006). Moreover, using DNA microarrays to 
compare  whole  genome  of microbes  (genomotyping)  combined  with  computerised 
algorithms  (i.e.  Bayesian-based algorithms)  allows the  discrimination of strains from 
different sources (Champion et al., 2005).
1.1.3  Transmission and epidemiology
Campylobacter spp.  are part of the commensal flora in a wide range of domestic and 
wild animals including chicken, cattle and swine (Park, 2002). Transmission therefore 
occurs mainly  via  food,  dairy products  and contaminated water-based environmental 
sources (Ketley, 1997). C. jejuni represents the leading cause of acute bacterial enteritis 
world-wide.  Incidence  of infection,  pattern of occurrence  and mode  of transmission 
differ significantly between countries and continents.
In several developed countries the number of reported C. jejuni cases currently exceeds 
80 per  100,000 people  (Friedman et al,  2000).  In England and Wales, 44,342 cases 
(-80 per 100,000) were reported in 2005 (Department for Environment Food and Rural 
Affairs,  2005), while average numbers in the US  are lower with annual  incidence of 
21.9 cases per 100.000 (Samuel et al., 2004). As Campylobacter enteritis rarely requires 
hospitalization, under-reporting is most likely such that the true incidence is likely to be
23CHAPTER 1
much  higher  (Tauxe,  1992;  Friedman  et  al.,  2000).  Campylobacter  enteritis  in 
industrialized countries is mainly due to sporadic infection transmitted via consumption 
of contaminated raw or undercooked meat (Deming et al.9  1987; Kapperud et al., 1992). 
However,  outbreaks  do  occur  and  are  frequently  associated  with  contaminated  milk 
(Kalman et al., 2000; Jimenez et al., 2005). More recently, non live stock C. jejuni has 
been identified as major sources of human disease (Champion et al., 2005).  Infection 
shows  a  seasonal  pattern  with  peaks  during  warmer  months  of the  year,  possibly 
associated with climatic  conditions (Altekruse et al.,  1999;  Padungton and Kaneene,
2003).  Several case control studies have identified a number of major risk factors for 
acquiring infection in industrialized countries including handling or eating of raw or 
undercooked  chicken,  contact  with  pets  or  farm  animals  and  travel  abroad  (Tauxe, 
1992; Neal and Slack, 1997). All age groups can be affected, with one peak in children 
<4yrs, and a second peak in young adults (15-24yrs)  (Tauxe,  1992;  Friedman et al., 
2000).  In  developing  countries  Campylobacter  is  hyperendemic  owing  to  poor 
sanitation and close contact with animals (Tauxe,  1992).  Despite a lack of incidence 
data  from  national  surveys,  case-control  community-based  studies  have  provided 
estimates  of 40,000  to  60,000/100,000  for  children  <5yrs  of age  (Oberhelman  and 
Taylor, 2000; Rao et al., 2001). Typically there is a decreasing infection-to-illness ratio, 
shortening of infection duration and by late childhood symptomatic infections are rare 
while  asymptomatic  carriage  being  frequently  observed  (Megraud  et  al.,  1990).  An 
estimated incidence of 90/100,000 for the general population further confirms that C. 
jejuni infection in developing countries is mainly a paediatric disease (Tauxe, 1992; Rao 
et al., 2001).
1.1.4  Clinical manifestations
The most common Campylobacter strains causing human disease are C. jejuni and C. 
coli  (Lastovica  and  Skirrow,  2000).  Although  infection  typically  causes
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gastroenteritis/enterocolitis, the clinical picture varies significantly in duration, severity 
and associated symptoms (Ketley, 1997). Furthermore, despite being self-limiting in the 
majority, post-infectious complications can be severe, and occasionally life threatening. 
The spectrum of disease associated with C. jejuni is summarized in Table 1.1.
1.1.4.1  Intestinal manifestations
The  most  common  manifestation  of  C.  jejuni  infection  is  acute  gastroenteritis. 
Following  an  incubation  period  of ~24-72h,  symptoms  develop  including  cramping 
abdominal pain which can sometimes be associated with fever, vomiting and headaches 
(Alios, 2001). Pain can be generalized or localized, the latter case sometimes difficult to 
distinguish from acute appendicitis (Blakelock and Beasley, 2003). Diarrhoea typically 
develops  shortly  after  onset  of abdominal  pain  and  can  vary  significantly  amongst 
individuals, i.e. from a mild non-inflammatory watery presentation to severe and bloody 
(Blaser,  1997).  Sigmoidoscopy if performed, usually reveals mucosal changes ranging 
from  oedema  and  hyperaemia,  petechial  haemorrhages  and  mucosal  friability. 
Inflammation  can  also  be  observed  in  parts  of the  ileum  and jejunum  commonly 
associated with mesenteric adenitis (Ketley, 1997; Wassenaar and Blaser, 1999). 
Infection  typically  lasts  for  ~7  days  in  an  otherwise  healthy,  immunocompetent 
individual. One may hypothesize that disease outcome is likely to be dependent on both 
the  virulence  of  the  infecting  strain  and  the  host  immune  status.  Intriguingly,  in 
developing  countries  where  symptomatic  infection  is  restricted  to  young  children, 
clinical presentation tends to be mild, with watery, non inflammatory diarrhoea (Blaser, 
1997;  Oberhelman  and  Taylor,  2000).  In  contrast,  in  the  developed  world,  infected 
individuals generally suffer severe symptoms with more frequent, bloody, inflammatory 
diarrhoea.  Importantly,  patients  acquiring  infections  abroad typically  present  clinical 
features of their country  of origin, thus highlighting a major impact of host immune 
status  on  disease  pathogenesis  (Oberhelman and  Taylor,  2000).  As  a post-infectious
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intestinal manifestation, irritable bowel syndrome (IBS) has been increasingly linked to 
enteric C. jejuni infection. IBS is characterised by abdominal pain sometimes associated 
with  altered  bowel  habit  following  bacterial  enteritis  (Spiller,  2007).  Various  other 
intestinal complications have been reported and are summarized in Table 1.1.
Spectrum of disease caused by Campylobacter spp.
Gastrointestinal_________________________________
•  Enteritis, (Crushell et al., 2004)
•  Appendicitis, (Campbell et al., 2006)
•  Irritable bowel syndrome, (Spiller, 2007)
•  Toxic megacolon and perforation, (Larvol et al., 1994)
•  Hepatitis, (Korman et al., 1997)
•  Pancreatitis, (Kandula et al., 2006)
•  Cholecystitis, (Dakdouki et al., 2003)
•  Peritonitis, (Calonge Raventos et al., 2002)
•  Splenic rupture, (Frizelle and Rietveld, 1994)__________
Rheumatological______________________________
•  Reactive arthritis, (Hannu et al., 2004)
•  Reiters Syndrome, (Peterson, 1994)
•  Septic arthritis, (Cone et al., 2003)
•  Henoch-Schonlein purpura, (Apostolopoulos et al., 1999)
Neurological__________________________________
•  Guillain-Barre syndrome, (Kuwabara, 2007)
•  Miller-Fischer syndrome, (Godschalk et al., 2007)
•  Brainstem encephalitis, (Hussain et al., 2007)
•  Meningoencephalitis, (Tsugawa et al., 2004)___________
Skin_________________________________________
•  Cellulitis, (Monselise et al., 2004)
Lung  ___________________________________
•  Pneumonia, (Sakran et al., 1999)_____________________
Intravascular__________________________________
•  Septic shock, (Meyrieux et al., 1996)
•  Endocarditis, (Sitter et al., 1992)
•  Myocarditis, (Pena and Fishbein, 2007)
•  Thrombophlebitis, (Ozaki etal., 1999)
•  Hemolytic uremic syndrome, (Dolezel et al, 1993)
•  Aneurysm, (Grollier etal., 1993)_____________________
Table 1.1: Spectrum of reported disease caused by Campylobacter spp.
26CHAPTER 1
1.1.4.2  Extraintestinal manifestations
Overall, incidence of extraintestinal manifestations associated with C. jejuni infection is 
low compared to enteric disease. However, when they do occur they can be severe and 
potentially  live  threatening.  To  date  the  most  extensively  studied  is  Guillain-Barre 
syndrome (GBS), an acute post-infectious ascending paralysis that can affect peripheral 
and cranial nerves (particularly VII,  facial nerve),  in severe  cases requiring  artificial 
ventilation  (Kuwabara,  2007).  C.  jejuni  is  now  recognised  as  the  most  common 
identifiable pathogen associated with development of GBS. Molecular mimicry of the 
peripheral  nerve  gangliosides  by  C.  jejuni  lipooligosaccharide  (LOS)  results  in  the 
generation  of  auto-reactive  antibodies  causing  inflammation  and  tissue  damage 
(Komagamine and Yuki, 2006; Godschalk et al., 2007). Several other conditions have 
been reported  in  association with  C. jejuni  infection  including  pneumonia,  hepatitis, 
nephritis, reactive arthritis and myocarditis but are mostly limited to few reported cases 
(Table 1.1). In contrast to otherwise healthy individuals, immunocompromised patients 
such  as  human  immunodeficiency  virus  (HIV)  positive  individuals,  generally  suffer 
from  more  severe,  prolonged  and/or  relapsing  illness.  Furthermore,  occurrence  of 
extraintestinal manifestations is more frequent, most likely due to a higher incidence of 
bacteraemia in these patients (Pigrau et al., 1996; Manfredi et al., 1999; Crushell et al.,
2004).  Recently  an  association  between  C. jejuni  infection  and  immunoproliferative 
disease of the small intestine has been reported (Lecuit et al., 2004).
1.1.5  Antibiotic resistance
Although C. jejuni infection is self-limiting, antibiotics are recommended to those with 
severe  and/or  prolonged  enteritis,  septicaemia  or  extraintestinal  complications.  For 
confirmed C. jejuni infection, the macrolide antibiotic erythromycin is the first choice 
of treatment (Williams et al.,  1989). Fluoroquinolones (ciprofloxacin) are also used in
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enteritis of unknown origin, particularly in suspected travellers’  diarrhoea (Al-Abri et 
al,  2005).  Resistance  to  both  macrolides  and  fluoroquinolones  has  been  increasing 
amongst Campylobacter species (Engberg et al., 2001; Gibreel and Taylor, 2006). This 
is  most  likely  due  to  persistent  antibiotic  use  in  livestock  (Angulo  et  al.,  2004). 
Amplification  and  geographical  spread  of strains  (clonal  dissemination)  might  also 
contribute  to  the  observed  increase  in  Campylobacter  resistance  (Bae  et al,  2007). 
Induction of antibiotic resistance in humans is well recognised particularly for the use of 
fluroquinolones (Engberg et al, 2004). However, with human-to human transmission 
being rare in Campylobacter infection, the overall effect of this mechanism to resistance 
development is probably minimal.
In  recent  years,  greater  insight  into  the  development  of  antibiotic  resistance  of 
Campylobacter has been gained, hopefully opening up potential  for new strategies to 
combat resistant strains. Campylobacter is known to express two multidrug efflux pump 
systems CmeABC and CmeDEF, and evidence suggests a role in mediating resistance 
to  several  antibiotics (Akiba et al,  2006;  Quinn et al,  2006).  For example,  specific 
inhibition of CmeABC by an efflux pump inhibitor can decrease the Minimal Inhibitory 
Concentration (MIH) of erythromycin resistant strains and increase the effect of various 
antibiotics,  suggesting  a  potentially  promising  approach  in  preventing  and  treating 
antibiotic resistance of Campylobacter in humans and animal reservoirs (Martinez and 
Lin, 2006). Furthermore, mutagenesis of genes coding for antibiotic target sites such as 
23S rRNA as target site for macrolide antibiotics and gyrase (i.e. gyrA and parC), for 
fluoroquinolones  are  well  recognised  in  Campylobacter  strains  resistant  to  the 
corresponding antibiotic (Engberg et al, 2001; Gibreel and Taylor, 2006).
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1.1.6  C. jejuni disease pathogenesis
C. jejuni colonises warm blooded animals and birds without causing disease. However, 
in humans,  ingestion  of a relatively  low dose can  cause  a wide  range  of pathology 
(Black et a l, 1988). Despite the serious health problem caused by the bacterium disease 
pathogenesis remains poorly defined. Bacterial adhesion and invasion of the intestinal 
epithelium is a well-established early event prior to initiation of inflammatory processes 
and diarrhoeal development. The “invasiveness” of C. jejuni strains is often used as a 
measure  for  bacterial  virulence  reflecting  the  involvement  of  multiple  bacterial 
structures and mechanism(s) in this process. In the following section, bacterial factors 
and mechanism(s) implicated in C. jejuni disease pathogenesis are described.
1.1.6.1 General microbiology of C. jejuni
Campylobacter  (Greek  “curved  rod”)  is  a  Gram-negative,  spirally  shaped  organism 
measuring  1.5-6  pm in length and 0.2-0.5  pm in width (Figure  1.1).  The bacterium 
contains a polar flagellum at one or both ends leading to a high degree of motility and 
the typical darting and spinning movements observed under the microscope. For ideal 
growth, Campylobacter requires a microaerophilic environment with O2 concentrations 
of 3-15% and CO2 levels of 3-5%.  The optimal growth temperature lies between 37- 
42°C most likely reflecting adaptation to its natural habitat, i.e. the intestine of warm­
blooded animals and birds (Ketley, 1997).
1.1.6.2 Lipooligosaccharide (LOS)
Lipopolysaccharide  (LPS) and LOS  are major constituents of the outer membrane of 
Gram-negative  bacteria  and  play  a  critical  role  in  the  pathogenesis  of a  variety  of 
bacterial infections (Jacques,  1996; Preston et al.,  1996).  LPS  and LOS contribute to 
serum resistance, antibiotic resistance and endotoxicity to pathogens.  LPS consists of 
three major components:  lipid A,  core oligosaccharide,  and an O-chain consisting of 
oligosaccharide units.
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Figure  1.1:  Scanning  Electron  Micrograph  of  Campylobacter jejuni.  The  spiral 
shape and bipolar flagella are illustrated (from Homepage of the Department of Tropical 
and Infectious Diseases, LHTM, London, UK).
LOS lacks the O-chain, with only one oligosaccharide unit present (Moran et al, 1996). 
Until the publication of the whole genome sequence, C. jejuni was believed to produce 
either  LPS  or LOS.  However,  repeating  oligosaccharide  units  once  thought to  be  an 
LPS-associated O-chain is now considered to be  capsular in origin (Karlyshev et al, 
2000).  Antigenic mimicry of human gangliosides by C. jejuni LOS contributes to the 
development of GBS (Goodyear et al, 1999; Komagamine and Yuki, 2006). Moreover, 
levels of LOS phase variation seems to be associated with serological responses of C. 
jejuni and the capacity of ganglioside mimicry (Guerry et al, 2002; Prendergast et al,
2004).
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1.1.6.3  Capsular polysaccharide (CPS)
CPSs are a common feature on bacterial surfaces, known to play an important role in 
bacterial  survival,  persistence  in  the  environment  and  often  contribute  to  disease 
pathogenesis (Roberts,  1996; Watts et al, 2005). They can exhibit structural variation, 
mimicry to host antigens, resistance to phagocytosis and complement-mediated killing 
(Moe and Granoff, 2001; Segura et al, 2004; Schneider et al, 2007). Thus CPSs allow 
bacteria to evade host immunity via several mechanisms. Evidence for the production of 
CPSs by C. jejuni was suggested by its genome sequence. Identification of kps genes 
potentially  involved in capsule biosynthesis of NCTC11168  (Karlyshev  et al,  1999) 
prompted  a  systematic  genetic  analysis  of the  corresponding  locus  and  resulted  in 
identification of CPSs in a number of C. jejuni strains (Karlyshev et al, 2000). These 
molecules represent major antigens in the Penner serotyping scheme (Karlyshev et al, 
2000). Studies performed on C. jejuni 81-176 suggested a role for the capsule in serum 
resistance, epithelial invasion and diarrhoeal disease (Bacon et al, 2001).  Subsequent 
characterisation  (Karlyshev  and  Wren,  2001)  led  to  visualisation  of the  capsule  by 
electron microscopy (Figure 1.2) (Karlyshev et al, 2001). These experiments suggested 
that  the  previously  described  high  molecular  weight  “lipopolysaccharides”  (HMW 
LPSs) of C. jejuni are in fact CPSs. A role for C. jejuni CPS in disease pathogenesis 
was suggested as a capsule-deficient 81-176 mutant strain shows reduced invasion and 
virulence in vitro and in a ferret diarrhoeal model (Bacon et al, 2001). Another study 
utilising  a  capsule-deficient  mutant  of  parental  strain  81116  also  noted  reduced 
adherence  to  human  intestinal  epithelia,  in  contrast  no  significant  difference  in 
colonization of the chicken gut was found between wild-type and mutant,  suggesting 
contribution  of bacterial  CPS to  host-pathogen interactions maybe  species dependent 
(Bachtiar et al, 2007).
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Figure  1.2:  C.  jejuni  capsular  polysaccharide  (CPS).  Transmission  electron 
microscopy of C. jejuni stained with Alcian blue at two magnifications.  CA indicates 
capsular polysaccharide  (from Karlyshev et al. ,2001).
1.1.6.4  Flagellin
The basic structure of bacterial flagellum consists of a basal body, which is embedded 
in the cell envelope and connected to the filament via a universal joint, the torsion hook. 
The  flagellar  filament  consists  of  several  thousands  of  self-assembling  protein 
(flagellin) monomers arranged in a helix (Macnab, 2003). The major C. jejuni flagellar 
filament subunits are Flagellin A (FlaA) and Flagellin B (FlaB); their encoding genes 
flaA  and flaB  are  arranged  head-to-tail  on  the  genome  and  show  >90%  sequence 
homology (Guerry et al., 1990).
Campylobacter contains a single unsheathed flagellum at one or both poles providing 
the organism with a high degree of motility (Figure 1.1). This is necessary to overcome 
peristalsis and entry into the mucous layer.  C. jejuni flagellum-mediated motility is a 
prerequisite in both human disease and in successful colonisation in animals (Wassenaar 
et al.,  1993). An association between the presence of intact flagellum and ability of C. 
jejuni to  adhere  and  invade  has  been reported  (Wassenaar et al.,  1991;  Grant et al., 
1993; Nachamkin et al.,  1993;  Yao  et al.,  1994).  Mutants with reduced motility but
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intact  FlaA  expression  colonise  chickens  to  a  similar  extent  as  the  parental  strain 
(Wassenaar  et  a l,  1993).  In  contrast,  fully  motile  mutants  but  deficient  in  FlaA 
expression exhibit significantly impairment in their ability to  colonize the avian gut, 
suggesting  an  additional  role  for  flagellum  in  virulence,  distinct  from  motility 
(Wassenaar et al., 1993). Absence of genes encoding a type III secretion apparatus in C. 
jejuni NCTC11168 led two independent groups to demonstrate that C. jejuni in fact uses 
its flagella as an export apparatus to secrete both flagellar and non-flagellar proteins, 
some  of which involved in adhesion and invasion (Konkel  et al,  2004;  Song et al,
2004). C. jejuni flagellin is also decorated by glycostructures that are antigenic, this will 
be discussed later.
1.1.6.5  Cytolethal distending toxin (CDT)
CDT  is  produced  by  several  Gram-negative  bacteria  including  E.  coli,  Salmonella, 
Haemophilus ducreyi and Helicobacter spp.  (Johnson and Lior,  1988b; Okuda et al, 
1995; Cope et al, 1997). CDT was first identified as a component of C. jejuni in 1987, 
since  then  considerable  progress  has  been  made  in  elucidating  its  role  in  disease 
pathogenesis (Johnson and Lior,  1988a). Briefly, CDT causes eukaryotic cells to arrest 
in the G2/M phase of cell-cycle, preventing them from entering mitosis leading to cell 
death. The toxin was named after the morphological changes associated with its action; 
cytoplasmic  distension.  CDT consists of three subunits  (CdtA, B  and C)  encoded by 
three  adjacent or  slightly overlapping  open reading  frames  (ORFs)  assigned cdtABC 
(Ceelen et al, 2006).  CdtB  is the active  subunit sharing homology  with mammalian 
DNase I (Lara-Tejero and Galan, 2000). In order to function as a DNase CdtB needs to 
gain access to the nuclear compartment and it is suggested that CdtA & C may promote 
delivery  of CdtB  into  host  cell  (Lara-Tejero  and  Galan,  2001).  This  hypothesis  is 
supported by Lee and colleagues who demonstrated binding of CdtA and CdtC, but not 
CdtB to HeLa cells (Lee et al, 2003).
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All three CDT proteins are membrane-associated and required for the induction of pro- 
inflammatory cytokine IL-8 (Hickey et al., 2000). The same authors also suggest a role 
for CdtC in mediating or enhancing cytotoxicity. Utilising a Nuclear factor-icB (NF-kB) 
deficient murine  infection  model,  Fox  and  colleagues  confirmed  a role  for  CDT  in 
eliciting inflammatory responses in vivo (Fox et al., 2004).
1.1.6.6  Glycosylation systems
The function of post-translational glycosylation in eukaryotic cells is manifold (Rudd et 
al.,  2001).  Only  recently,  the  long  accepted  dogma that bacteria  only  express  non­
glycosylated proteins has been disproved conclusively, opening the door to new insights 
into prokaryotic protein structure and function (Schmidt et al., 2003).
As early as  1989, Logan and colleagues provided clear evidence that Campylobacter 
flagellin  was  post-translationally  modified  (Logan  et  al.,  1989).  Following  their 
observation,  studies  began  to  unravel  new  aspects  of Campylobacter  glycosylation. 
Today we know that Campylobacter is almost unique as it contains both a general N- 
linked protein glycosylation pathway (responsible for post-translational modification of 
at  least  30  proteins)  as  well  as  an  O-linked  system  (responsible  for  flagellar 
gylcosylation) (Szymanski et al., 2003; Karlyshev et al., 2005a; Szymanski and Wren,
2005).
The A-linked glycosylation machinery of C. jejuni is encoded by a single gene cluster 
named pgl  (protein  glycosylation)  (Szymanski  et al.,  1999).  The  key  enzyme in the 
general  glycosylation locus is PglB,  identified as the  first example  of a bacterial N- 
linked  oligosaccharyltransferase.  Functionality  of  this  enzyme  was  elegantly 
demonstrated by Wacker et al. who transferred the pgl locus into E. coli and monitored 
effective glycosylation of a co-expressed C. jejuni protein AcrA (Wacker et al., 2002). 
Studies  investigating  the  biological  role  for vV-linked  glycosylation  clearly  link  it to 
bacterial  virulence.  An  isogenic  81116  pglH  mutant  is  deficient  in  its  ability  to
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glycosylate a number of proteins and showed reduced ability to adhere/invade human 
epithelia and colonize  chicks  (Karlyshev et al,  2004).  Kakuda and DiRita tested 22 
different glycosylation mutants in strain 81-176, one of which, Cj 1496c was found to 
influence invasion of human epithelium cells and colonisation of the avian gut (Kakuda 
and  DiRita,  2006).  Studies  have  shown  O-linked  glycosylation  is  essential  for 
successful  flagellin  assembly  and  motility  hence  influencing  adhesion,  invasion  and 
virulence in-vivo (Thibault et al., 2001; Guerry et al., 2006). In contrast to the A-linked 
system, the genetic locus of the O-linked system is more heterogeneous and genetically 
diverse (Parkhill et al, 2000a; Champion et al., 2005). A predominant mechanism for 
this  variability  is the  presence  of seven  contingency  or  phase  variable  genes  in the 
flagellin glycosylation locus that can contribute to antigenic variation (Karlyshev et al, 
2005a). Such genes, also found in the capsule locus, enable rapid reversible expression 
of genes by slip strand mispairing (Karlyshev et al, 2005b). This can be considered as a 
simple  primordial  mechanism  used  by  bacteria  for  variable  gene  expression.  It  is 
tempting  to  speculate  that  Campylobacter  flagellin  glycostructure  and  CPS 
determinants  undergo  these  changes  in  response  to  pressures  exerted  by  the  host. 
However, this is not proven and it could be due to other evolutionary pressures such as 
avoidance of bacteriophage that also frequent the natural habitat of C. jejuni (i.e. avian 
gut).
1.1.6.7  Chemotaxis, adhesion and invasion
Some  evidence  suggest  that  in  addition  to  motility,  chemotaxis  is  important  for 
intestinal  colonisation by  C. jejuni (Takata et al.,  1992;  Hendrixson et al.,  2001).  A 
number of genes involved in motility other than flagellin have been identified, including 
cheY, cetA, and cetB (Yao et al,  1994; Hendrixson et al, 2001; Golden and Acheson, 
2002).
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Once  motility  and  chemotaxis  allow  C. jejuni  to  reach  the  surface  of the  intestinal 
epithelium, adherence has to be established as a prerequisite for cell invasion. Unlike 
invasion, intestinal colonization can be established in the mucous layer without the need 
for adherence (Lee et al, 2005). In addition to factors mediating C. jejuni adherence 
and  invasion mentioned  above,  specific molecules,  named  adhesins  are  also  directly 
involved in this process. Adhesins are located on the bacterial surface and interact with 
corresponding receptors on the host cell surface to initiate adhesion.  Several C. jejuni 
adhesins  have  been  identified  including  the  outer  membrane  proteins  CadF  (a 
fibronectin  binding  protein)  (Monteville  et  al,  2003),  PEB1  (a homolog  of Gram- 
negative  ABC  transport  system)  (Pei  and  Blaser,  1993),  JlpA  (surface  lipoprotein, 
Jejuni lipoproteinA) (Jin et al, 2003), major outer membrane protein (MOP) (Moser et 
al,  1997),  the  autotransporter  protein  CapA  (Ashgar  et  a l,  2007)  and  LOS 
(McSweegan  and  Walker,  1986).  In  contrast,  only  few  receptors  on  host  intestinal 
epithelia that interact with C. jejuni are known. CadF has been shown to interact with 
Fibronectin  (Fn)  not  only  leading  to  adherence  but  also  initiating  host  signalling 
associated with bacterial uptake (Monteville and Konkel, 2002). Bacterial JlpA can bind 
to the eukaryotic heat shock protein (HsP) 90, leading to activation of host signalling 
events (Jin et al, 2003). As for other invasive enteropathogens, rearrangement of host 
cytoskeletal  structures,  i.e.  microtubules  (MT)  and  microfilaments  (MF)  have  been 
suggested to mediate internalisation of C. jejuni (Biswas et al,  2003).  Additionally, 
more recently involvement of host cell small GTPases (Racl  and Cdc42) in bacterial 
internalization  has  been  suggested  (Krause-Gruszczynska  et  al,  2007).  C.  jejuni 
preferentially enters host cells via the basolateral surface of polarized epithelia while 
entry via the apical surface seems to be less efficient (Monteville and Konkel, 2002). 
Whether  C.  jejuni  translocates  to  the  basolateral  surface  via  a  paracellular  route 
(migration between cells) or a transcellular route (migration via M-cells, followed by
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intracellular trafficking) remains unclear (Figure 1.3) (Kopecko et al., 2001a). However, 
there is no doubt that host bacterial cross-talk is intimately linked to activation of innate 
and  adaptive  immune  responses  leading  to  inflammation,  diarrhoea  and  ultimately 
clearance of the infective agent.
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Figure 1.3: Interaction of C. jejuni with polarised intestinal epithelia. Multiple host 
bacterial  interactions  are  involved  in  C.  jejuni  adhesion  and  invasion  of polarised 
epithelia leading to activation of immune responses (from Kopecko et al, 2001).
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1.1.7  Host response
The variable  clinical picture  of C. jejuni enteritis  and lack of direct correlation with 
strain virulence underlines the crucial role of host immune response(s) in determining 
disease severity and outcome. Furthermore, given the generally self-limiting nature of 
infection,  insight  into  immune  defence  mechanism(s)  that  allow  successful  bacterial 
clearance is essential to further our understanding of C. jejuni disease pathogenesis.
1.1.7.1  Innate host response
a)  Intestinal epithelium
As the first line of defence, the epithelial lining of the gut not only provides a crucial 
physical barrier protecting the underlying mucosa from the external environment but 
also actively participates in microbial sensing and mounting appropriate innate immune 
responses  by  the  production  of  chemokines,  cytokines  and  antimicrobial  peptides 
(Kagnoff and Eckmann, 1997; Eckmann, 2005).
The  NF-xB/rel  family  of transcription  factors  comprises  structurally  related  DNA 
binding/transactivation proteins known to be central regulators in early host immunity 
against infection (Ghosh et al.,  1998). Upon activation, NF-kB initiates expression of 
several innate immune genes (Elewaut et al.,  1999;  Sansonetti, 2006).  Several studies 
have  demonstrated  activation  of intestinal  epithelial NF-kB  in response  to  C. jejuni 
infection  (Mellits  et  a l,  2002;  Jin  et  al.,  2003;  Chen  et  a l,  2006;  Johanesen  and 
Dwinell, 2006). C. jejuni surface protein JlpA interacts with epithelial Hsp90 promoting 
bacterial adhesion leading to NF-kB and p38MAP kinase activation (Jin et al, 2003). 
The cytokine Interleukin (IL)-8 is a potent chemo-attractant known to recruit immune 
cells including neutrophils to the site of local inflammation. Release of IL-8 in response 
to  bacterial  infection  is thought to  be  a critical event  in  diarrhoea  development and 
clearing of infection. C. yey'ww'-mediated induction and release of intestinal epithelial IL- 
8  is well established, to date bacterial adhesion/invasion (Hickey et al,  1999) and the
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presence of CDT (Hickey et al, 2000) have been shown to be critical mediators of IL-8 
production. The degree of IL-8 induction varies in in-vitro models of infection as not 
surprisingly, the response is dependent on both bacterial strain and cell-line employed 
(MacCallum et al.,  2006).  Progress has been made in delineating  signal transduction 
events that lead to IL-8 production during C. jejuni infection. Both ERK and p38 MAP 
kinases are involved in C. ye/ww-mediated host responses with the ERK pathway critical 
for  IL-8  induction  (MacCallum  et  al,  2005;  Watson  and  Galan,  2005).  Prior  to 
activation  of  MAP  kinases  and  NF-kB,  host  sensing  of  bacteria  and/or  bacterial 
components  is required.  In principal this  interaction can be  fulfilled by  host pattern 
recognition receptors (PRRs) known to interact with conserved bacterial motifs called 
pathogen-associated molecular patterns  (PAMPs)  (Akira et al,  2006;  Sanderson and 
Walker, 2007). The most extensively studied family of PRRs are the Toll-like receptors 
(TLRs)  with  TLR5  expressed  at  the  basolateral  surface  of the  intestinal  epithelium 
(Gewirtz  et  al,  2001b).  TLR5  recognises  flagellin  of  enteropathogens  such  as 
Salmonella,  leading  to  activation  of NF-kB  (Hayashi  et  al,  2001).  Recent  studies 
suggest C. jejuni flagellin to be a poor activator for epithelial TLR5. (Andersen-Nissen 
et al, 2005; Watson and Galan, 2005; Johanesen and Dwinell, 2006). This seems to be 
due to differences in amino acid sequences of C. jejuni flagellin known to bind to TLR5 
(Andersen-Nissen  et  al,  2005).  At  present the  role  of other  PRRs  in  eliciting  host 
responses during C. jejuni infection remains unknown, 
b)  Other innate immune cells
Once C. jejuni has breached the intestinal epithelium cell (IEC) layer, the bacterium will 
encounter  the  underlying  lymphoid  tissue  harbouring  various  other  immune  cells 
including  macrophages,  lymphocytes and dendritic  cells  (DCs).  Several  studies have 
demonstrated that C. jejuni is able to survive phagocytosis by human mononuclear cells, 
induce secretion of chemokines, and mediate apoptosis (Kiehlbauch et al,  1985; Jones
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et al,  2003;  Hickey et al.,  2005).  Importantly, prolonged intracellular survival of C. 
jejuni for up to 7 days combined with bacterial replication might favour dissemination 
within the host (Hickey et al, 2005). DCs are capable of traversing the tight junctions 
of the intestinal mucosa allowing them to interact directly with luminal bacteria (Niess 
and Reinecker, 2005). They have been shown to play a major role during infection with 
eneropathogens  such as E.  coli (Torres et al,  2006),  Salmonella spp.  (Bueno  et al.,
2005),  both via  antigen presentation  and cytokine  production  (Niess  and Reinecker,
2006). Activation of NF-kB and production of several cytokines including IL-ip, IL-6, 
IL-8, IL-10 and IL-12, INF-y and TNF-a by DCs in the presence of C. jejuni has been 
noted.  High IL-12 production with low IL-10 levels suggests C. jejuni initiates Thl- 
polarized immunity (Hu et al, 2006b). At present, our understanding of DC activation 
in C. jejuni-mediated disease remains limited.
1.1.7.2  Adaptive immune response
a)  Antibody response
Infection with C. jejuni is known to correlate with an increase in serum titres of specific 
IgG, IgM, and IgA antibodies (Blaser,  1997;  Strid et al., 2001).  While IgM and IgA 
levels quickly decrease after infection, IgG antibodies can remain elevated for months 
or even years (Strid et al., 2001). Re-challenge of previously infected adults who had 
proven  serum  antibody  response  were  found  to  be  protected  from  illness  but  not 
colonization, suggesting a role for humoral immunity in disease outcome (Black et al., 
1988). Furthermore, in developing countries recurrent infections result in an age-related 
rise in specific serum-antibodies, leading to successively milder  symptoms with each 
infection  (Taylor  et  al.,  1993).  Immunocompromised  patients,  specifically  those 
deficient  in  immunoglobulin  production,  suffer  from  more  severe,  prolonged  and 
relapsing illness lending further support for the involvement of humoral immunity in
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disease  outcome  (Coker  et  al,  2002).  Taken  together,  these  findings  suggest  an 
important role for the humoral/antibody response in C. jejuni infection,
b)  Cellular response
To date we have limited information on the role of cellular adaptive immune responses 
to C. jejuni. However, the established association of GBS with C. jejuni suggests that 
activation of T cells in response to infection can occur.  In addition to cross-reactive 
antibodies, T lymphocytic infiltrations in affected nerve tissue and activated T cells in 
the  blood  from  GBS  patients  have  been  demonstrated  (Van  den  Berg  et  al,  1995; 
Schmidt et al.,  1996). A T cell line established from a nerve biopsy of a GBS patient 
with a preceding C. jejuni infection was shown to consist entirely of T cells expressing 
the y6-TCR (Ben-Smith et al,  1996).  The  same  authors  also  observed expansion of 
human y6-T cells after stimulation of Peripheral Blood Mononuclear Cells (PBMCs) 
with C. jejuni (Ben-Smith et al,  1997). However, the role, if any, of T cells in acute 
intestinal C. jejuni infection remains unknown.
1.2  Defensins: a family of antimicrobial peptides
Antimicrobial peptides (AMPs) are part of an ancient defence system of all forms of 
life. To date hundreds of AMPs have been isolated from single-celled organisms (e.g. 
bacteria),  insects, plants,  birds,  fish and mammals  including humans  (Lehrer,  2007). 
AMPs are generally small size (12 to  100 amino acids), positively charged (cationic) 
and amphiphilic in nature (Ganz, 2003; Selsted and Ouellette, 2005). In addition to their 
antimicrobial properties, AMPs can also function as multieffector molecules capable of 
enhancing  phagocytosis,  stimulate  prostaglandin  release,  neutralize  septic  effects  of 
LPS and recruit various immune cells to the site of infection (Lehrer, 2007).  In humans 
two major subgroups of cationic AMPs are found: defensins and cathelicidins. Both are 
structurally  and  evolutionarily  distinct  with  similar  distribution  in  human  tissues,
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antimicrobial properties, AMPs can also function as multieffector molecules capable of 
enhancing  phagocytosis,  stimulate  prostaglandin  release,  neutralize  septic  effects  of 
LPS and recruit various immune cells to the site of infection (Lehrer, 2007).  In humans 
two major subgroups of cationic AMPs are found: defensins and cathelicidins. Both are 
structurally  and  evolutionarily  distinct  with  similar  distribution  in  human  tissues,
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predominantly  the  epithelium  and  circulating  phagocytes.  In  other  mammals  AMPs 
such  as  histatins  (Devine,  2003),  dermicindin  (Schittek  et  al.,  2001)  and  anionic 
peptides (Brogden et al., 1997) have been found. However, these are restricted to a few 
animal species and tissues.
In the following section, gene- and protein-structure, tissue distribution, regulation and 
function  of human defensins  are  described with  a focus  on the  gastrointestinal  (GI) 
tract.
1.2.1  Gene and protein structure
Defensins are defined as an evolutionary conserved, gene-encoded family of vertebrate 
AMPs. They are between 38 and 44 amino acids long and contain a framework of six 
disulphide-linked cysteines (Figure 1.4) (Selsted and Ouellette, 2005). Like most other 
AMPs, defensins are cationic in nature (net charge ranging from +1 to +11) mainly due 
to the high percentage  of arginine residues.  Three  defensin  subfamilies  are found in 
vertebrates:  a-defensins,  P-defensins  and  0-defensins.  In  humans,  however  only  a- 
defensins  and  p-defensins  are  expressed  while  9-defensin-expression  is  restricted  to 
rhesus monkey leucocytes (Tang et al, 1999). Structurally, a- and p-defensins differ in 
the length of peptide segments and their di-sulphide pairing (Figure 1.4), however both 
adapt an antiparallel beta-sheet (“defensin fold”) structure. In  p-defensins, the p-sheet 
is flanked by an N-terminal a-helical segment of variable length (Hoover et al., 2001). 
The  main  defensin  gene  locus  coding  for  all  a-defensins  and  several  p-defensins  is 
located on a cluster on the short arm of chromosome 8  (8p22-23.1) near the telomere 
region (Harder et al, 1997b; Liu et al, 1997). The a-genes are flanked by the p-genes, 
the  close  proximity  suggesting  a  common  ancestral  progenitor.  Three  additional  p- 
defensin gene clusters within chromosomes 6 (6pl2) and 20 (20qll.l  and 20pl3) have 
been identified with comprehensive  searches revealing  up to  40 potential  p-defensin
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sequences (Schutte et al., 2002; Patil et al, 2005). Evidence suggests rapid evolution of 
mammalian  defensin  genes  through  duplication  and  diversification,  a  likely 
evolutionary response to changes in microbial exposure (Lynn et al., 2004;  Semple et 
al., 2006). The genomic organization consists of two short exons separated by a large 
intron. Exon I encodes for the prepro peptide, consisting of an N-terminal hydrophobic, 
leucine rich signal sequence. Exon II encodes an anionic pro-segment and a C-terminal 
cationic segment that on cleavage yields the active peptide  (Figure  1.4)  (Lehrer and 
Ganz,  2002;  Semple  et al.,  2006).  Neutrophil  defensins  (HNP1-4)  have  a short extra 
exon that encodes the leading peptide, Exon I and II encode for an untranslated region 
and the preproregion, respectively (Semple et al., 2006).
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Figure 1.4: Defensin gene and peptide structure (from Selsted and Ouellette, 2005).
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1.2.2  Tissue distribution
Defensins  are  expressed  in  various  cells  and  tissues  that  are  exposed  to  microbes 
(Table 1.2).  Human  a-defensins  1-4  are  predominantly  expressed  in  promyelocytes 
(precursor cells derived from bone marrow) and stored in primary, azurophilic granules 
of neutrophils (Ganz et al.,  1985; Ganz,  1987).  They are therefore also referred to as 
human neutrophil peptides (HNPs).
More recently it has been shown that monocytes, natural killer (NK) cells and T cells 
also express HNPs (Table  1.2) (Agerberth et al, 2000; Chalifour et al, 2004). Human 
a-defensins HD-5  and HD-6  are  expressed in Paneth cells,  which are located in the 
crypts of Liberkuhn throughout the small intestine (Jones and Bevins,  1992; Ouellette,
2006).  Although the  main  sites  of human a-defensin production  are  leukocytes  and 
Paneth cells, HD-5 has also been shown to be expressed in the female reproductive tract 
and  in a rare  intestinal  epithelium cell type,  similar to  mucin producing  goblet cells 
(Quayle et al, 1998; Cunliffe et al., 2001).
In  contrast  to  a-defensins,  p-defensins  are  more  widely  expressed  mainly  by  the 
epithelial  lining  of the  skin,  kidney,  respiratory  tract,  pancreas,  reproductive  tract, 
conjunctiva, urinary-, and GI tract (Table  1.2) (Klotman and Chang, 2006; Pazgier et 
al,  2006).  Expression by  monocytes,  macrophages  and  DCs  has  also  been reported 
(Duits et al., 2002). Although the human genome suggest the presence of more than 30 
human  P-defensin (hBDs),  to  date expression and regulation  of only  four human  P- 
defensins (hBD-1 to -4) have been described (Schutte et al., 2002; Ganz, 2003; Patil et 
al., 2005; Pazgier et al., 2006). The first human p-defensin hBD-1 was isolated from the 
serum of patients with renal disease (Bensch et al.,  1995).  Subsequently, hBD-2 and 
hBD-3 were isolated from psoriatic scales with their structure and function now being 
well characterised (Harder et al., 1997a; Garcia et al, 2001b). Expression of hBD-4 has 
been demonstrated at the mRNA level only (Garcia et al., 2001a). A synthetic form of
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the peptide has been characterized further (Garcia et al., 2001a), however, isolation of 
natural hBD-4 has not been reported.
Distribution and source of defensins
Defensin Tissue distribution Cell source Synthesis and 
regulation
HNP1-3 Placenta, intestinal mucosa and 
cervical mucus plug
Neutrophils*, 
monocytes 
macrophages, natural 
killer cells, B cells and 
yb T cells
Constitutive
HNP4 Not determined Neutrophils* Constitutive
HD5 and 
HD6
Salivary glands, small bowel, 
inflamed large bowel, stomach, 
eye, female genital tract (HD5 
only), breast milk and inflamed 
urethral lumen
Intestinal Paneth cells* 
and vaginal epithelial 
cells (HD5 only)
Constitutive or 
inducible, such as 
by sexually 
transmitted 
infection
HBD1 Oral and nasal mucosa lungs, 
plasma, salivary glands, small 
and large bowel, stomach, 
skin, eyes, mammary glands, 
urogenital tract and kidneys
Epithelial cells*,
monocytes,
macrophages,
monocyte-derived
dendritic cells and
keratinocytes
Constitutive or 
inducible in 
response to 
interferon-y, 
lipopolysaccharide 
and peptidoglycan
HBD2 and 
HBD3
Oral and nasal mucosa, lungs, 
plasma, salivary glands, small 
and large bowel, stomach, 
skin, eyes, mammary glands, 
urogenital tract and kidneys
Epithelial cells*,
monocytes,
macrophages,
monocyte-derived
dendritic cells and
keratinocytes
Inducible in 
response to viruses, 
bacteria,
lipopolysaccharide, 
peptidoglycan, 
lipoproteins, 
cytokines (IL-lp, 
TNF) and growth 
factors
HBD4 Gastric antrum and testes Epithelial cells* Constitutive or 
inducible in 
response to PMA 
and bacteria
*Main cellular source. HBD, human p-defensin; HD, human a-defensin; HNP, 
human neutrophil peptide; IL-ip, interleukin-lp; PMA, phorbol 12-myristate 13- 
acetate; TNF, tumour-necrosis factor.
Table  1.2:  Tissue  distribution,  cell  source  and  regulation  of human  a-  and  p-
defensins (from Klotman and Chang, 2006).
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1.2.3  Transcriptional regulation
Our  current  understanding  of the  transcriptional  regulation  of epithelial  a-defensins 
(HD-5 and -6) is limited mainly due to the lack of availability of a Paneth cell derived 
cell line.  Under most conditions, expression of a-defensins is constitutive.  However, 
transcriptional  regulation  seems  to  occur partly  through  factors  intimately  linked to 
cellular differentiation.  Specifically, Tcf7-L2 has been identified as key transcription 
factor involved in Paneth cell a-defensin expression (Clevers, 2006).  Activity of this 
transcription factor is liked to the Wnt/p-catenin signalling pathway, a central regulator 
for Paneth cell differentiation (van Es et al., 2005).  Furthermore,  HD-5  and -6 have 
been found to be present prenatally in human Paneth cells. However, levels are low in 
human neonates and increase dramatically with maturation, suggesting that regulatory 
mechanism(s) inducing their expression are likely to be operative (Mallow et al., 1996). 
In contrast to a-defensins, transcriptional regulation of P-defensin gene expression has 
been studied extensively. HBD-1  is expressed constitutively in various epithelial cells 
including the lining of the intestinal tract (O'Neil et al., 1999). However, expression can 
be further modulated by infection and inflammation. In the GI tract constitutive hBD-1 
gene and peptide expression has been shown to be down-regulated during infection with 
Shigella (Islam et a l,  2001)  and Cryptosporidium parvum  (Zaalouk et al.,  2004).  In 
contrast, hBD-1  induction in inflamed Helicobacter pylori (H. pylori)-infected gastric 
mucosa has been reported (Bajaj-Elliott et al, 2002). HBD-2 and hBD-3 are inducible 
in  nature  with  induction  occurring  in  response  to  bacterial  infection  or 
proinflammmatory  stimuli.  Stimulators  for  hBD-2  include  IL-ip,  TNF-a,  INF-y, 
phorbol  12-myristate 13-acetate (PMA),  1.25-dihydroxyvitamin D3 and bacterial LPSs 
(Table  1.3).  In the  GI  epithelium hBD-2  has been  shown to  be  induced by  various 
enterophathogens such as H. pylori, Salmonella enteritidis, the probiotic bacterium E. 
coli Nissle  1917 and in states of chronic inflammation such as ulcerative colitis (UC)
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(Wada et al.,  1999;  Ogushi  et al.,  2001; Bajaj-Elliott et al.,  2002;  Wehkamp  et al, 
2003b; Wehkamp ef a/., 2004a) . Similar to hBD-2, expression of hBD-3 is induced by 
various inflammatory mediators (TNF-a, INF-y) as well as microbes including bacteria 
and  yeast  (Table  1.2)  (Dhople  et  al.,  2006).  Expression  of  hBD-4  can  be  both 
constitutive and/or inducible, with induction following a similar pattern than hBD-2 and 
-3 (Table 1.2) (Pazgier et al., 2006; Semple et al., 2006).
1.2.4  Signalling pathways and host receptors involved in defensin expression
Variable expression and induction patterns of defensins suggest involvement of multiple 
signalling  pathways  in  the  regulation  of these  AMPs.  Promoter  analysis  shows  the 
presence  of  consensus  NF-IL6  and  interferon-y  (INF-y)  sites  in  hBD-1  promoter 
(Diamond et al., 2000). Similarly, hBD-2 promoter contains multiple binding sites for 
NF-kB, activated protein (AP)-l, AP-2 and NF-IL6 (Yang et al., 2004). Induction of 
hBD-2 expression in various tissues by cytokines and bacterial components has been 
shown to be mediated through activation of NF-kB,  sometimes  assisted by  activated 
AP-1,  MAP-kinases  and by protein kinase  C  (PKC)  (Krisanaprakomkit et al.,  2000; 
Mineshiba et al., 2005; Wehkamp et al., 2006). In contrast to hBD-2, hBD-3 does not 
contain  any NF-kB  binding  sites  in  its promoter  suggesting  pathways  distinct  from 
those for hBD-2 expression might be responsible (Boughan et al., 2006). Induction of 
hBD-3 has been shown in response to transforming growth factor alpha (TGF-a), EGF 
receptor transactivation and insulin-like growth factor 1  (IGF-1) (Sorensen et al, 2003; 
Boughan et al., 2006).
Several  studies have demonstrated that TLRs mediate  p-defensin expression.  HBD-2 
mRNA and peptide induction in airway epithelia and hBD-3 induction in keratinocytes 
occurs  via  TLR2  and  its  ligand  lipopeptide  (Hertz  et al.,  2003;  Wang  et al.,  2003; 
Sumikawa et al., 2006). In the GI tract both TLR2 and TLR4 have been implicated in
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hBD-2 expression (Vora et al, 2004). TLR3 agonists polyI:C and double-stranded RNA 
activate  p-defensin  expression  in  uterine  and  airway  epithelia  (Proud  et  al,  2004; 
Schaefer et al., 2005). In addition to TLRs, a second family of PRRs named nucleotide 
binding  oligomerisation  domain  (NOD)  like  receptors,  have  been  implicated  in 
mediating human a- and (3- defensin expression in the GI tract. Unlike TLRs, which are 
located  either  on  the  cell  surface  or  in  the  cytoplasm,  NODs  are  exclusively 
intracellularly  located  (Inohara  et  al.,  2005).  NODI  (encoded  by  the  caspase- 
recruitment domain 4 gene; CARD4) and NOD2 (encoded by CARD15) recognize the 
intracellular presence of peptidoglycan (the major component of the cell wall of Gram- 
positive and Gram-negative bacteria (Inohara and Nunez,  2003;  Inohara et al,  2005; 
Franchi et al., 2006). H. pylori has been shown to induce IL-8 and hBD-2 expression 
via activation of NODI  (Viala et al, 2004; Boughan et al, 2006). Voss and colleagues 
identified NOD2 as a major intracellular PRR for hBD-2 in human embryonic kidney 
cell-line  and  primary  keratinocytes.  Induction  of hBD-2  required  functional  binding 
sites for NFk-B and API  in the hBD-2 promoter (Voss et al, 2006). A role for NODI 
as a major sensor for enteroinvasive Escherichia coli (E. coli) was proposed by Kim and 
colleagues (Kim et al., 2004), while NOD2 has been implicated in IEC defence against 
Salmonella (Hisamatsu et al.,  2003b), further highlighting the role  of these PRRs in 
microbial sensing and mediating innate host defence. Although mechanism(s) by which 
HD5 and HD6 expression is modulated in response to bacteria remains unclear, several 
studies  suggest NOD2  is  required  for peptide  expression  in  vivo  (Lala et al,  2003; 
Wehkamp et al, 2004b).
1.2.5  Peptide processing and secretion
Both a- and p-defensins are translated as large precursor polypeptide chains containing 
a signal peptide,  a propiece and the mature peptide.  Following transport to the Golgi
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body,  the  hydrophobic  signal  peptide  is  proteolytically  cleaved.  Cleavage  of  the 
propiece  varies  between  defensin  families.  The  signal  peptide  of  HNP1-4  is 
proteolytically  removed  together  with  the  propiece  in  the  Golgi  body,  followed  by 
storage of the mature peptide in neutrophil granules (Ganz et al,  1985).  In contrast, 
HD5 and HD6 are stored in specialized granules in an inactive precursor form (propiece 
and mature peptide), in close proximity to the inactive form of the processing enzyme, 
trypsin (trypsinogen). On appropriate stimuli (bacterial products or cholinergic agonists) 
(Ayabe et a l, 2000; Ouellette, 2006), the inactive defensin proform is secreted into the 
intestinal  crypt  where  trypsin  mediates  the  enzymatic  removal  of the  propiece  and 
activates the precursor protein (Ayabe et al, 2000; Ghosh et al, 2002). Serine protease 
inhibitors (also produced and released by Paneth cells) add further complexity to the 
regulation of HD-5  and HD-6 by controlling the enzymatic activity of trypsin in the 
lumen of the intestinal crypt (Ghosh et al, 2002).
At present  enzyme(s)  involved  in post-translational  modifications  of P-defensins  are 
unknown.  Although P-defensins are secreted upon induction, recent evidence suggest 
that intracellular storage and activity may also occur (Sorensen et al, 2005).
1.2.6  Function and effector mechanisms
1.2.6.1  Antimicrobial activity and mode of action
Defensins  exhibit  broad-spectrum  antimicrobial  activity  against  bacteria,  fungi, 
protozoa and  enveloped  viruses  reflecting their  role  in  innate  defence.  Defensins  in 
general are  salt sensitive,  exhibiting maximum bactericidal  activity in buffers of low 
ionic  strength and neutral pH.  In vivo physiological  salt concentrations might act as 
natural regulators of their antimicrobial action restricting their activity to sequestered 
environments such as the immediate epithelial surface of skin and GI tract. Although 
the  exact  concentration  of defensins  at  their  expression  site  is  not  known,  in  vitro
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studies suggest effective microbicidal activity at concentrations in the range of 0.5-5 
pM (Selsted and Ouellette, 2005).
Our understanding of the mechanism(s) by which defensins mediate their antimicrobial 
activity is still incomplete. It is generally accepted that bactericidal activities of AMPs 
depends upon their interaction with the microbial cell membrane (Hancock and Rozek, 
2002).  The first step in this interaction is the attraction between the peptide and the 
target microbe  involving  electrostatic  and/or hydrophobic  bonding.  The  cationic and 
amphiphatic  nature  of  defensins  plays  a  key  role  in  selectively  interacting  with 
hydrophilic, negatively charged microbial membranes as opposed to eukaryotic cells, in 
which uncharged lipids predominate (Jenssen et al., 2006). Events that occur following 
initial AMP membrane interaction are less well defined and several models have been 
put forward including carpet hole, barrel-stave, toroidal pore and the aggregated model 
(Figure  1.5). In each model system the peptide either causes target cell depolarization 
followed permeabilization, and/or translocates across the membrane into the cytoplasm. 
While  the  first  mechanism  most  likely  leads  to  irreversible  damage  of the  target 
membrane  potentially  followed  by  leakage  of  cytoplasmic  contents,  peptide 
translocation across the membrane can have several implications. A growing number of 
peptides  have  been  shown  to  translocate  across  the  membrane  and  accumulate 
intracellularly, where they target a variety of essential cellular processes to mediate cell 
killing including inhibition of nucleic acid-, protein-, cell wall synthesis and induction 
of autolytic enzymes (Figure 1.5) (Sahl et al., 2005; Jenssen et al., 2006).
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Figure  1.5:  Mechanisms  of  action  of  antimicrobial  peptides.  Several  models  of 
membrane  permeablilization  are  demonstrated  (A-D).  Mechanisms  of  action 
independent  of bacterial  membrane  permeabilization  are  summarized  in  E  to  I  (from 
Jenssen et a l 2006).
A: Aggregate model;
B: Toroidal pore model;
C: Barrel-stave model;
D: Carpet model;
E: Inhibition of DNA/RNA synthesis;
F: Interference with protein synthesis;
G: Interference with protein folding;
H: Inhibition of enzymes involved in aminoglycosides modification;
I: Inhibition of cell wall synthesis.
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1.2.6.2  Additional functions
In addition to their antimicrobial activity defensins contribute to host innate defence in 
multiple ways. Their chemotactic properties form an important link between the innate 
and  adaptive  immune  system.  In  contrast  to  the  antimicrobial  activity  of defensins 
requiring  pM  concentrations,  the  chemotactic  activity  occurs  in  a  nM  range. 
Chemotactic  activity reported to  date  include HNP1-3,  hBD3  and -4  chemoattracting 
monocytes (Territo et al.,  1989; Garcia et al., 2001b; Garcia et al., 2001a) and hBD2 
mast cells (Niyonsaba et al., 2002). hBDl-3 are also chemotactic for immature dendritic 
cells (iDCs) (Yang et al,  1999; Yang et al., 2002). Murine (3-defensin 2 mediates this 
interaction via binding to the  chemokine receptor CCR6 present on DCs and T  cells 
(Biragyn  et al.,  2001).  Additional  studies  in mice  have demonstrated that  a-  and  (3- 
defensins are very effective in promoting antigen specific immune responses (Brogden 
et al., 2003; Yang et al., 2004). Further functions of defensins include degranulation of 
mast cells,  induction of neovasculogenesis and enhanced wound closure  (Figure  1.6) 
(Selsted and Ouellette, 2005).
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Figure  1.6:  Mobilization,  induction  and  interactions  of defensins  (from  Selsted 
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1.2.7  Role in health and disease
The pathogenesis of several infectious diseases and associated medical conditions have 
been linked to expression and function of defensins. Amongst the first to be reported 
was  cystic  fibrosis.  Due  to  a  genetic  defect  in  a  chloride  channel,  luminal  salt 
concentrations  in the  airway  surface  fluid are  increased,  inhibiting  the  antimicrobial 
activity of hBDl  (Smith et al,  1996; Goldman et al.,  1997). This local impairment of 
host defence is thought to contributes to the increased susceptibility of these patients to 
chronic  bacterial  infections  (Goldman et al.,  1997).  Additionally,  increased defensin 
levels  have  been  observed  in  inflammatory  lung  diseases,  such  as  diffuse 
panbroncheolitis  (DPB),  idiopathic  pulmonary  fibrosis  (IPF)  and  acute  respiratory 
distress syndrome (ARDS), further highlighting a potential involvement of defensins in 
disease pathogenesis (Aarbiou et al., 2002).
More  insight  into  the  role  of defenins  in-vivo  has  been  provided  by  investigating 
defensin expression in human skin.  HBD-2 and LL-37 (the only human cathelicidin) 
have been shown to be expressed in high levels in keratinocytes of patients suffering 
from psoriasis,  providing  one explanation as to why these patients  are less prone to 
bacterial skin infections (Christophers and Henseler,  1987; Liu et al.,  1998; Schroder 
and  Harder,  1999).  Conversely,  the  reported  impaired  defensin  expression  in  atopic 
dermatitis  may  explain  the  associated  increased  risk  in  acquiring  bacterial  skin 
infections (Howell et al, 2005).
Recently,  increasing  evidence  suggests  involvement  of  a-  and  p-defensins  in 
controlling  HIV  infection.  Studies  have  demonstrated  that  defensins  can  directly 
inactivate HIV-1 virions (Quinones-Mateu et al, 2003). Additionally, reported anti HIV 
effects of defensins in-vivo include the interference with coreceptor(s) required for viral 
entry,  ultimately  leading  to  reduced  replication  (Munk  et  al,  2003).  Besides  HIV,
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defensins exhibit antiviral activity against other viruses further highlighting their critical 
role in host protection against virally mediated disease (Klotman and Chang, 2006). 
Increasing evidence suggests that genetic factors such as polymorphisms and/or number 
of defensin gene copies influence defensin expression and possibly function. The gene 
copy  number  of a-  and  P-defensins varies  amongst  individuals with  increased copy 
numbers correlating with high peptide expression in vivo (Linzmeier and Ganz, 2005), 
suggesting  genetic  variation  may  contribute  to  host  susceptibility  to  infection  and 
disease.  Single nucleotide polymorphisms (SNPs)  are a recognized feature of hBD-1 
gene  (DEFB1)  and recent reports have  linked their presence  to  the  susceptibility  of 
developing  atopic  dermatitis,  chronic  obstructive  pulmonary  disease  (COPD)  and 
asthma (Matsushita et al, 2002; Levy et al., 2005; Prado-Montes de Oca et al, 2007). 
These findings are supported by in vivo studies demonstrating that deletion of murine P- 
defensin-1  gene (Defbl) results in defective clearance of Haemophilus influenzae from 
the lung (Moser et al, 2002). Furthermore, a study by Morrison and colleagues showed 
increase in Staphylococcae species in the bladders of Defbl K/O mice (Morrison et al., 
2002).
Due to the constant exposure of the intestinal epithelium to a wide range of commensal 
bacteria,  defensin expression at this mucosal  surface is likely to not only effect host 
susceptibility to enteropathogens but also influence bacterial flora. Increasing evidence 
suggest that differential expression of defensins in the small and large bowel may have 
a significant impact on the content and type of resident bacterial flora (Salzman et al,
2007). Furthermore, high expression levels of enteric a-defensins in the lumen of small 
intestinal crypts provide sterility, ensuring protection of stem cells found at the bottom 
of the intestinal crypt (Bevins et al, 1999).
Studies in mice and humans have highlighted a role for defensins in GI innate defence 
against infections.  Cryptidin (mouse alpha-defensin) maturation was abrogated in the
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small  intestine  by  targeting  the  matrilysin  gene  (.MMP7,  enzyme  responsible  for
H  / processing murine pro-alpha-defensin).  MMP7 null  (Mmp *  *)  mice  lacked  detectable 
mature cryptidins which led to increased susceptibility to oral challenges with enteric 
bacteria including E.  coli and Salmonella typhimurium (S.  typhimurium) (Wilson et al., 
1999). Conversely, a transgenic mouse expressing HD-5 was found to be immune to the 
oral  challenge  with  virulent  S.  typhimurium  (Salzman  et  al.,  2003).  In  humans 
increased risk of infectious diarrhoea in an African cohort with decreased a-defensin 
expression has been noted (Kelly et al, 2006).
Both enteric a- and P-defensins have been implicated in disease pathogenesis of chronic 
inflammatory  bowel  diseases  (IBD),  i.e.  ulcerative  colitis  (UC)  and  Crohn’s  disease 
(CD). While UC is generally restricted to the colon, CD frequently affects the ileum of 
the  small  bowel  and  the  colon.  Studies  initiated  by  Wehkamp  and  colleagues  have 
demonstrated decreased expression of a-defensins HD5 and HD6 in patients suffering 
from ileal CD (Wehkamp et al., 2005). Independent studies have shown expression of 
the intracellular PRR NOD2 in Paneth cells and established a link to a-defensins (Lala 
et al., 2003). Importantly, about one third of CD patients are known to have a mutation 
in the gene coding for NOD2, and particularly those patients were found to express low 
levels of HD5 and HD6 (Wehkamp et al., 2004b).
In addition to  Paneth cell  defensins,  expression of human  p-defensins has  also  been 
found to be impaired in CD patients. Specifically, induction of hBD-3 and hBD-4 was 
found to be significantly reduced in the inflamed colonic mucosa of CD patients when 
compared  to  samples  taken  from  individuals  suffering  from  UC  (Wehkamp  et  al., 
2003b).  More  recently,  Fellermann  and  colleagues  were  able  to  demonstrate  a 
correlation between low hBD-2 copy numbers and peptide expression in vivo, leading to 
a significantly increased risk for the development of CD (Fellermann et al., 2006).
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Taken  together  these  findings  highlight  the  important  role  of defensins  during  GI 
infection  and  inflammation,  significantly  contributing  to  disease  susceptibility  and 
outcome.
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The main aim of this thesis is to further our understanding of the role and regulation of 
intestinal  host  innate  immunity  during  C.  jejuni  infection.  We  hypothesise  that 
modulation of intestinal innate host defence by C. jejuni contributes to the self-limiting 
nature of disease. Identification of molecular mechanism(s) leading to clearance of the 
infective agent may help us identify susceptible individuals and develop new preventive 
and/or therapeutic strategies in the future.
The specific aims of this project are:
1)  To  delineate  the  modulation  of intestinal  human  p-defensin  expression 
during C. jejuni infection.
2)  To test susceptibility of C. jejuni to human p-defensins.
3)  To  investigate  the  potential role  of C. jejuni capsular  polysaccharide  in 
modulating  innate  host  defence  and  providing  protection  against 
p-defensins.
4)  To identify the potential role of the intracellular PRRs NODI and NOD2 
in mediating intestinal innate host response to C. jejuni.
5)  To develop an ex-vivo infection model and improve existing in-vitro models 
to investigate C. jejuni disease pathogenesis.
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Materials and Methods
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2.1  Mammalian cell culture
2.1.1  Cell culture reagents
All plastic  including  6,  12,  24,  96  well plates,  25  cm2,  75  cm2 tissue  culture  flasks, 
pipettes  and  polypropylene  coated  Eppendorf  tubes  were  purchased  from  Fisher 
Scientific,  Leicestershire,  UK.  Cell culture reagents were purchased from Invitrogen, 
Paisley, UK, unless otherwise stated.
2.1.2  Epithelial cell lines
The  human  intestinal  epithelium  cell  (IEC)  lines  Caco-2,  HT-29  and  the  larynx 
carcinoma cells Hep-2  were used throughout the  study.  Caco-2  and HT-29 cells are 
derived  from  colorectal  adenocarcinoma  and  upon  reaching  confluence,  express 
characteristics of enterocytic differentiation. Both IEC lines were maintained in DMEM 
+glutamax culture medium,  supplemented with  10% heat inactivated fetal calf serum 
(FCS; Sigma, Poole, UK), 100 units/ml penicillin, 100p,g/ml streptomycin, and 1% non- 
essential amino acids. This media is referred to as complete media thereafter. Similarly 
for  Hep-2  cells,  Minimal  Essential  Media  (MEM)  was  supplemented  with  2mM  L- 
glutamine  plus  above.  The  cells  were  maintained  at  37°C  in  a  5%  CO2  humidified 
incubator (Galaxy CO2 Incubator, Wolf Laboratories Ltd., Pocklington, UK).
2.1.3  Cell passage
Cells were  examined regularly under the microscope and checked for morphological 
features of growth as well as contamination. Cells were passaged upon reaching 80-90% 
confluency.  Cells  were  washed  twice  with  sterile  phosphate  buffered  saline  (PBS) 
before  addition  of  Trypsin-EDTA  for  5-10min  at  37°C.  This  treatment  allowed 
detachment  of  adherent  cells.  Trypsin  activity  was  inactivated  by  the  addition  of 
complete  media  containing  10%  FCS.  Resultant  cell  suspension  was  centrifuged  at
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1200rpm for  lOmin at 4°C (Rotina 46R centrifuge, Wolf Laboratories, UK). The cell 
pellet was resuspended in complete media and re-centrifuged in order to remove any 
remaining  trypsin.  Finally,  cells  were  seeded  at  an  appropriate  cell  density  and 
maintained in 25cm2 or 75cm2 culture flasks, 6 or 96 well plates as required.
2.1.4  Counting viable cells
Cells were quantified as follows:  lOpl of resuspended cells were mixed with an equal 
volume of 0.4% trypan blue (Sigma, Poole, UK). lOpl of this mixture was placed onto a 
haemocytometer (Hawksley+Sons Limited, West Sussex, UK) counting chamber, and 
viable cells  counted  (Zeiss Microscope,  Germany)  at a magnification of x  40.  Non- 
viable cells were distinguished from viable cells by the uptake of dye. Concentration of 
viable cells was determined as:
Number of cells
within 25 squares  x  dilution factor (2)  =  Total number of cells  x  104 cells/ml
2.1.5  Freezing cells
For long-term storage, confluent adherent cell lines were trypsinised, centrifuged and 
resuspended  in  media  containing  80%  FCS,  10%  complete  media  and  10%  sterile 
dimethyl sulphoxide (DMSO; Sigma, Poole, UK) and transferred into cryovials (Nunc, 
Roskilde,  Denmark).  To  maintain  greater  viability  and  integrity  cells  were  cooled 
gradually over a 24h period prior to long-term storage at -80°C or liquid nitrogen.
2.1.6  Thawing cells from -80°C storage
Cryovials were removed from -80°C storage and placed in a 37°C water bath to achieve 
rapid  thawing.  Complete  media  (37°C)  was  added  and  cells  centrifuged  (1200rpm, 
lOmin, 4°C) to remove DMSO. The cell pellet was resuspended in complete media and
61CHAPTER 2
transferred into a 25cm  tissue culture flask. After overnight incubation, non-viable cells 
were removed by change of media and adherent cells were allowed to grow.
2.2  Bacterial culture
2.2.1  Preparation of blood agar plates
Bacterial  reagents  for  maintaining  C. jejuni  strains  including  horse  blood,  agar  and 
selective supplements were purchased from Oxoid, Basingstoke, UK. Wild type (WT) 
C. jejuni strains were grown on blood agar plates prepared using Columbia Agar Base 
(39g/L), supplemented with 5% horse blood and C. jejuni selective (Dent) supplement. 
C. jejuni selective supplements contained Vancomycin (lOmg/L), Polymyxin B (2,500 
IU/L),  Trimethoprim (5mg/L), Amphotericin B (2mg/L), Cephalothin (15mg/L). One 
vial of supplement was resusupended by adding 2ml of aseptic, sterile PBS and mixed 
gently to dissolve.  The contents were then added to  500ml of Columbia Blood Agar 
Base cooled to 50-55°C and mixed well before pouring into sterile Petri dishes (Fisher 
Scientific, Leicestershire, UK).
2.2.2  C. jejuni strains
All C. jejuni strains used throughout this study were provided by Dr. N. Dorrell and Mr. 
A. Elmi (LSHTM) and are listed in Table 2.1. C. jejuni strains were grown at 37°C in a 
microaerobic chamber (Don Whitley Scientific Ltd,  Shipley, UK) containing 85% N2, 
5% O2 and 5% CO2 on blood agar plates or in Mueller-Hinton (MH) broth. A sterile 
loop was used to streak bacteria onto blood agar plates.
Prior to  experiments,  C. jejuni was routinely  grown on blood  agar plates  over 24h, 
providing a “mixed” culture bacterial population with organisms in various phases of 
growth. Bacteria referred to as “mid-log” phase were transferred from 24h blood agar
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plates into MH broth and grown over an additional 16h leading to a bacterial population 
mainly consisting of mid-log phase organisms.
C. jejuni  strain Characterisation Reference
WT 11168H Hypermotile clinical isolate. 
Derived from the sequenced strain 
C. jejuni NCTC 11168.
Shows high levels of intestinal 
colonization in a chicken 
colonization model.
(Jones et al., 2004)
kpsM Isogenic  capsule-deficient  mutant 
of11168H.
Deficient in kpsM.
(Karlyshev et al, 2000)
WT 81-176 Clinical isolate from a multistate 
gastroenteritis outbreak
(Korlath et al, 1985) 
(Black et al, 1988)
Table  2.1:  Campylobacter jejuni  strains,  clinical  isolates  and  isogenic  mutant
utilised in the present study.
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2.2.3  Quantification and inactivation of C. jejuni
Bacterial  colonies were  resuspended  in antibiotic  free  media  supplemented with  1% 
FCS (infection media) using a sterile bacterial spreader. Suspension was diluted 10-fold 
and  optical  density  (OD)  measured  spectrophotometrically  at  600nm  (6300 
Spectrophotometer,  Jenway,  UK).  According  to  initially  performed  viable  counts,  a 
suspension with an OD600  of 1   contained approximately  lxlO9  colony  forming units 
(CFU) per ml. Bacterial inactivation was achieved by fixation in 4% paraformaldehyde 
(PFA) in PBS for  15min followed by 3 washes in infection media.  100% inactivation 
was confirmed by viable counting.
2.3  Bacterial and cytokine stimulation of Intestinal Epithelium  Cells 
(IECs)
For bacterial co-culture experiments cells were set up in 6 well plates or 25cm2 tissue 
culture flasks and grown to 80-90% confluency.  16-24h prior to exposure to bacteria, 
cells were serum starved by the replacement of complete media with infection media. 
Infections were routinely conducted at a multiplicity of infection (MOI) of 100  [i.e., 
1x10  epithelial cells: 1x10  bacteria] unless stated otherwise. MOI of 100 was chosen as 
previous  studies  have  shown  maximum  expression  of epithelial  host  defence  genes 
under these conditions (Bajaj-Elliott et al, 2002).
Cytokine  stimulation  experiments  were  undertaken  in  media  supplemented  with  1% 
FCS, in the presence of antibiotics. Recombinant cytokines (Peprotech, London, UK) 
were reconstituted according to manufacturer’s instructions and used at the following 
concentrations: Interleukin-1(3 (IL-lp) and tumour necrosis factor- a (TNF-a): 20ng/ml, 
interferon-y (IFN-y): 40ng/ml (~100U/ml). At the end of the experimental time-period, 
media was removed, followed by two washes with sterile PBS. Cells were either stored 
at -80°C until required or used immediately for RNA extraction.
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2.4  RNA extraction, reverse transcription and polymerase chain 
reaction (RT-PCR)
All reagents for RNA extraction, reverse transcription  and polymerase chain reaction 
(PCR) were obtained from Invitrogen, Paisley, UK unless stated otherwise.
2.4.1  Total RNA extraction and quantification
For  total  cellular  RNA  isolation  a  monophasic  solution  of phenol  and  guanidine 
thiocyanate  (TRIZOL)  was  utilized,  of  which  1ml  was  added  directly  to  cell 
monolayers. Detachment and homogenization of cells was achieved by gentle shaking 
(Rotatest, Denley, UK) for  lOmin at RT. The viscous solution (due to cellular DNA) 
was transferred into a sterile 1.5ml eppendorf tube. Vigorous repeated dispersion of the 
solution through a syringe and needle (25gauge,  Terumo,  Leuven,  Belgium) allowed 
further homogenization of cellular contents. The resultant Trizol solution was allowed 
to  stand  at RT  for  5min to  permit  greater dissociation between nucleic  acid-protein 
complexes.  200pl chloroform (Sigma, Poole, UK) was added to each  1ml Trizol and 
mixed thoroughly (Vortex Genie-2,  Scientific Industries, NY, USA) for 30sec before 
centrifugation (13000rpm,  20min, 4°C; Eppendorf 5415R microfuge,  Eppendorf AG, 
Hamburg, Germany). This organic extraction procedure allows total RNA to remain in 
the aqueous phase leaving denatured proteins at the interface and DNA in the organic 
phase.  Following  centrifugation,  the top aqueous  layer was  aspirated  (approximately 
400pi)  and  transferred  into  a  fresh  eppendorf tube.  RNA  was  precipitated  by  the 
addition of an equal volume of isopropanol (Sigma, Poole,  UK)  and stored at -20°C 
overnight.  Total  RNA  was  pelleted  by  centrifugation  (13000rpm,  20min,  4°C)  and 
washed with ice-cold 70%  ethanol  (BDH Laboratories,  Poole, UK).  The RNA pellet 
was either vacuum (Heto Vacuum Centrifuge, Jencons PLC, UK) or air-dried to remove 
traces of ethanol prior to resuspension of RNA in RNase-  free water (Sigma,  Poole,
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UK). Resuspended RNA was quantified by spectrophotometry. RNA concentration was 
determined by absorbance (U-1800 Spectrophotometer, Digilab Hitachi, Tokyo, Japan) 
measured at 260nm and 280nm. The amount of RNA (pg/pl) was calculated as follows: 
[(reading at 260nm) x (dilution factor) x 40] /1000.
The RNA ratio at 260/280 also allowed the assessment of the degree of purity of the 
RNA  preparation.  Pure  RNA  gives  a value  of  1.8  at 260/280  nm  (Sambrook et al., 
1989).  Integrity of extracted RNA was also confirmed by gel electrophoresis.  5fig of 
each  sample  was  routinely  run  on  1%  agarose  gels  (Invitrogen,  Life  Technologies, 
Paisley,  UK)  in  Tris  Borate  EDTA  (TBE)  buffer  (Sigma,  Poole,  UK).  Bands  were 
visualized by ethidium bromide (Sigma, Poole, UK) staining. Sharp, clear 28S and 18S 
rRNA bands were indicative of good quality total RNA.  A representative RNA gel is 
shown in Figure 2.1.
28S
18S
Figure 2.1: Total cellular RNA from IEC Caco-2 cell line. A representative series of 
RNA  preparations  is  shown.  28S  and  18S  rRNA  subunits  are  clearly  defined  with 
minimal evidence of RNA degradation.
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2.4.2  Reverse transcription
5pg  of total  cellular RNA was reverse transcribed to  complementary  DNA (cDNA) 
using  Moloney  murine  leukaemia  virus  reverse  transcriptase  enzyme.  In  a  typical 
reverse transcription reaction of 20pl total volume,  lpl (0.5pg) oligo-dT was added to 
5pg of RNA and heated to 70°C for  lOmin followed by immediate chilling on ice to 
enhance  specific  annealing  between  oligo-dT  primer  and  the  poly-A  tail  of mRNA 
molecules.
The remaining components of the reaction mix:
5 x First strand buffer  4pl
0.1MDTT  2pl
deoxynucleoside Triphosphates (dNTPs)  lpl 
100U Enzyme (reverse transcriptase)  1  pi
were added to the RNA : oligo-dT complex and the reaction allowed to proceed at 42°C 
for lh. Reaction was terminated by heat inactivation at 70°C for lOmin.
2.4.3  Polymerase chain reaction (PCR)
cDNA obtained was used in subsequent PCR reactions. Each reaction volume was 50pl, 
comprising the following components:
10 x PCR Buffer [200mMTris-HCl (pH8.4), 500mM KCL]  5pl
50mM MgCl2  1.5pl
1  OmM dNTP mix  1  pi
20 pmol each oligonucleotide primer  2 pi
0.5 units Taq polymerase  0.2pl
cDNA  1-5 pi
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The remainder consisted of RNase free water to make up a total volume of 50pl. Master 
mixes  were  prepared  for  multiple  reactions  to  minimize  inter-sample  variation. 
Sequences of innate defence gene primers utilised in this study are listed in Table 2.2. 
The contents of the PCR reaction were briefly centrifuged prior to amplification in a 
thermal cycler (Peltier Thermal Cycler, MJ Research, Massachusetts, USA). Conditions 
were:
a)  94°C for 3min to denature the template
b)  94°C denaturation for 90sec 
60°C annealing for 90sec 
72°C extension for 90sec
1  cycle
>-  - 32-37 cycles
c)  72°C for lOmin - 1  cycle
PCR products were separated by agarose gel electrophoresis and visualized by ethidium 
bromide  staining.  Semi-quantitative  analyses  were  performed  by  densitometric 
measurements of innate gene expression bands and normalized to the house-keeeping 
gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Alpha Imager, Multimage 
Light Cabinet, Alpha Innotech Corporation, Essex, UK).
68CHAPTER 2
Target gene Sense primer Anti-sense primer Product 
size in (bp)
hBD-1 lraTTG  TCT  GAG  ATG 
GCC  TCA  GGT  GGT 
AAC136
362ATA CTT CAA AAG CAA 
TTT TCC TTT AT337
253
hBD-2 1 1  CCA  GCC  ATC  AGC 
CAT GAG GGT CTT34
287CAT GTC GCA CGT CTC 
TGA TGA GGG AGC261
276
hBD-3 202GGT  GAA  GCC  TAG 
CAG CTA TGA GGA TC227
385GAG CAC TTG CCG ATC 
TGT TCC TCC362
183
Lysozyme ,08GAA  CTC  TGA  AAA 
GAT TGG GAA TGG A 1 3 2
463ACA ACC TTG AAC ATA 
CTAACGGACA439
355
IL-8 4IATG ACT tcc aag ctg 
GCC GTG62
308TCT CAG CCC TCT TCA 
AAA ACT TCT C332
291
NODI 22W GTT  GTC  CAA  AGC 
CAA ACA GAA ACTC 2233
237IGCC CAC GTT CAT CTG 
GAT GCTG2392
183
NOD2 i»7AXg  TGC  TCG  CAG 
GAG GCT TTT CAG GCA
213
988 GTG CTG GTG GTG GGT 
GAG GCG 1008
823
GAPDH 63U cta  ctg  gcg  ctg
GCAAGGCTGT6 5 1
789GCC ATG AGG TCC ACC 
ACC CTG CTG966
359
Table 2.2: Sequences of synthetic oligonucleotide primers utilized in this study.
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2.5  Protein analysis
Equipment and reagents for Western blotting were from Bio-Rad Laboratories, Hemel 
Hempstead, UK and Amersham Biosciences, St Albans, UK. A detailed list of all gel 
components  and  buffer  recipes  used  is  provided  in  Table  2.3  and  2.4  respectively. 
Antibodies used are listed in Table 2.5.
Gel Components
16% Resolving gel
Component Volume 
(~30ml ) 1  large gel
5% Stacking gel
Component Volume 
(~20ml) for 2 gels
Water 5.9 10.0
Glycerol 4g (a 3.17ml) None
30% Acrylamide mix
(Protogel, National Diagnostics, UK)
10.8 3.4
3 M Tris-Cl (pH 8.45) 10.0 6.2
10% SDS 0.3 0.2
10% Ammonium persulphate 0.05 0.05
TEMED 0.015 0.025
Table 2.3: Composition of Tris-Tricine SDS- Polyacrylamide Gels.
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Buffer Composition
SDS Sample buffer (lx) 200mM Tris-HCl (pH 6.8), 40% glycerol, 2% SDS, 0.04% 
Coomassie Blue
Electrophoresis Buffer 
(pH 8.3)
lOOmM Tris, lOOmM Tricine, 0.1% SDS
Transfer Buffer lOOmM Tris, lOOmM Tricine
Blocking buffer 1  x TBS/0.1 % Tween-20, 5% w/v nonfat dry milk (Marvel)
Table  2.4  Buffer  composition  for  Tris-Tricine  SDS  PAGE.  All  reagents  were 
purchased from Sigma or BDH Laboratories, Poole, UK.
Primary Antibody Source Dilution Company
hBD2 Goat polyclonal IgG 1:500 Autogen Bioclear, 
Wiltshire, UK.
hBD3 Rabbit polyclonal IgG 1:1000 Gentaur Molecular, 
Brussels, Belgium.
Secondary Antibody
Anti-rabbit  antibody 
conjugated to  horseradish 
peroxidase
Goat anti-rabbit IgG 1:2000 Cell Signalling Technology, 
Boston, USA.
Anti-goat  antibody 
conjugated to horseradish 
peroxidase
Rabbit anti-goat IgG 1:2000 Dakocytomation Ltd, 
Cambridgeshire, UK.
Table 2.5: Antibodies utilised in the present study.
71CHAPTER 2
2.5.1  Intestinal epithelial p-defensin peptide extraction
Experiments were routinely set up in 25cm2 or 75cm2 tissue culture flasks and bacterial 
co-culture performed over 24h. Protein was extracted from both cells and supernatants 
of infected cells as well as uninfected controls. Supernatants were removed and glacial 
acetic  acid  (100%)  added in appropriate  amounts to  achieve  a final concentration of 
20%. 4ml of 20% acetic acid was added to each 75cm  tissue culture flask.  Following 
overnight incubation on a rotary shaker (Rotatest shaker, Denley, UK), cell lysates and 
supernatants were transferred into  1.5ml eppendorfs, and homogenised by shearing and 
sonication (Bandelin Sonopuls, Bandelin Electronics, Berlin, Germany) for 10-15 sec on 
a power setting of  ~60%. Resuspended proteins post centrifugation  (1.200g, 20min) 
were  further  concentrated  by  lypholization  (Heto  Dry Winner,  Allerod,  Denmark). 
Lypholised protein contents were resuspended in  lOnM acetic  acid and quantified by 
Bradford assay as described below (Sigma, Poole, UK).
2.5.2  Protein quantification (Bradford assay)
Protein  amounts  were  determined  using  a  Bradford  assay.  Bovine  Serum  Albumin 
(BSA)  standards of varying concentrations  (2pg to  25 pg)  and protein samples were 
prepared in a volume of 1ml. Equal amount of Bradford reagent (Sigma, Poole, UK) was 
added  to  each  sample,  vortexed  gently  and  left  at  37°C  for  30min,  prior  to  OD 
measurements at 595nm. Protein concentration was determined using the standard curve 
plotted for BSA.
2.5.3  Tris-Tricine Sodium Dodecyl Sulphate Page Electrophoresis (SDS-PAGE)
Samples  were  prepared  by  the  addition  of  tris-tricine  loading  buffer  (Bio-Rad 
Laboratories, Hemel Hampstead, UK) and lOmM P-Mercaptoethanol prior to heating at 
95-100°C for 5min. After cooling on ice and centrifugation, samples were subjected to
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Tris-Tricine  SDS-PAGE.  Commercial  Tris-tricine  markers  (Bio-Rad  Laboratories, 
Hemel Hempstead, UK) allowed for molecular weight determination and a visual check 
for transfer  efficiency.  Recombinant peptides  (hBD-2,  4.3kDa  and  hBD-3,  5.1kDa; 
Peprotech, Ltd., London, UK) served as positive controls.  Typically, 20pg total protein 
was loaded and run at 100V for 2-4h. Protein detection was followed by silver staining 
(Bio-Rad  Laboratories,  Hemel  Hampstead,  UK).  Following  electrophoresis,  proteins
'y
were transferred onto a polyvinylidene difluoride (PVDF) membrane at 0.8mA/cm  for 
40min  using  a  semi-dry  transfer  system.  Prior  to  transfer,  PVDF-membrane  was 
prepared by soaking in  100% methanol followed by three washes in PBS.  Membrane 
and gels were allowed to equilibrate in chilled transfer buffer for at least 5min.  After 
transfer,  UV  cross-linking  (auto-crosslink  setting)  was  performed  on  membrane 
followed by blocking of non-specific binding in 5% non-fat milk/Tris-buffered saline 
(TBS,  Sigma, Poole, UK) for l-2h at RT with gentle  shaking.  This was followed by 
overnight  incubation  in  anti-hBD-2  or  hBD-3  antibody  in  blocking  buffer  on  a 
suspension mixer at 4°C. After 3-4 washes in TBS with 0.1% Tween-20 (TBS/T) for 
lOmin each, the blot was incubated in relevant secondary antibody for lh on the rotary 
shaker at RT. Blots were washed 3-4 times for lOmin with TBS/T before being exposed 
to an enhanced chemiluminescence (ECL) reaction for 5min, where  1ml of reagent A 
was  added  to  25pi  of reagent  B  (ECL  plus,  Amersham  Biosciences,  UK).  Excess 
solution was drained, the membrane placed between a sheet of clingfilm and exposed to 
an  x-ray  film  (Hyperfilm  ECL).  Development  of  film  ranged  between  3-5min  as 
necessary.
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2.5.4  IL-8 Enzyme linked immuno-sorbent assay (ELISA)
IL-8 protein concentration was measured in cell supernatants using Quantikine Human 
CXCL8/IL-8 Immunoassay (R&D Systems, Abingdon, UK). All solutions, buffers and a 
96 well polystyrene microplate coated with mouse monoclonal  antibody  against IL-8 
were  included  in the kit.  Analysis was performed according to  instructions provided. 
Briefly, IL-8 standard was diluted in Calibrator Diluent to concentrations ranging from 
2000 to 15.6pg/ml. lOOpl of assay diluent (RD1-85) was placed in each well and 50pl of 
standard, control or sample added. Following 2h incubation at RT, wells were washed 4 
times using 400pl of wash buffer.  Complete removal of all liquid was ensured and wells 
incubated with lOOpl of conjugate for lh at RT. Following washes, 200pl of substrate 
solution was added and left for 30min prior to addition of 50pl stop solution. Optical 
density  was  measured  within  30min  using  a  microplate  reader  set  at  450nm  (MRX 
Revelation,  MTX Lab  System Inc., Virginia, USA)  and amount of protein calculated 
according to standard curve.
2.6  Luciferase promoter-constructs and over-expression plasmids
Renilla,  IL-8, and NF-kB promoter plasmids and pcDNA were generous gifts from Dr 
.Andrew Bowie  (Trinity  College,  Dublin,  Ireland).  Luciferase  reporter  constructs  of 
hBD-2 and hBD-3 were kind gifts from Mr Shao-ren Wang (Institute of Child Health, 
London,  UK)  and  Dr  Ole  Sorensen  (Lund  University,  Lund,  Sweden)  respectively. 
NOD2  overexpression  plasmids  were  kindly  provided  by  Professor  G.  Nunez 
(Department of Pathology and Comprehensive Cancer Centre, University of Michigan 
Medical School, Ann Arbor, Michigan, USA).
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2.6.1  Transformation of plasmid DNA
Plasmid DNA was transformed into JM109 competent cells (Promega,  Southampton, 
UK) according to the protocol provided. Plasmid DNA (l-10ng) was added to 50pl of 
thawed competent cells and left on ice for 30min. Sporadic flicking of the tube ensured 
DNA adherence to cell membranes. Cells/DNA complex were heat-shocked for 2min at 
42°C and immediately placed on ice for a further 5min.  1ml LB (Luria Bertani) broth 
(Merck, Hertfordshire, UK) containing lOmM MgCl2 and lOmM D-glucose was added 
and the mixture further incubated for lh at 37°C with gentle shaking. Dilutions of the 
transformation reaction were plated (lOOpg/ml  ampicillin in LB  agar) and incubated 
overnight at 37°C. The following day colonies were analysed appropriately.
2.6.2  Purification of plasmid DNA
Plasmid  DNA  was  purified  using  Qiagen  (Crawley,  West  Sussex,  UK)  EndoFree 
Plasmid Maxi Kit, which included instructions and all reagents. Briefly, a single colony 
was used to inoculate a starter culture of 5ml LB broth (plus ampicillin lOOpg/ml) and 
incubated for a few hours at 37°C with vigorous shaking (300rpm,  Innova Incubator 
Shaker, New Brunswick Scientific, UK). The starter culture was diluted further (1  in 
50) and shaken overnight at 37°C for a large scale plasmid preparation.
Bacterial  cells  were  harvested  16h  later  by  centrifugation  (6000rpm,  15mins,  4°C, 
Sorvall RC SB,  Survall Instruments, Connecticut, USA). The resulting cell pellet was 
resuspended  in  10ml  of Buffer  PI,  followed by the  addition  of 10ml  of buffer  P2. 
Contents were mixed by inversions and incubated at RT for 5min.  10ml chilled Buffer 
P3  was added and mixed by inversion before incubation on ice for 20min.  The latter 
step allowed precipitation of proteins and chromosomal DNA from the bacterial cell 
suspension.
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Cellular debris was removed by  centrifugation (13,000rpm,  30min,  4°C;  Sorvall RC 
SB). The resultant supernatant containing plasmid DNA was removed and recentrifuged 
to ensure complete removal of particulate debris.  Plasmid DNA was further purified 
using the Qiagen-tip column. The column was equilibrated in 10ml Buffer QBT prior to 
usage.  Supernatant was applied to the  column under gravity  and washed twice with 
30ml Buffer QC. Plasmid DNA was eluted from the column in 15ml buffer QF. Plasmid 
DNA  was  precipitated  by  the  addition  of 0.7  volumes  isopropanol  and  centrifuged 
promptly at 15,000g for lOmin (Sorvall RC SB). The resultant DNA pellet was allowed 
to air-dry for lOmin before the addition of Tris EDTA buffer, pH 8. Integrity of plasmid 
DNA  was  checked  by  agarose  gel  electrophoresis  and  concentrations  calculated  by 
spectroscopy (ratio 260/280nm), as follows:
[(reading at 260nm) x (dilution factor) x 50] /1000.
2.6.3  Transient transfection of epithelial cell lines
In initial optimisation experiments three epithelial cell lines were utilised.  Cells were 
seeded in 96-well plates at a density of 1  x 104 cells /well in 200pl DMEM (for Caco-2 
and HT-29) or MEM (for Hep2) complete media. Transfection was performed when cell 
monolayers  reached  50-80%  confluency.  For  transfection,  FuGene  reagent  (Roche, 
Lewes, UK) in a ratio of 4:1 (DNA in pg : FuGene in pi) was used as recommended. 
Each transfection comprised a total DNA content of 230ng. This included:
a)  60ng:  Firefly  luciferase  construct  under  investigation,  i.e.  NFkB,  hBD-2,  -3 
promoter, or over-expressing NOD 2 plasmids.
b)  20ng:  Renilla  luciferase  construct,  to  measure  transfection efficiency and
account for cell loss (only for luciferase reporter gene assay).
c)  150-170ng: Empty vector (pcDNA) was added to  equalise the total  amount  of
DNA between all experiments.
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A master mix of transfection reagent was prepared by adding FuGene (0.8pl/well) to 
low serum media (9.2 p 1/well, Optimem, Invitrogen, Paisley, UK) and incubated at RT 
for a minimum of 15min. DNA was added and the mix incubated for a further 20min to 
allow DNA- Fugene complex formation, before the addition of lOpl of this master mix 
to each well. Negative controls (empty vector alone and no DNA) were also included. 
Transfections were allowed to proceed for 24h prior to cytokine or bacterial stimulation.
2.6.4  Luciferase reporter gene assay
Following  transfection of luciferase  and renilla reporter  constructs  and bacterial  co­
culture, cells were harvested by removing media followed by washes with ice-cold PBS. 
50pl of 1   x passive lysis buffer (Promega, Southampton, UK) was added to each well. 
Plates were left at -80°C until required. For analysis, 20pl cell lysate was transferred to 
2  luciferase assay plates.  One plate was subjected to Renilla luciferase  assay, where 
40pl of its substrate, Coelentrazine (Insight Technologies, London, UK) was added to 
each well.  lOOpl firefly luciferase substrate (Promega, Southampton, UK) was added to 
each well in the  second plate.  IL-ip (20ng/ml), a potent agonist for IL-8 and hBD-2 
gene expression was included as a positive control. A 96-well plate luminometer was 
utilised  for  measuring  luciferase  and  renilla  activity  (LUCY1,  Anthos  Labtech 
Instruments,  Salzburg,  Austria).  Promoter  activity  was  analysed  by  normalising 
luciferase readings against renilla. Fold induction compared to non-stimulated control 
cells was deduced as follows:
Stimulated cells: [(luciferase reading) / (renilla reading)]
---------------------------------------------------------------------------------  = Fold induction
Non-Stimulated cells: [(luciferase reading) / (renilla reading)]
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2.7  Statistics
Results  are  routinely  presented  as  mean  +/-  Standard  Error  of Mean  (+/-SEM).  All 
experiments  were  conducted  at  least  three  times  with  transfection  and  colonisation 
assays performed in triplicate in each experiment.  Statistical analyses were performed 
using GraphPad Instat statistical software, variables were compared using a t test, and a 
probability value of <0.05 was regarded as significant.
78CHAPTER 3
Regulation of intestinal epithelial IL-8 
and human p-defensins in response
to C. jejuni
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3.1  Introduction
The intestinal epithelium is formed by a monolayer of highly specialized cells, joint by 
tight junctions and covered by a thick mucus film.  It is now widely accepted that it 
provides not only a physical barrier between the lumen and the underlying mucosa but 
also functions as a critical sensor for infections (Eckmann, 2006).  Following specific 
sensing of a potential pathogen, the Gl-epithelium is able to produce an array of innate 
defence molecules including cytokines, chemokines and antimicrobial peptides (Bevins 
et al., 1999; O'Neil et al, 1999; Ouellette, 2004; Eckmann and Kagnoff, 2005). Studies 
investigating the role of intestinal epithelial innate defence during C. jejuni infection are 
limited.  Previous  studies  have  shown  induction  of  the  proinflammatory  cytokine, 
interleukin-8  (IL-8)  by  the  intestinal  epithelium  in  response  to  C.  jejuni  infection 
(Hickey et al., 1999; Hickey et al, 2000; Watson and Galan, 2005). IL-8 and other pro- 
inflammatory  mediators  are  thought  to  be  involved  in  initiating  the  host  mucosal 
inflammatory response leading to diarrhoea and clearance of infection suggesting a role 
in disease pathogenesis (MacCallum et al, 2006). Endogenous antimicrobial peptides 
such as the a- and p-defensin family, LL37 and lysozyme are known to be produced by 
the GI Paneth cells and epithelia. Evidence is accumulating suggesting a role for these 
peptides in GI host defence. However, the potential role of IEC antimicrobial peptides, 
specifically hBDs, in C. jejuni disease pathogenesis remains unknown. To gain a better 
understanding  of IEC  innate  defence  in  response  to  C.  jejuni  we  initiated  studies 
investigating a potential role of hBDs during C. jejuni infection. Using two intestinal 
epithelium cell lines (HT-29 and Caco-2) as an in-vitro model, co-culture experiments 
with live WT C. jejuni strains 11168H and 81-176 were performed and hBD gene and 
protein expression was analysed by RT-PCR and Western blotting respectively.  IL-8 
gene expression was followed in parallel and used as a marker for infectivity in our 
model system. Furthermore, transcriptional regulation of IL-8, hBD-2 and hBD-3 wasCHAPTER 3
also studied utilising their respective luciferase promoter constructs. As a known key 
regulator of innate gene transcription, an NF-kB promoter construct was included in our 
studies.
C. jejuni expresses several potential virulence determinants including flagellin mediated 
motility, adhesion and invasion of IECs (Wassenaar et al.,  1993; Hickey et al,  1999; 
Zheng et al, 2006). Additionally, the genome sequence of C. jejuni 11168 revealed the 
presence of a previously unsuspected capsular polysaccharide (CPS) locus that encodes 
a structure similar to the group II CPS described for Escherichia coli (Karlyshev et al, 
2000; Parkhill et al, 2000b; Karlyshev et al, 2001).  The role of this capsule to date 
remains poorly defined. In order to gain further insight into the potential contribution of 
the bacterial capsule in eliciting host responses, an isgenic capsule mutant of C. jejuni 
strain 11168H (kpsM) was utilised in the present study.
3.2  Results
3.2.1  Modulation of IEC IL-8 and fi-defensins gene expression during C. jejuni 
infection
IEC IL-8,  hBD-1, hBD-2,  and hBD-3  gene  expression during  infection with WT  C. 
jejuni was  investigated.  Two virulent  WT  strains  81-176  and  11168H  were  chosen, 
which have been used frequently in other studies and shown to vary in their virulence 
and genetic set up (Bacon et al, 2000; Ringoir and Korolik, 2003; Poly et al, 2005). 
Co-culture experiments were performed over 24h, earlier innate immune events were 
monitored at 6h and lOh time points. Induction of IL-8 was observed in Caco-2 and HT- 
29 cells with two WT strains, these results were in agreement with previously published 
reports (Figure 3.1a and b, top lane). HBD-1  was found to be expressed in uninfected 
cells  and  no  further  modulation  was  observed  during  the  24h  course  of infection, 
suggesting no direct effect of C. jejuni (Figure 3.1a and b,  second lane).  HBD-2 andCHAPTER 3
hBD-3 expression was undetectable in uninfected control cells; however, both bacterial 
strains  induced the  expression of these two  antimicrobial  peptides  in both cell lines 
(Figure 3.1a and b third and fourth lane). Similar to IL-8, induction of hBD-2 and hBD- 
3 mRNA levels was observed as early as 6h and induction persisted over the 24h time 
interval.  No  significant  difference  in  IL-8,  hBD-2  and  hBD-3  gene  regulation  was 
observed between time points, bacterial strains or cell-line. However, induction of hBD- 
3 in response to both WT strains was found to be consistently modest in HT-29 when 
compared to Caco-2 cells (Figure 3.1a and b, fourth line).
In order to  further investigate potential  kinetic differences  of innate  gene regulation 
between the two bacterial strains, semi-quantitative analysis was performed using spot- 
densitometry.  Data  from  two  to  three  independent  experiments  were  analyzed  and 
average +/- SEM calculated. As shown in Figure 3.1c and d, constitutive expression of 
hBD-1  was  confirmed  with  no  further  modulation  observed  in  either  cell  line 
irrespective of WT strain utilised. Regulation of inducible innate genes was found to be 
similar for both WT strains and cell lines tested with an average of 2-3 fold increase in 
mRNA  expression.  Although,  no  significant  differences  were  observed  a  trend  for 
maximum gene induction of IL-8, hBD-2 and hBD-3  at  lOh post-infection was noted 
(Figure 3.c and d). Further, WT strain 81-176 was found to be more potent in inducing 
innate gene expression compared to 11168H strain, however this did not reach statistical 
significance.
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Figure  3.1a  and  b:  Modulation  of IEC  IL-8  and  hBD  gene  expression  during 
C. jejuni  infection  in  Caco-2  (a)  and  HT-29  (b)  cells.  Semi-confluent  cells  were 
infected with WT C. jejuni strain  11168H and 81-176 at an MOI of 100. Experiments 
were stopped after 6, 10 and 24h and innate gene expression analysed by RT-PCR. Un­
infected  cells  and  cells  stimulated  with  IL-lp  (20ng/ml)  were  used  as  negative  and 
positive  control,  respectively.  Experiments  were  performed  at  least  3  times,  a 
representative gel is shown.
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Figure 3.1c:  Semi-quantitative analysis of IL-8  and hBD  gene expression during 
C. jejuni infection  in  Caco-2  cells.  Cells  were  infected  with  WT  C. jejuni  strains 
11168H and 81-176. IL-8, hBD-1, hBD-2 and hBD-3 gene expression 6h, lOh and 24h 
post-infection was determined by RT-PCR. Gels were subjected to spot densitometric 
analysis and induction of mRNA levels presented as n-fold calculated compared to un­
infected controls.  Analysis of the housekeeping gene GAPDH was used to normalize 
gene expression. Data shown as mean (+/- SEM) induction of two to three independent 
experiments.
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Figure 3.1d:  Semi-quantitative analysis of IL-8 and hBD gene expression during 
C. jejuni infection in HT-29 cells. Data expressed as n-fold induction of mRNA levels 
compared to uninfected control cells. Error bars indicate mean (+/- SEM) induction of 
two to three independent experiments with similar results.
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3.2.2  Induction of hBD-2 and hBD-3 peptide expression in response to C. jejuni 
infection
Expression  of  hBD-2  and  hBD-3  peptides  by  IEC  in  response  to  C.  jejuni  was 
investigated. Caco-2 cells were infected with WT strain 11168H and Western blotting 
performed  following  24h  co-culture.  In  order  to  determine  if  hBDs  are  stored 
intracellularly  or  are  mainly  secretory  in  nature,  both  cell  lysates  and  culture 
supernatants were analysed for the presence of peptide. Recombinant hBDs were used 
as  positive  controls.  As  shown in Figure  3.2  (top  lane)  hBD-2  was  undetectable  in 
uninfected controls (cells or supernatant), however the peptide was found to be present 
in the supernatant of cells infected with C. jejuni.  Similarly, we observed undetectable 
levels of hBD-3 in un-stimulated cells (and supernatant, data not shown). However, the 
lysate of cells infected with C. jejuni 11168H was found to contain significant amounts 
of mature hBD-3 protein (Figure 3.2, bottom lane).
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Figure  3.2:  HBD-2  and  hBD-3  peptides  are  induced  in  response  to  C.  jejuni 
11168H.  Semi confluent Caco-2 cells were infected with WT C. jejuni strain  11168H 
for 24h. Culture supernatants (top lane) and cell lysates (bottom lane) were subjected to 
Tris-Tricine  SDS-PAGE,  followed  by  Western  blotting.  Recombinant  peptides  were 
included as positive control.
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3.2.3  The role of C. jejuni capsular polysaccharide (CPS) in modulating IEC 
innate defence
An isogenic capsule deficient mutant of C. jejuni NCTC 11168H; kpsM was employed 
to investigate the role of CPS in modulating innate immune gene expression. As for WT 
bacteria,  kpsM was grown on blood agar plates over 24h prior to use.  Bacterial co­
culture with Caco-2 and HT-29 cells was performed at an MOI of 100 and expression of 
innate  genes  analyzed  using  RT-PCR.  In  figure  3.3a  (Caco-2)  and  b  (HT-29)  a 
representative of at least 3 independent experiments is shown.
Similar to the parental WT strain (Figure 3.1a and b), the capsule deficient mutant was 
found to induce IL-8, hBD-2 and hBD-3 as early as 6h post infection in both cell-lines 
tested and induction was maintained until the 24h time point (Figure 3.3a and b lanes
1.3 and 4). Importantly, the absence of CPS did not lead to any detectable difference in 
modulation of hBD-1, with expression remaining constitutive throughout the tested time 
interval  (Figure 3.3a and b lane 2).  Semi-quantitative analysis by  spot densitometry 
suggested a 2 to 3-fold induction of IL-8, hBD-2 and hBD-3 by kpsM in both cell-lines 
(Figure  3.3c and d). No  significant differences were observed between magnitude  or 
kinetics of all innate genes tested when compared to parental WT strain 11168H (Figure 
3.1c and d).
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Figure 3.3a and b:  Modulation of IEC IL-8 and hBD gene expression by capsule 
deficient C. jejuni kpsM in Caco-2 (a) and HT-29 (b) cells. Semi-confluent cells were 
infected with an  isogenic  capsule  deficient mutant strain of C. jejuni  strain  11168H, 
kpsM at an MOI of 100. Experiments were stopped after 6,  10 and 24h post infection, 
innate gene expression was analysed by RT-PCR. Un-infected cells and cells stimulated 
with  IL-l|3  (20ng/ml)  were  used  as  negative  and  positive  control,  respectively. 
Experiments were performed at least 3 times, a representative gel is shown.
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Figure 3.3c:  Semi-quantitative analysis  of IL-8 and hBD  gene expression  during 
C. jejuni kpsM infection in Caco-2 cells.  Cells were infected with capsule deficient 
isogenic mutant of WT C. jejuni 11168H, kpsM. IL-8, hBD-1, hBD-2 and hBD-3 gene 
expression  6h,  lOh  and  24h  post-infection  was  determined  by  RT-PCR.  Gels  were 
subjected  to  spot  densitometric  analysis  and  induction  of mRNA  levels  calculated 
compared to un-infected controls. Housekeeping gene GAPDH was used to normalize 
gene expression. Increases in mRNA levels are expressed as n-fold induction compared 
to  uninfected control  cells.  Data shown is mean (±  SEM)  induction of two  to three 
independent experiments.
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Figure 3.3d:  Semi-quantitative analysis of C. jejuni kpsM mediated modulation of 
IL-8  and  hBD  expression  in  HT-29  cells.  Spot-densitometry  was  performed  and 
modulation of IL-8 and hBD expression in response to C. jejuni kpsM analysed. Results 
are presented as mean +/- SEM of two to three independent experiments.
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3.2.4  IEC innate gene promoter studies during C. jejuni infection
Luciferase  reporter  gene  assays  are  a powerful  tool  for  molecular  analysis  of gene 
regulation. The promoter region of the gene of interest is cloned into a vector, which 
can then be  introduced into target cells, by  a mechanism referred to  as transfection. 
With  the  promoter  cloned  upstream  of  luciferase  coding  sequence,  appropriate 
promoter-activation  should  drive  the  expression  of  the  luciferase  enzyme.  The 
subsequent  measurement  of  luciferase  enzymatic  activity  is  therefore  indicative  of 
promoter function. Further, greater reliability is achieved by co-transfection of renilla, a 
vector that is  expressed constitutively  regardless  of any  stimuli.  Inclusion  of renilla 
vector provides a standard against which differences in cell numbers and transfection 
efficiency can be normalized. Finally, comparison of unstimulated versus infected cells 
allows quantification of the degree of promoter activation of the gene of interest. For 
greater detail notes by Promega Ltd. are recommended.
As RT-PCR only provided a semi-quantitative measure  of IL-8  and  (3-defensin gene 
induction in response to C. jejuni, it was thought pertinent to investigate gene activation 
in greater detail. This was done by the inclusion of measurements of IL-8, hBD-2 and 
hBD-3 promoter-specific luciferase function. Furthermore, as a known central regulator 
of IEC innate gene transcription, an NF-kB promoter construct was also included in 
order to investigate potential differences of WT and mutant strains in their ability to 
modulate innate immune response.
3.2.4.1  Method optimization
For initial optimization Hep2 cells were utilized mainly because this cell line exhibits 
high transfection efficiency.  Various parameters (e.g. amount of DNA transfected, ratio 
of DNA to transfection reagent, cell numbers and time course) were optimized using 
NF-kB and  IL-8 promoter constructs. A representative experiment is shown in Figure 
3.4. Following transfection, cells were co-cultured with WT C. jejuni 11168H and 81-
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176 strains over 6 and 20h. TNF-a, like IL-l p is a potent activator of IEC responses and 
was included as positive control. A 2 to 2.5-fold induction of IL-8 and NF-kB promoter 
activity was noted in response to both WT strains (Figure 3.4a). A maximum of 3.5-fold 
induction after stimulation with TNF-a was observed both at 6 and 20h.
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Figure  3.4a:  Optimization  of IL-8  promoter activity  in  response  to  C. jejuni in 
Hep2 cell line. Hep2 cells were transiently transfected over 20h followed by co-culture 
with WT  C. jejuni  strains  11168H and  81-176  for 6  and 24h.  Cells  stimulated with 
TNF-a  were  included as positive  controls.  Following  stimulation,  luciferase  activity 
was measured and individual readings normalized against renilla.  Fold induction was 
calculated compared to unstimulated control cells. Experiments were performed two to 
three times in triplicates.  A representative experiment is  shown;  arrow bars  indicate 
average +/- SEM of triplicate values.
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Following  optimization  in  Hep2  cells,  experiments  were  conducted  in  intestinal 
epithelial  HT-29  and  Caco-2  cell-lines.  Dose  dependant  induction  of IL-8  promoter 
activity by WT C. jejuni  11168H was found after 20h (Figure 3.4b). IL-l(3, a potent 
agonist  for  IL-8  and  hBD2  induction  was  routinely  included  as  a positive  control. 
Amongst the two cell-lines tested, Caco-2 cells consistently showed greater and more 
reliable transfection efficiency with higher promoter activity when compared to HT-29 
cells (Figure 3.4b). For this reason subsequent studies were performed in Caco-2 cells.
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Figure 3.4b and c:  Optimization of IEC IL-8 promoter activity in response to C. 
jejuni. HT-29 (b) and Caco-2 (c) cells were transiently transfected over 20h followed by 
co-culture with WT C. jejuni strain 11168H for 20h. Infection was performed at an MOI 
of 1   and  100 in HT-29 and MOI of 100 in Caco-2 cells. Cells stimulated with IL-lp 
served as a positive control. Luciferase activity was normalized against renilla and fold 
induction calculated compared to unstimulated control cells. A representative of 2 to 3 
independent experiments is shown; arrow bars indicate average +/- SEM of triplicate 
values.
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3.2.4.2  Regulation of innate immune gene promoter activity by C. jejuni
Following  optimization,  the  ability  of  WT  C.  jejuni  81-176,  11168H  and  capsule 
deficient isogenic mutant kpsM to regulate innate immune genes was investigated. NF- 
kB and IL-8 promoter constructs were transiently transfected into Caco-2 cells followed 
by bacterial co-culture over 20h. As shown in Figure 3.4d, two to three-fold induction 
of NF-kB  promoter  activity  was  observed  for  all  bacterial  strains  tested,  with  no 
significant differences noted between WT or mutant strain. Induction of IL-8 promoter 
was also found to be similar for all bacterial strains tested (Figure 3.4e).  Stimulation 
with IL-l p led to 4-fold induction of both NF-kB and IL-8 (Figure 3.4d and e). Initial 
time  course  experiments  revealed  no  significant  differences  in  promoter  activities, 
however  induction  was  found  to  be  most  consistent  after  20h  co-culture  (data  not 
shown).
Regulation of hBD-2 and hBD-3 promoter activity by C. jejuni was also investigated. 
Similar to NF-kB and IL-8, WT C. jejuni caused two to three fold induction of both 
hBD-2 (Figure 3.4f) and hBD-3 (Figure 3.4g) promoters with the latter one providing a 
more modest response.  The kpsM mutant was found to be equally potent in inducing 
hBD-2 and hBD-3 promoter activity.
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Figure 3.4d  and  e:  NF-kB  and  IL-8  promoter activity  in  response to  C. jejuni.
Caco-2 cells were transiently transfected with NF-kB and IL-8 promoter constructs over 
24h.  Bacterial  co-culture  with  WT  C.  jejuni  strains  81-176,  11168H  and  isogenic 
capsule deficient kpsM was performed at MOI of 100 for 20h. Cells stimulated with IL- 
1(3 (20ng/ml) were included as positive control. Luciferase activity was measured and 
individual readings normalized against renilla. Promoter activity is expressed as n-fold 
induction compared to unstimulated control cells. Arrow bars indicate average +/- SEM 
of three independent experiments performed in triplicate.
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Figure 3.4f and g:  HBD-2  and hBD-3 promoter activity in response to C. jejuni.
Caco-2 cells were transiently transfected with hBD-2 and hBD-3 promoter constructs 
over 24h. Co-culture with WT C. jejuni strains 81-176,  11168H and isogenic capsule 
deficient kpsM was carried out for 20h at MOI  of 100.  Cells  stimulated with IL-lp 
(20ng/ml) served as positive control. Luciferase activity was measured and individual 
readings normalized against renilla. Promoter activity is expressed as n-fold induction 
compared to unstimulated control cells. Arrow bars indicate average +/- SEM of three 
independent experiments performed in triplicate.
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3.3  Discussion
C. jejuni is a commensal organism of poultry but represents a major health burden in 
humans. Poultry are routinely colonized with up to  1000 C. jejuni cells per g of cecal 
contents  in  an  apparently  commensal  association that  causes  little  or  no  pathology 
(Shreeve et al, 2000). In contrast, as few as 800 C. jejuni cells are sufficient to cause 
severe inflammatory gastroenteritis in human volunteer studies (Black et al, 1988). The 
bacterium  causes  a  spectrum  of  clinical  diseases,  yet  in  the  majority  of  healthy 
individuals, the infection is short lived and self limiting, suggesting an important role 
for  innate  immunity  in  detecting  and  clearing  the  infective  agent.  The  intestinal 
epithelium  as  the  first  line  of defence  not  only  provides  a  physical  barrier  to  the 
underlying mucosa but also produces several innate defence molecules upon microbial 
sensing, such as the pro-inflammatory cytokine IL-8. Several studies have demonstrated 
secretion of IL-8 by IEC in response to C. jejuni and this mechanism is thought to play 
an important role in initiating the inflammatory response observed in-vivo (Hickey et 
al, 1999; Hickey et al, 2000; Watson and Galan, 2005). As a second part of host innate 
defence, host epithelial antimicrobial peptides have been shown to  contribute to host 
defence at mucosal surfaces (Ganz, 2003; Salzman et al, 2003; Dommett et al, 2005). 
Dynamic modulation of p-defensins has been demonstrated with various models of GI 
infection and inflammation (O'Neil et al,  1999; Bajaj-Elliott et al, 2002; Wehkamp et 
al,  2003a).  However,  to  date,  the  role  of these  peptides  during  C. jejuni  infection 
remains unknown.
The aim of this part of the study was to investigate the regulation of IEC p-defensins 
during  C.  jejuni  infection.  Expression  of  IL-8  was  also  investigated  in  parallel, 
primarily as it served as an indicator for degree of infectivity in our cell line model. 
Using two IEC-lines (Caco-2 and HT-29), we demonstrated constitutive expression of 
hBD-1. Infection with two WT strains of C. jejuni 11168H and 81-176 did not have any
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effect on hBD-1  gene expression in either cell line over a 24h time course, suggesting 
that C. jejuni does not regulate expression of this AMP (Figure 3.1a and b, lane 2). In 
contrast, uninfected IECs did not express hBD-2 or hBD-3, but the presence of C. jejuni 
resulted in increased expression as early as 6h post infection (Figure 3.1a and b, lanes 3 
and 4). This data highlights the ability of IECs to directly mount a fast antimicrobial 
response to the presence of C. jejuni.  In agreement with other studies we confirmed 
induction of IL-8 by both WT strains in Caco-2 and HT-29 cells (Figure 3.1a and b, 
lane 2). Induction of all innate genes tested was found to follow similar kinetics with 
induction observed as early as 6h and still maintained 24h post-infection,  suggesting 
overlapping  signalling  pathway(s)  are  likely  to  be  responsible  for  early  host  innate 
defence. Despite the lack of statistical significance, the magnitude of this response was 
found to be consistently greater with the WT 81-176 strain compared to 11168H. It has 
previously been shown that different C. jejuni strains elicit different levels of IL-8, this 
response maybe associated with the invasive potential of the bacterium under study (Hu 
and Hickey, 2005; Watson and Galan, 2005). Differences in the invasive capacity of 81- 
176  and  11168H  might  therefore  explain  the  observed  differences  in  innate  gene 
activation. Furthermore, C. jejuni strain 81-176 has been shown to harbour a plasmid 
pVir,  which has been  linked to  bacterial  virulence.  This plasmid  is  absent in  strain 
11168H providing an alternative/additional explanation for our findings (Bacon et al., 
2000;  Ringoir and Korolik, 2003;  Hu et al,  2006a).  Data obtained by RT-PCR was 
confirmed and further extended using promoter gene studies. We observed an average 2 
to 3-fold induction of NF-kB, IL-8, hBD-2 and hBD-3 promoter activity by both WT 
strains (Figure 3.4d-g).
Investigation  of hBD-2  and  hBD-3  protein  expression  in  response  to  WT  C. jejuni 
11168H  confirmed  correlation  between  innate  gene  and  protein  expression  of both 
antimicrobial peptides  (Figure  3.2).  Additionally,  hBD-2  was recovered from culture
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supernatant,  confirming  the  secretory  nature  of this  peptide  (Sorensen  et  al.,  2005; 
Kumar et al., 2006).  In contrast, hBD-3 was found in the cellular fraction.  One may 
hypothesize  that  the  differential  compartmentalization  of  hBD-2  and  hBD-3  may 
represent different frontiers of host defence, i.e. hBD-2 targeting adhering, extracellular 
bacteria, whereas hBD-3  might act on invading organisms.  In accordance with these 
findings, a similar differential distribution of hBD-2 and hBD-3 was recently reported 
in a skin model of infection and inflammation (Sorensen et a l, 2005).
Bacterial CPS has been reported to play a role in modulating host immune response. 
Investigation into the role of C. jejuni CPS in IEC responses surprisingly showed that 
the  capsule-deficient  isogenic  kpsM mutant  modulated  IL-8  and  p-defensins  gene 
expression to a similar extent to that observed for the  11168H parental strain (Figures
3.3  and 3.4).
In summary, these studies confirmed the ability of WT C. jejuni to induce expression of 
IL-8 and NF-kB.  However, this is the first study to highlight increase of hBD-2 and 
hBD-3 gene and protein expression in response to WT strains 81-176,  11168H and the 
capsule deficient mutant kpsM.
To  date,  mechanism(s)  implicated in  C. jejuni mediated  IEC  IL-8  induction include 
bacterial adherence and/or invasion, de-novo protein synthesis and the presence of CDT 
(Hickey et al., 2000; Watson and Galan, 2005). An 81-176 kpsM mutant has previously 
been shown to have a reduced ability to invade INT407 cells (Bacon et al., 2001). This 
suggests that if the 11168H kpsM mutant employed in our study also has reduced ability 
to invade intestinal epithelial cells, then induction of IL-8  by this mutant may occur 
primarily via CDT-dependant mechanism. The invasive capacities of all strains used in 
this study are currently being investigated in a collaborative study (A. Elmi, N. Dorrell,
B.  Wren,  unpublished  data).  However,  even  reduced  levels  of  invasion  might  be 
sufficient to induce IL-8 and P-defensin expression. This is supported by recent studies
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showing that despite an association between IL-8 induction and invasion, there seems to 
be no direct correlation. This aspect will be addressed in more detail in chapter 5.
In order for p-defensins to play a major role in disease pathogenesis it is not sufficient 
for these petides to be up-regulated early during the course of infection, but also to be 
capable  of inactivating  and/or  killing  the  pathogen.  The  bactericidal  potency  of p- 
defensins  against  C. jejuni  was therefore  investigated  as  described  in  the  following 
chapter.
101CHAPTER 4
Susceptibility of C. jejuni to human
|3- defensins
102CHAPTER 4
4.1  Introduction
It is becoming increasingly evident that p-defensins like chemokines are multifunctional 
molecules  with  a  wide  range  of  properties  (Ganz,  2003;  Eckmann,  2005).  What 
distinguishes these cationic peptides from other innate defence molecules is their ability 
to  directly  cause  damage  and  ultimately  kill  pathogens.  These  peptides  exhibit 
antimicrobial activity against a range of micro-organisms including Gram-positive and 
Gram-negative  bacteria,  fungi,  protozoa  and  even  enveloped  viruses  (Ganz,  2003; 
Agerberth and Gudmundsson, 2006; Dann and Eckmann, 2007).
We demonstrated induction of  IEC hBD-2 and hBD-3 gene and peptide expression in 
response to C. jejuni infection (Chapter 3) suggesting a potential involvement of these 
molecules  in  disease  pathogenesis.  However,  in  order  to  play  an  important  role  in 
limiting  bacterial  colonisation  and  ultimately  clearing  infection,  P-defensins  must 
exhibit bactericidal activity against the bacterium. The aim of this part of the study was 
therefore to investigate the susceptibility of C. jejuni to antimicrobial peptides known to 
be expressed by the IEC. These include hBD-1, -2 and -3  and lysozyme, a ubiquitous 
AMP known to be expressed constitutively in the upper GI tract and  small intestine 
(Montero and Erlandsen,  1978). The potential role of IEC LL-37 in C. jejuni disease 
pathogenesis was not investigated in the present study.
Bacterial CPSs have been shown to mediate protection against the bactericidal activity 
of AMPs.  For example  CPS  of Klebsiella pneumoniae protects the  organism against 
host  innate  immune  defence  by  limiting  interaction  of  AMPs  with  the  bacterial 
membrane  (Campos  et  al.,  2004).  Although  C.  jejuni  CPS  did  not  contribute  to 
intestinal innate defence and hBD expression (Chapter 3), it’s primary function maybe 
to provide a protective shield against the antimicrobial action of hBDs or other AMPs 
(i.e. lysozyme).
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In  order  to  investigate  the  above  hypothesis,  a  bactericidal  assay  was  established. 
Briefly, C. jejuni bacterial cells were exposed to recombinant hBDs and lysozyme over 
various time periods. Bactericidal activity was assessed by plating out serial dilutions 
and  quantifying  viable  counts 2-3  days  later.  We  also  employed  Scanning  Electron 
Microscopy  (SEM)  to  further  our  understanding  of structural  changes  to  C. jejuni 
caused by (3-defensin action.
4.2  Methods
4.2.1  Bactericidal assay
C. jejuni was routinely  grown on blood agar plates  over  24h  (mixed-phase  culture) 
followed by resuspension and a further 16h incubation in MH broth preformed to obtain 
mid-log phase culture. Prior to assay, bacteria were resuspended in  lOmM phosphate 
buffer  pH  7.4  and  number  of bacteria  quantified.  Approximately  1   x  105   CFU/ml 
organisms were exposed to recombinant hBDs and lysozyme for indicated time periods 
at 37°C  under microaerophilic  conditions.  C. jejuni  in buffer alone  was  included to 
establish and distinguish bacterial survival rate in low salt conditions versus survival in 
the  presence  of  defensin  peptides.  Experiments  were  terminated  by  plating  serial 
dilutions of the reaction mix in triplicates onto blood agar plates. Bactericidal activity 
was accessed by counting viable bacteria after 2 to 3 days.
4.2.2 Scanning Electron Microscopy (SEM)
Firstly, a bactericidal assay was performed, exposing WT C. jejuni (NCTC 11168H) to 
recombinant hBD-3 (10'6 M) for 30min. Prior to this, silicon wafers were prepared by 
immersion in 0.1% (v/v) poly-L-Lysine (Sigma-Aldrich, UK) for 15min followed by air 
drying  for  30min.  lOOpl  of hBD-3  exposed  bacterial  suspension was  adsorbed onto 
wafer for 15min. Bacteria coated wafers were immersed in 0.5 % (v/v) glutaraldehyde
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(Sigma-Aldrich, UK) in PBS for 5min at ambient temperature and stored in PBS at 4°C 
until further processing.
The following steps were performed by Mr. K. Pell (Department of Biological Sciences, 
University of London at the Queen Mary’s School of Medicine and Dentistry, London 
UK). Wafers were washed in distilled water prior to immersion in  1% (w/v) osmium 
tetroxide (Sigma-Aldrich, UK) for 15min. Following a second series of three washes in 
distilled water, the wafers were passed through a series of ascending concentrations of 
ethanol (30%, 50%, 70%, and 90%) washes for 5min each followed by two washes in 
absolute ethanol for  lOmin. Wafers were then dried using absolute ethanol as transfer 
fluid in a BALZER'S CPD 030 critical point drier (Bal-Tec, Liechtenstein). The wafers 
were finally mounted on carbon supports, sputter coated with gold using a BALZER'S 
SCD  030  sputter coater (Bal-Tec, Liechtenstein),  and examined in a JEM  1200EXII 
scanning  transmission  electron  microscope  (Jeol,  Tokyo,  Japan)  operating  in  the 
scanning mode, between 40 and 60 kV.
4.3  Results
4.3.1  Recombinant hBD-2 and hBD-3 exhibit potent bactericidal activity against 
WT C. jejuni NCTC 11168H
Firstly, bactericidal activity of hBD-1, hBD-2 and hBD-3 against WT C. jejuni 11168H 
was tested. Approximately lxl 05  CFU of a 24h bacterial culture (i.e. colony from blood 
agar  plates)  was  exposed  to  10'6M  recombinant  peptides  for  30  or  60min prior  to 
streaking out serial dilutions. Time course and concentration of recombinant peptides 
were chosen according to preliminary experiments and previous work undertaken in our 
laboratory (George et al., 2003). Bactericidal activity was calculated as the percentage 
of viable counts obtained in buffer alone minus those exposed to recombinant peptides. 
Data is shown as an average of 3 independent experiments (preformed in triplicates) and
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error bars indicating +/-SEM.  As shown in Figure 4.1,  hBD-2  and hBD-3  exhibited 
potent bactericidal activity, with more than 99% of bacteria killed after 30min exposure 
to  peptides.  In  contrast,  the  constitutively  expressed  hBD-1  was  found  to  be 
significantly less potent and more variable (large SEM), its bactericidal activity ranging 
from 0 to 20%. Interestingly, we noted increased survival of bacteria exposed to hBD-1 
for 60min compared to 30min. However, this effect was not statistically significant.
With bactericidal activity of both inducible hBD-2 and hBD-3 reaching almost 100% at 
a  concentration  of  10‘6M,  peptides  were  further  diluted  in  order  to  investigate 
differences in their potency and establish a minimal concentration required for killing. 
As  shown  in  Figure  4.2,  hBD-3  exhibited  a  slightly  higher  bactericidal  activity  at 
concentrations tested when compared to hBD-2. Both hBD-2 and hBD-3 proved to be 
highly  efficient  at  10‘7M,  rendering  >99%  of  bacteria  nonviable.  The  minimal 
concentration  required  for  killing  was  found  to  be  5xlO'8M  for  both  peptides. 
Interestingly,  lower  concentrations  did  not  demonstrate  any  bactericidal  effect, 
highlighting an “all or none” mode of action. The observed potent bactericidal activity 
of hBD-3 led us to further investigate kinetics of hBD-3 mediated C. jejuni killing. As 
shown in Figure 4.3  following only a 5min exposure,  10‘7M hBD-3  killed more than 
99.5% of bacteria, suggesting rapid killing kinetics of this AMP against C. jejuni.
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Figure 4.1: Bactericidal activity of recombinant hBDs against WT C. jejuni strain 
11168H.  105  CFU/ml C. jejuni were exposed to  10'6M hBD-1, hBD-2 and hBD-3  in 
lOmM  phosphate  buffer.  Viability  was  assessed  after  30  and  60min  exposure. 
Bactericidal  activity  was  calculated  against  control  samples  containing  bacteria  in 
buffer  alone.  Data represents the  mean +/-SEM  of 3  independent  experiments,  each 
performed in triplicate.
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Figure 4.2: Dose dependent bactericidal activity of hBD-2 and hBD-3 against WT 
C. jejuni strain 11168H. C. jejuni WT 11168H was incubated with recombinant hBD-2 
and hBD-3  in a 10'  to  10' M concentration range for 30min and bactericidal activity 
calculated.  Data  represents  mean  +/-SEM  of three  experiments,  each  performed  in 
triplicate.
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Figure  4.3:  Kinetics  of  antimicrobial  activity  of  hBD-3  against  WT  C.  jejuni 
11168H. C. jejuni WT  11168H was incubated with  10'7M hBD-3  and serial dilutions 
plated out on blood agar after 5,  15 and 30min.  Data represents the mean +/-SEM of 
three independent experiments, each performed in triplicate.
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4.3.2  Effect of bacterial growth phase on susceptibility of C, jejuni to hBDs
Bacterial growth phase is known to be associated with changes in expression of various 
surface  structures  of  C.  jejuni  including  capsular  polysaccharide  and  changes  in 
metabolic activity  (Bacon et al.,  2001;  Karlyshev et al,  2002; Vandecasteele et al., 
2004).  These  changes  can  influence  resistance  to  the  action  of  antibiotics  and 
antimicrobial  peptides  (McLeod  and  Spector,  1996;  Kobayashi  et  al,  2006).  We 
investigated  the  impact  of  C.  jejuni  growth  phase  on  its  susceptibility  to  the 
antimicrobial action of hBDs. Bacteria grown on blood agar plates for 24h represented a 
mixed population of organisms, whereas C. jejuni grown further in Muller Hinton broth 
for  16h  were  considered  mid-logarithmic  (mid-log)  phase  bacteria,  the  latter 
representing  dividing,  metabolically  active  organisms.  As  shown  in  Figure  4.4,  no 
significant difference in the susceptibility to the antimicrobial action of 10‘6M hBD-2 
and  hBD-3  was  observed  between  mid-log  and  mixed  phase  bacterial  cultures. 
Interestingly,  an average  difference  of approximately  20%  higher killing  of mid-log 
phase bacteria by hBD-1 was observed, suggesting actively dividing bacteria might be 
more  susceptible to hBD-1. However,  due to  large variability (expressed in large +/- 
SEM) between experiments this difference was found not to be statistically significant. 
Further dilutions might be necessary to investigate if these potential differences are real.
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Figure 4.4: Impact of bacterial growth phase on susceptibility to the antimicrobial 
activity of hBDs.  105  CFU/ml of mid-log phase and mixed cultured C. jejuni 11168H 
were incubated in 10‘6M hBDs for 30min prior to serial dilution plating. Data are shown 
as mean +/- SEM of three independent experiments, each performed in triplicate.
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4.3.3  Bactericidal activity of lysozyme against C. jejuni
Another  epithelial  antimicrobial  peptide  known  to  be  expressed  in  the  GI  tract  is 
lysozyme. Firstly, we investigated expression of lysozyme in our tissue culture model 
during a 24h infection with WT C. jejuni 11168H. As shown in Figure 4.5, we found 
constitutive lysozyme expression in control Caco-2 cells with no further modulation by
C.  jejuni  noted  during  24h  of  infection  (Figure  4.5  middle  lane).  Infectivity  was 
confirmed by following induction of IL-8 in the same experiment (top lane).
Having confirmed the presence of lysozyme in our model system, we wished to test the 
bactericidal  activity  of  lysozyme  against  WT  C.  jejuni  11168H.  Further,  we  also 
investigated any  potential  synergistic  effects  between  lysozyme  and hBD-1,  as  both 
peptides are constitutively expressed and are likely to be present at the same time at the 
GI  mucosal surface.  As shown in Figure 4.6,  1.4p,M (20jxg/ml)  lysozyme and  10'6M 
hBD-1  exhibited a similar range of bactericidal activity against C. jejuni. Interestingly, 
combining both AMP  in equal concentrations lead to  increased bactericidal  activity, 
suggesting an additive and/or synergistic effect (Figure 4.6 left column).
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Figure  4.5:  Expression  of lysozyme  in  Caco-2  cells  infected  with  WT  C. jejuni 
strain 11168H. Caco-2 cells were co-cultured with WT C. jejuni strain  111 68H at an 
MOI of 100. Lysozyme and IL-8 gene-expression was followed by RT-PCR after 6, 10 
and  24h  and  normalized  against  GAPDH.  Uninfected  cells  served  as  control.  A 
representative gel of three independent experiments is shown.
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Figure  4.6:  Bactericidal  activity  of  the  constitutively  expressed  antimicrobial 
peptides hBD-1 and lysozyme against C. jejuni. WT C. jejuni 11168H was incubated 
with  either  10'6M  hBD-1,  1.4xlO'5M  (20pg/ml)  lysozyme  alone  or  both  peptides 
combined for 30min. Data represents an average +/- SEM of two to three independent 
experiments, each performed in triplicate.
114CHAPTER 4
4.3.4  The role of C. jejuni capsular polysaccharide in protection against AMPs
Studies illustrated in chapter 3 revealed that the capsule deficient isogenic mutant strain 
of C. jejuni  WT  11168H  was  equally  potent  in  inducing  IL-8,  hBD-2  and  hBD-3 
expression suggesting a minor role of this structure in modulating host epithelial innate 
immune defence. However, it has been shown that bacterial capsule is protective against 
antimicrobial  peptides  in  other  Gram-negative  bacteria  (Campos  et  al.,  2004).  To 
investigate the potential role of C. jejuni CPS in protecting the organism against AMPs, 
kpsM was subjected to bactericidal assays using recombinant hBDs and lysozyme. As 
shown in Figure 4.7 hBD-2 and hBD-3 were equally potent against WT and kpsM. In 
contrast there was a trend for the capsule deficient mutant to be more susceptible to 
hBD-1 when compared to its parental WT strain expressing CPS. Similar findings were 
observed when testing for susceptibility to  lysozyme  (Figure 4.7).  The  difference in 
susceptibility between WT and kpsM for both hBD-1 and lysozyme was found not to be 
statistically  significant.  This  is  again  mainly  due  to  the  large  variation  of  the 
antimicrobial  potency  of  hBD-1  against  C.  jejuni  observed  between  individual 
experiments. The reason for this remains unclear.
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Figure 4.7:  Comparison of C. jejuni susceptibility  to the  antimicrobial action  of 
hBD-1, -2, -3 and lysozyme, WT 11168H versus the capsule deficient mutant strain 
kpsM. Bactericidal assays were performed as described above using  10‘6M hBDs and 
1.4x10'5M (20 (ig/ml) lysozyme. Bactericidal activity of each peptide was assessed after 
30min  incubation.  Data  represents  average  +/-SEM  of  two  to  three  independent 
experiments, each performed in triplicate.
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4.3.5  Structural damage caused by hBD-3 to C. jejuni cell membrane
The  mechanism(s)  by  which hBDs  cause  damage  to  bacteria remain unclear.  Using 
SEM,  the  structural damage  caused to  C. jejuni  11168H by recombinant hBD-3  (the 
most potent bactericidal peptide against C. jejuni) was investigated.  WT bacteria were 
exposed tolO'6M hBD-3  for 30min prior to preparation and examination by SEM.  In 
parallel,  viability of bacteria maintained in low salt phosphate buffer  (minus hBD-3) 
was confirmed by comparison to C. jejuni incubated in Muller Hinton Broth. As shown 
in Figure 4.8, after 30min, control bacteria remained undamaged, retaining their spiral 
shape irrespective of incubation media utilised (Figure 4.8a in MH broth versus 4.8b in 
low  salt  buffer).  In  contrast,  bacteria  incubated  with  hBD-3  were  non-viable  when 
plated out onto solid media and showed apparent thinning out and/or pealing of the cell 
wall (Figure 4.9).
(a)  (b)
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Figure 4.8a and b:  C. jejuni WT  11168 examined by SEM.  (a) Bacteria in Muller 
Hinton  Broth,  (b)  Bacteria  in  low  salt  phosphate  buffer.  Bacterial  spiral  shape  and 
bipolar flagella were preserved in both media.
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Figure 4.9a-d: Structural damage of C jejuni 11168H following exposure to hBD-3.
WT C. jejuni  11168H was exposed to  10'6M hBD-3 for 30min and structural changes 
examined using SEM. Arrows indicate thinning of membrane (a) and pore formation (b- 
d). Images are representative for samples exposed to hBD-3.
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4.4  Discussion
Defensins have been shown to  exhibit antimicrobial activity against a wide range of 
Gram-positive and Gram-negative bacteria, fungi, parasites and even enveloped viruses 
(Selsted and Ouellette, 2005; Jenssen et al, 2006; Lehrer, 2007). However, some micro­
organisms have developed protective mechanisms allowing them to overcome this part 
of  innate  host  defence  potentially  causing  disease  (Peschel  and  Sahl,  2006).  We 
demonstrated dynamic modulation of p-defensins by WT  C. jejuni with induction of 
hBD-2 and hBD-3. In order to contribute to limiting bacterial colonisation and infection 
in  vivo,  p-defensins  must  exhibit  bactericidal  activity  against  the  bacterium.  We 
therefore investigated the susceptibility of C. jejuni to the antimicrobial properties of 
these peptides. Incubation of recombinant hBD-2 and hBD-3 with WT C. jejuni 11168H 
revealed  potent  and  fast  acting  antimicrobial  activity  of both  peptides  against  the 
organism  with  more  than  99%  of bacteria killed  within  a  30min  incubation  period 
(Figure 4.1).  Equally potent killing of C. jejuni by hBD-2  and hBD-3  was observed 
when  comparing  mid-log  phase  bacteria  to  mixed  culture  organisms,  suggesting 
bactericidal activity of these peptides seems to be independent of bacterial growth phase 
and their metabolic status (Figure 4.4). Although luminal concentrations of hBD-2 and 
hBD-3  in the GI tract during C. jejuni infections remain unknown, bactericidal dose- 
dependant studies shown in Figure 4.2 are compatible with those suggested for other 
Gram-negative bacteria,  with effective killing at a micro molar range  (Ghosh  et al., 
2007).  Investigating killing kinetics of hBD-3, we found evidence  of lethal bacterial 
damage as early as 5min of exposure to the peptide, with >99.5% of bacteria rendered 
nonviable in this short period of time (Figure 4.3). In contrast to hBD-2 and hBD-3, the 
constitutively expressed hBD-1  was found not only to be  significantly less potent in 
killing WT C. jejuni but also more variable, with killing ranging from 0-50% (Figure 
4.1). Intriguing was the finding of higher percentage of bacterial kill by hBD-1 at 30minCHAPTER 4
post  incubation  compared  to  its  activity  after  60min  (Figure  4.1).  Furthermore,  we 
observed a trend for mid-log phase bacteria to be more susceptible to the bactericidal 
activity of hBD-1  when compared to a mixed culture population, suggesting that this 
peptide might be more active against actively dividing bacteria (Figure 4.4). The reason 
for differences between inducible hBD-2/3 and constitutively expressed hBD-1 remain 
unclear, however, one may hypothesise that given the constitutive expression of hBD-1 
its reduced bactericidal activity might be an evolutionary necessity to ensure survival of 
commensal bacteria. Furthermore, it may be possible that hBD-1  action is sufficient in 
certain circumstances to prevent bacterial colonization from proceeding for example by 
synergising with the effect of other constitutively expressed AMPs. Lysozyme has been 
shown to be differentially expressed in various parts to the upper GI tract and small 
intestine (Montero and Erlandsen,  1978). We confirmed constitutive expression of this 
AMP  in our  in  vitro  model  (Figure  4.5)  during  C. jejuni  infection  and  went  on to 
investigate its bactericidal activity against the organism on its own and in combination 
with  hBD-1.  In  a  concentration  of  1.4xlO'5M  (20pg/ml),  lysozyme  demonstrated  a 
similar bactericidal  activity  against WT  C. jejuni  11168H  when  compared to  10'6M 
hBD-1  (Figure  4.6).  Combining  both  AMPs  led  to  an  increase  in  bacterial  kill 
suggesting  synergistic  and/or  additive  effects  (Figure  4.6).  Taken  together  these 
findings indicate that various constitutive and/or inducible defensins may act together to 
provide adequate host defence.
C.  jejuni  bacterial  capsule  was  found  to  play  a  minimal  role  in  modulating  hBD 
expression during  infection (chapter  3).  Studies  by  Campos  et al.  demonstrated that 
CPS of K. pneumoniae mediated protection against AMPs (Campos et al., 2004), we 
hypothesised  similar  findings  for  C. jejuni.  Surprisingly,  WT  C. jejuni  11168H  was 
found to be equally susceptible to the antimicrobial action of hBD-2 and hBD-3 when 
compared to the capsule deficient mutant strain kpsM suggesting a minor role for this
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bacterial component in mediating protection  (Figure 4.7).  We consistently observed 
greater efficiency of hBD-1  in killing the kpsM mutant when compared to the parental 
WT strain (Figure 4.7). Similar observations were also noted for lysozyme, which was 
slightly more effective against the isogenic  CPS  deficient mutant strain (Figure 4.7). 
Despite the lack of statistical significance, these observations point towards a potential 
role of C. jejuni CPS in providing protection against constitutively expressed AMPs, a 
possible advantage in early bacterial-epithelial contact, aiding the bacterium to adhere 
and  invade  the  intestinal  epithelium.  There  is  some  evidence  that  C.  jejuni  down- 
regulates CPS as the bacteria adheres to and invades IECs (N. Dorrell and P. H. Everest, 
unpublished data). This would not only support the lack of protection against AMPs but 
also  explain our  findings  suggesting  that  C. jejuni  capsule  may  not  be  involved  in 
modulating intestinal epithelial innate immune responses.
To  date  the  mechanism(s)  by  which  defensins  mediate  their  antimicrobial  activity 
remain unclear. However, evidence is accumulating that following the initial contact of 
the defensin peptide with the target cell, membrane permeabilization can occur (Sahl et 
al., 2005; Jenssen et al, 2006). Scanning electron microscopy allowed visualisation of 
the structural damages to  WT C. jejuni  11168H caused by hBD-3.  Following 30min 
incubation we observed peeling of bacterial membrane accompanied by disruption of 
cell  wall  leading  to  spillage  of cellular  contents  (Figure  4.9a-d).  Importantly,  these 
changes were absent in bacteria resuspended in buffer alone suggesting these effects are 
most likely specific to defensin action.
In conclusion, data presented in this chapter lends further support to our hypothesis that 
P-defensins play an important role in C. jejuni disease pathogenesis. Specifically, with 
expression of hBD-2 and hBD-3 being induced by C. jejuni combined with their potent 
and  fast  acting  antimicrobial  activity  against  the  bacterium,  these  AMPs  might
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contribute to the self-limiting nature of disease via enhanced clearance in the healthy 
host.
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The role of intestinal epithelial 
Nucleotide Oligomerisation Domain 1 
(NODI) in mediating host innate 
response to C. jejuni
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5.1  Introduction
Prior to the induction of innate defence, host cells are required to sense the presence of 
potential  pathogens.  In  the  GI  tract  the  constant  presence  of  the  diverse  enteric 
microflora adds further complexity to this task. The intestinal epithelium as front line of 
defence faces the challenge to discriminate between pathogens and harmless commensal 
bacteria.  Mechanisms  leading  to  the  observed  tolerance  of the  intestinal  epithelium 
towards luminal commensals and their products (Cario and Podolsky, 2005) include the 
reduced surface expression of TLRs (i.e. TLR4) (Cario and Podolsky, 2000; Abreu et 
al, 2001; Naik et al, 2001) and tight control of their signalling such as expression of 
the TLR-signaling suppressor Tollip (Melmed et al, 2003). In contrast, expression of 
cytoplasmic PRRs (i.e. of the NOD family) allows recognition of invaded bacteria and 
presence of cytoplasmic bacterial products (Kufer et al., 2006).
As  a well  recognised  early  event in  host  C. jejuni  interaction,  several  studies  have 
investigated mechanisms involved in C. jejuni mediated IEC IL-8 production (Hickey et 
al., 1999; Hickey et al, 2000; Watson and Galan, 2005; Johanesen and Dwinell, 2006). 
Both bacterial structural [e.g. cytolethal distending toxin (CDT)] components and active 
processes such as adhesion/invasion and de novo protein synthesis have been implicated 
in eliciting epithelial innate immune responses (Hickey et a l, 2000; Mellits et al, 2002; 
Watson and Galan, 2005). However, despite these advances in our understanding of the 
role  and  contribution  of bacterial  factors  implicated  in  C. ye/wra-mediated  epithelial 
responses, at present our knowledge remains rudimentary as to how the host senses the 
presence of the bacterium and initiates an effective immune response.
Recent  evidence  suggesting  that  C. jejuni  flagellin  is  a  poor  ligand  for  IEC  TLR5 
(Watson and Galan, 2005; Johanesen and Dwinell, 2006), combined with the observed 
association of bacterial invasion and innate immune activation (Hickey et al, 1999), led 
us to hypothesise that cytoplasmic NOD proteins might be involved in host sensing of
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C. jejuni (Inohara et al, 2005). NODI  (encoded by the caspase-recruitment domain 4 
gene;  CARD4)  and  NOD2  (encoded  by  CARD15)  recognize  components  of 
peptidoglycans  (PGNs),  ubiquitous  constituents  of bacterial  cell  walls  (Inohara  and 
Nunez, 2003; Inohara et al, 2005; Franchi et al, 2006). The minimal PGN structure 
that acts as a specific ligand for NODMCARD4 is y-D-glutamyl-meso-diaminopimelic 
acid (iE-DAP), a signature motif found in most Gram-negative and some Gram-positive 
bacterial  PGNs  (Chamaillard  et  al,  2003;  Girardin  et  al,  2003b).  In  contrast, 
NOD2/CARD15 is a more global bacterial sensor as it interacts with N-acetylmuramyl- 
L-alanyl-D-isoglutamine (muramyl dipeptide; MDP), a motif common to both Gram- 
negative and Gram-positive bacterial PGNs (Girardin et al, 2003a; Inohara and Nunez, 
2003).
In the  following  chapter we investigated the potential  role  of NODI  and NOD2  as 
cytoplasmic  PRRs  involved  in  initiating  host  IEC  innate  immunity  in  response  to 
C. jejuni.
5.2  Methods
5.2.1  Bacterial strains and culture conditions
The C. jejuni wild-type strains used were as described in chapter 2.  WT encapsulated 
Streptococcus pneumoniae (S. pneumoniae,  serotype FI9) was kindly  provided by Dr. 
Helen Baxendale (Department of Infectious Diseases and Microbiology, Institute of Child 
Health, London UK). S. pneumoniae were grown on Columbia agar plates supplemented 
with 7% v/v defibrinated horse blood at 37°C with 5% C02  over 24h. Single colonies were 
resuspended in Todd-Hewitt broth (Sigma-Aldrich, Gillingham, UK) supplemented with 
0.5% yeast extract and incubated at 37 °C for 3-4h (100 rpm) to reach mid-logarithmic 
phase  (A600  =  0.2-0.4).  Bacteria were harvested  by  centrifugation  and  resuspended in 
tissue  culture  medium  (DMEM  minus  antibiotics)  to  a final  concentration  of 2 x  108  
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5.2.2  Localisation of C. jejuni in Caco-2 co-cultures by confocal microscopy
5.2.2.1  Fluorescent labeling and PFA treatment of C. jejuni 81 -176
Prior  to  bacterial  co-culture,  fluorescent  labeling  of  WT  C.  jejuni  81-176 
(approximately  1   x  108   CFU/ml)  was  performed  by  incubating  bacteria  in  PBS 
containing 0.1 mg/ml Fluorescein isothiocyanate (FITC) (Sigma-Aldrich, Gillingham, 
UK) for 15min at RT. Bacteria were washed twice in PBS to remove unbound FITC and 
resuspended in antibiotic free DMEM medium supplemented with 1% FCS. Fixation of 
one  proportion  of  FITC-labeled  C.  jejuni  81-176  was  achieved  by  incubation  in 
paraformaldehyde (PFA 4%) for 15min at RT, followed by 3 washes in tissue-culture 
media to  remove residual traces of PFA.  100%  inactivation  by  PFA  treatment was 
confirmed by plating out bacterial suspension on blood agar plates followed by viable 
counting after 2 to 3 days.
5.2.2.2  Bacterial co-culture with FITC-labeled C. jejuni (live versus PFA fixed) 
Caco-2 cells were grown on cover slips in 24 well plates over 7 days to reach complete 
confluency. Co-culture of Caco-2 cells with live or PFA fixed FITC-labeled C. jejuni 
(MOI of 100) was carried out in DMEM for 5h to allow for adhesion and invasion to 
occur.  Following incubation time, cells were washed twice with PBS and fixed in 4% 
PFA for 20min at RT.
5.2.2.3  Immuno-labeling of extracellular C. jejuni post co-culture
Following 2 washes in PBS to remove residual PFA, non-specific binding was blocked 
by  incubating  cells  with  1%  BSA  (in PBS)  for 45  min.  Extracellular bacteria were 
labelled  with  primary  unconjugated  goat  anti-C. jejuni  antibodies  (KPL,  Maryland, 
USA) at a concentration of 5pg/ml for 60min at RT, followed by incubation with Alexa 
Fluor 568-conjugated rabbit anti-goat IgG (Molecular Probes, Eugene, Oregon, USA) 
for  30min.  Bacteria and cell  nuclei were counterstained with  TO-PRO-3  (Molecular 
Probes) for 30min. After each step, cells were washed 3 times with PBS. Co-cultures
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were visualised with a Radiance 2100  confocal  laser  scanning microscope  equipped 
with an Argon-Krypton laser and a red diode (Bio-Rad, UK). As intracellular bacteria 
were protected from antibody labelling, they  appear as  green (in merged image).  In 
contrast,  extracellularly  located  C. jejuni  appear  yellow  due  to  double  labelling  in 
merged image.
5.2.3  Small interfering (si) RNA experiments
Pre-designed siRNA sequences targeting NODI  (Sequence  1:  sense GGC CAA AGU 
CUA UGA AGA Utt, Sequence 2: sense GGG UGA GAC CAU CUU CAU Ctt) and a 
non-targeting negative (siNEG) control sequence (catalogue number AM 4611) were all 
purchased  from  Ambion  (Huntingdon,  Cambridge  UK).  Caco-2  cells  were  reverse 
transfected with siRNA using  siPORT NeoFX Transfection Reagent (Ambion).  This 
method allowed transfection to occur during the initial phase of cell adherence. 
siRNA was prepared in Opti-MEM serum-free medium (Invitrogen) by mixing 0.7 or 
0.8pi (per well) of the transfection reagent with 10 or 20nM siRNA respectively at RT 
for  lOmin.  Caco-2  cells  (8xl03cells/well)  were  then  transferred  to  a  96-well  plate 
containing siRNA-transfection reagent complexes and mixed by gentle flicking of the 
plate. Media containing transfection reagent was replaced after 20h by complete media 
(allowing  cell  recovery)  and  incubation  continued  for  an  additional  28h  prior  to 
bacterial  infection.  Gene  knock-down  was  confirmed  by  RT-PCR.  For  luciferase 
reporter  gene  assays,  a  second  transfection  step  was  performed  3 Oh  post  reverse 
transfection of siRNA.
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5.2.4  Transfection of Caco-2 cells with NOD2 overexpression plasmid
NOD2  overexpression  plasmid  was  kindly  provided  by  Professor  G.  Nunez 
(Department of Pathology and Comprehensive Cancer Centre, University of Michigan 
Medical School, Ann Arbor, Michigan, USA).  lOOng NOD2 plasmid was transfected 
into Caco-2 (8xl03) cells using FuGene reagent (Roche, Lewes, UK; chapter 2). For 
luciferase reporter gene assays, NOD2 plasmid was co-transfected with IL-8 or hBD2 
promoter constructs. NOD2 expression was confirmed by RT-PCR and bacterial co­
culture studies performed 48h post-transfection.
5.2.5  Isolation of peripheral blood mononuclear cells (PBMCs)
PBMCs  were  isolated  from  the  blood  of healthy  donors  using  Lymphoprep  Ficoll 
centrifugation gradient (Sigma, Poole, UK). Approximately 20mls of blood was diluted 
with an equal volume of RPMI 1640 + glutamine (Invitrogen, Paisley, UK). The diluted 
blood was slowly  layered onto  20mls of Ficoll  lymphoprep.  Resulting  solution was 
centrifuged (1800rpm,  30min,  no breaks;  Rotina 46R centrifuge,  Wolf Laboratories, 
UK) and PBMCs removed from the buffy coat layer (interface between the serparating 
gel  and  plasma  layer)  using  a  sterile  Pasteur  pipette.  Approximately  15mls  of the 
obtained cell suspension was re-centrifuged at 1600rpm for lOmin to remove traces of 
lymphoprep. The resultant pellet was subjected to RNA extraction and RT-PCR.
5.2.6  C. jejuni invasion assay
Initially, a standard gentamicin protection assay was optimized for C. jejuni in Caco-2 
cells. This included adjustment of incubation time sufficient to allow for adhesion and 
invasion,  concentration of gentamicin and  exposure time to  ensure  sufficient kill  of 
extracellular  bacteria.  Following  optimization,  the  assay  was  adjusted  to  use  in 
transfected cells as follows:  Caco-2  cells were plated in a 96-well plate  and reverse
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transfected  with  NODI  siRNA  or  over-expressing  NOD2  plasmid.  After  48h 
approximately 107 CFU/ml of C. jejuni 81-176 cells were added to each well. Following 
a 20h infection period, cells were incubated in media containing gentamicin (150pg/ml) 
for 60min. This procedure ensured complete kill of any adherent extracellular bacteria. 
Cells were washed 3 times with PBS prior to lysis with 0.2% v/v Triton X-100 (in PBS) 
for 15min at RT. Serial dilutions were plated onto blood agar plates and percentage of 
invasion calculated by counting viable CFU in the lysate compared to control untreated 
Caco-2 cells.
5.3  Results
5.3.1  Intracellular  C. jejuni bacterial  component(s)  play  an  important  role  in 
eliciting IEC innate immunity
Prior to investigating the role of cytoplasmic NOD proteins as potential PRR(s) for C. 
jejuni,  we  wished  to  establish  a  link  between  epithelial  responses  and  bacterial 
localisation in our co-culture model system. For this purpose, we compared epithelial 
responses of live versus PFA-fixed C. jejuni. PFA treatment allows maintenance of the 
structural integrity of the bacterial cells (albeit with reduced ability for conformational 
changes) while rendering the bacteria non-viable and unable to execute and participate 
in active, energy requiring processes. We observed potent induction of epithelial IL-8 
and hBD-2 gene expression in the presence of infection with live C. jejuni 11168H and 
81-176  cells,  with  the  response  markedly  reduced  on  exposure  to  PFA-fixed  cells 
(Figure 5.1a and b). Potency of infection with live bacteria was also confirmed at the 
protein level. In comparison PFA-fixed bacteria showed a significant reduction in their 
ability to induce IL-8 protein (Figure 5.2). Bacterial localisation was investigated  5h 
post-infection.  C. jejuni was  detected both intracellularly  (green)  and  extracellularly 
(yellow; merged image) following infection with live 81-176 strain (Figure 5.3; merged
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upper-panel).  In contrast, PFA-fixed bacteria showed mainly extracellular localisation 
(Figure 5.3; merged lower panel)
(a) (b)
C. jejuni 11168H
HBD2
GAPDH
C. Jejuni 81-176
1   Live PFA ir*»ct.
IL-8
HBD2
P  ADPVU u A ru rl
Figure 5.1a and b: Induction of IL-8 and hBD-2 by PFA fixed versus live G jejuni.
Co-culture experiments were performed in Caco-2 cells with live and PFA fixed WT C. 
jejuni strains 11168H (a) and 81-176 (b) at an MOI of 100. 8h post-infection, IL-8 and 
hBD-2 gene expression was analyzed by RT-PCR. Experiments were performed at least 
three times, a representative gel is shown.
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Figure  5.2:  Induction  of IL-8  protein  levels  by  live  versus  PFA  fixed  C. jejuni.
Caco-2 cells were infected with live and PFA fixed C. jejuni WT strain 11168H and 81- 
176.  24h post infection, IL-8 levels were analysed in culture supernatants by ELISA. 
Error bars indicate +/-SEM obtained from a minimum of two independent experiments 
performed in duplicates. *, P< 0.05; live versus PFA-fixed  C. jejuni cells.
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Figure  5.3:  Cellular  localization  of  live  and  PFA  fixed  C. jejuni  cells  5h  post­
infection.  Caco-2 cells were grown on cover-slips and co-cultured with  live or PFA- 
fixed FITC-labelled C. jejuni 81-176 (green) for 5h. To distinguish between intra- and 
extracellular  bacterial  localization,  non-permeabilised  cells  were  stained  with  anti-C. 
jejuni  antibodies  followed  by  Alexa  Fluor  568  conjugated  rabbit  anti-goat  IgG.  The 
latter treatment allowed  for additional  staining  of extracellular FITC  labeled  bacteria 
leading to a yellow appearance (merging of green FITC and red Alexa Fluor-568).  In 
contrast,  intracellular  bacteria remained  green.  Nuclei  were  counterstained  with  TO- 
PRO-3  (blue  in  merged  image).  Intracellular  bacterial  localization  is  highlighted 
(arrowheads).  A representative image from 2 experiments (performed in triplicates)  is 
shown.
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5.3.2  Intestinal  epithelial  NODI  and  NOD2  gene  expression  during  C. jejuni 
infection
Bacterial adherence to and subsequent invasion of the IEC is a well established early 
event in C. yeyww-mediated disease pathogenesis (Konkel and Joens,  1989; Szymanski 
et al., 1995; Monteville et al, 2003). The causal association of presence of intracellular 
bacteria  with  potent  IEC  responses  (Figure  5.1-5.3)  added  weight  to  our  initial 
hypothesis that epithelial, cytoplasmic NOD protein(s) may be potential PRR(s) for C. 
jejuni.  We  therefore  investigated  expression  of NODI  and  NOD2  during  C. jejuni 
infection in our tissue  culture model.  As shown in Figure  5.4a and b,  expression of 
NODI  in  Caco-2  cells  was  found  to  be  constitutive  (Figure  5.4a-b;  upper  panel). 
Interestingly, no modulation of NODI  expression was noted during the 24h infection 
period irrespective of bacterial strain tested (Figure 5.4a: 11168H, 5.4b: 81-176). These 
findings  were  confirmed  using  HT-29  cell  line  (Figure  5.5a  and  b).  Evidence  for 
infectivity was sought in parallel. This was investigated by following the expression of 
hBD-2; whose expression is known to be dependent on NODI engagement (Boughan et 
al,  2006).  No hBD-2 expression was noted in control;  uninfected Caco-2 or HT-29 
cells (Figure 5.4 and 5.5; second panel). In response to infection of both cell-lines with 
two different wild-type strains (11168H and 81-176), we observed induction of hBD-2; 
with initial expression noted as early as 6h post-infection (Figure 5.4 and 5.5; second 
panel). To delineate a role for NOD2 as a potential PRR for C. jejuni, we followed the 
expression of this molecule  during  infection.  NOD2  expression  was undetectable  in 
either uninfected or C. yeywra-infected Caco-2 or HT-29 cell-lines throughout the 24h 
course of infection (Figure 5.4 and 5.5;third panel).  Macrophages in PBMCs are known 
to express NOD2 and were therefore included in each experiment as a positive control.
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Figure 5.4a and b: Expression of NODI and NOD2 in Caco-2 cells during C. jejuni 
infection. Caco-2 cells were co-cultured with C. jejuni wild-type 11168H (a) or 81-176 
(b) strains at an MOI of 100 for up to 24h. Time-dependant gene expression of NODI 
(upper panel) and NOD2 (third panel) was followed by RT-PCR. In parallel, evidence 
for  infectivity  was  confirmed  by  analysing  induction  of hBD-2  expression  (second 
panel).  Peripheral  blood  mononuclear  cells  (PBMCs)  served  as  positive  control  for 
NOD2. Experiments were done at least 3 times, a representative gel is shown.
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Figure 5.5a  and b:  Expression  of NODI  and NOD2  in  HT-29 cell line during C. 
jejuni infection. HT-29 cell line was infected with WT C. jejuni 11168H (a) and 81-176 
(b) at an MOI of 100 over 24h.  Expression of NODI  (upper panel)  and NOD2  (third 
panel) was analyzed by RT-PCR. Infectivity was confirmed by demonstrating induction 
of hBD-2 (second panel). A representative gel of 3 independent experiments is shown.
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5.3.3  The presence of NODI small interfering (si) RNA inhibits IL-8 and hBD-2 
gene expression in response to C. jejuni infection
We next wished to establish if intestinal epithelial NODI  was involved in C. jejuni- 
mediated epithelial responses. Using pre-designed siRNA sequences targeting NODI, 
expression of the receptor was knocked down and the effect on C. jejuni mediated IL-8 
and hBD-2 expression investigated. During initial optimization experiments, amount of 
transfection reagent,  concentration of siRNA and incubation period were established 
aiming to achieve maximum gene silencing while keeping cell toxicity minimal. In all 
experiments, two distinct siRNA sequences specifically targeting NODI  (siNODl  a & 
b)  were  transiently  transfected  into  Caco-2  cell  line  and  NODI  gene  knock  down 
confirmed 48h post-transfection by RT-PCR (Figure 5.6a and b, third panel). In order to 
confirm  specificity  of  sequences  targeting  NODI,  equal  concentrations  of  a  non­
targeting siRNA sequence (siNEG) was routinely included as a negative control (Figure 
5.6a and b, third panel).
Having established specific knock down of NODI receptor, transfected Caco-2 cell line 
was co-cultured with WT C. jejuni  strain  11168H  (Figure  5.6a)  and  81-176  (Figure 
5.6b)  strains  for  8h.  As  shown  in Figure  5.6a and  b,  IL-8  (top panel)  and hBD-2 
(second panel) gene expression was significantly inhibited following transfection with 
siNODl (a & b), while siNEG did not exhibit any significant effect.
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Figure 5.6a and b: Effect of siNODl  on C. jejuni mediated induction of IL-8 and 
hBD-2  gene  expression.  Caco-2  cell  line  was  reverse  transfected  with  two  distinct 
siRNA  sequences  targeting  NODI  (siNODl  a  and  b)  and  a  non-targeting  (siNEG) 
sequence.  48h  post  transfection,  cells  were  co-cultured  with  C.  jejuni  WT  strains 
11168H (a) and 81-176 (b) for 8h. Expression of IL-8, hBD-2, NODI  and GAPDH was 
followed by RT-PCR. A representative gel of three independent experiments is shown.
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5.3.4  Reduced  NODI  expression  inhibits  C.  jejuni  mediated  IL-8  promoter 
activation and protein secretion
Leading on from the above findings, more detailed analysis of the role of NODI  in C. 
jejuni  driven  IEC  transcriptional  and  translational  innate  immunity  was  sought. 
Luciferase reporter gene assays were performed in cells treated with siRNA, and IL-8 
promoter constructs transiently transfected into Caco-2 cells. For each siRNA sequence 
two  different  concentrations  (10  and  20nM)  were  tested  and  their  effect  on  IL-8 
promoter function in response to C. jejuni investigated.
As shown in figure 5.7a and b, dose-dependent inhibitory effect of siNODla and b on 
C. jejuni-mediated IL-8  promoter function was  observed.  30-50%  inhibition of IL-8 
transcription  activity  index  was  routinely  achieved  in  the  presence  of  transfected 
siNODl  irrespective of the bacterial strain or sequence tested (Figure 5.7a and b). In 
parallel experiments, siNEG sequence (20nM) was found to have no significant effect 
on IL-8 promoter activity, further highlighting specificity of NODI knock down and its 
biological consequences on IL-8 promoter activity.
Once the greater inhibition of siNODl sequences at 20nM was established, the effect of 
this concentration on IL-8 protein induction in response to C. jejuni strains 11168H and 
81-187  was  tested.  Following  transfection  of siRNA  sequences,  Caco-2  cells  were 
infected with WT C. jejuni over 24h and IL-8  concentration measured by ELISA in 
culture supernatants. As shown in Figure 5.8, induction of IL-8 protein in response to 
infection with C. jejuni  11168H and 81-176  strains was significantly inhibited in the 
presence  of both  siNODl  a  and  b  sequences  with  siNEG  exhibiting  no  significant 
effect.
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Figure 5.7a and b: Dose-dependent effect of siNODla and b on C. y<?yw/z/-mediated 
IL-8  promoter  function.  IL-8  promoter  constructs  were  transiently  transfected  in 
Caco-2 cell line following treatment with siNODla and b (10 and 20nM) and siNEG 
(20nM). 48h post transfection, cells were co-cultured with WT C. jejuni 11168H (a) and 
81-176 (b) for 8h and promoter-luciferase activity assessed. IL-8 promoter activity in 
uninfected and C. jejuni infected Caco-2 cell line was included, the latter representing 
100%  induction.  Data represent the  average  +/-SEM three  independent  experiments 
performed in triplicates.
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Figure 5.8: Effect of siNODl on C. jejuni-mediated IL-8 protein production. Caco- 
2 cells were treated with siRNA targeting NODI  (siNODla and b) and non targeting 
negative control (siNEG).  48h post treatment,  cells were infected with C. jejuni WT 
strains  11168H  and  81-176  for  24h  and  IL-8  measured  in  cell  supernatants.  Data 
presented  are  average  +/-  SEM  of  two  independent  experiments  performed  in 
duplicates.  *,  PO.05  versus  IL-8  induction  in  untreated  and  non  targeting  siRNA 
treated Caco-2 cells.
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5.3.5  Silencing of NODI  expression inhibits C. jejuni mediated hBD-2 promoter 
activation
The  role  of  NODI  for  C.  jejuni  mediated  hBD-2  promoter  activity  was  also 
investigated.  As for IL-8, hBD-2 promoter constructs were transiently transfected in 
siRNA treated Caco-2 cells (20nM) followed by co-culture with WT C. jejuni 11168H 
(Figure 5.9a) and 81-176 (Figure 5.9b). 50-60% reduction in C. yeywm'-mediated hBD-2 
promoter function in the presence of siNODl  a and b was observed. Importantly, the 
presence of siNEG had minimal effect on hBD-2 promoter function (Figure 5.9).
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C.fijm(111MH 
NSD2
Control
C»un/81-176
HBD2
Control
Figure  5.9a  and  b:  Effect  of siNODl  on  G jejuni-mediated  hBD-2  promoter 
function.  HBD-2  promoter  constructs  were  transiently  transfected  in  Caco-2  cells 
following treatment with siNODla+b and siNEG (20nM). 48h post transfection, cells 
were co-cultured with WT C. jejuni  11168H (a) and 81-176 (b) for 8h and promoter- 
luciferase activity  assessed.  HBD-2 promoter activity in untreated,  C. jejuni infected 
Caco-2 cells were included as controls, the latter representing  100% induction.  Data 
represent  the  average  +/-  SEM  of  three  independant  experiments  performed  in 
triplicates.  *,  P<0.05  versus hBD-2  induction in untreated  and non targeting  siRNA 
treated Caco-2 cells.
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5.3.6  NOD2 plays a minimal role in intestinal epithelial immune defence against 
C. jejuni
Experiments  described  above  showed  that NOD2  gene  expression  was  not  seen  in 
resting or C. jejuni stimulated epithelial cells (Figure 5.4 and 5.5). However, during an 
in vivo infection, intestinal epithelial homeostasis is likely to be influenced indirectly by 
neighbouring  inflammatory  immune  cells  and  their  secretory  products  such  as 
cytokines,  molecules  known to  modulate  NOD2  expression  (Gutierrez  et  al,  2002; 
Rosenstiel  et  al.,  2003).  To  establish  if  epithelial  NOD2  (when  expressed  under 
inflammatory conditions) may also act as a potential PRR for C. jejuni,  we transiently 
transfected Caco-2 cells with a plasmid over-expressing NOD2. NOD2 gene expression 
48h post-transfection was  confirmed by  RT-PCR  (Figure  5.10a  and b;  third panel). 
Control and NOD2 transfected Caco-2 cells were exposed to C. jejuni wild-type strains 
11168H (Figure 5.10a) and 81-176 (Figure 5.10b). Infection with either strain resulted 
in no enhanced IL-8 or hBD-2 gene expression (Figure 5.9a and b). These findings were 
confirmed by using promoter constructs for both IL-8 and hBD-2. As shown in Figure 
5.10c and d, no increase in C. yey'wm-mediated IL-8 and hBD-2 promoter function was 
noted in the presence of NOD2 when compared to control cells lacking NOD2 (Figure 
5.10c and d).
Streptococcus  pneumoniae  (a  causative  agent  for  bacterial  meningitis)  transiently 
invades epithelial cells and utilises NOD2 as a PRR (Opitz et al, 2004). To confirm that 
the  transfected  NOD2  gene  in  our  cell  culture  system  was  biologically  active,  we 
included  S. pneumoniae  infection  as  a  control.  As  noted  for  gene  expression,  the 
presence of NOD2 had no effect on the levels of IL-8 protein production in response to 
C. jejuni strains 11168H or 81-176 (Figure 5.11). In contrast, a significant increase in 
IL-8 protein levels was observed in NOD2-transfected Caco-2 cells in response to  S. 
pneumoniae compared to infection in control, untransfected cells.
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Figure  5.10a-d:  Effect  of  IEC  NOD2  in  C.  y ey  mm/-mediated  IL-8  and  hBD-2 
induction.  Caco-2  cells  were  transiently  transfected  with  NOD2  over-expressing 
plasmid for 48h followed by infection with C. jejuni WT 11168H (a and c) or 81-176 (b 
and d) strains for 8h. IL-8 and hBD2 gene expression was analyzed by RT-PCR and a 
representative  gel  of 3  independent  experiments  is  shown  (a  and  b).  Transcriptional 
activity  was  also  quantified  by  promoter  luciferase  reporter  assay  (c  and  d).  Data 
represents +/-SEM of three experiments performed in triplicates.
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Figure 5.11: Effect of IEC NOD2 on C. jejuni- and S. pneumoniae-mediated IL-8 
protein  production.  Caco-2  cells  were  transiently  transfected  with  NOD2  over­
expressing plasmid for 48h followed by infection with C. jejuni WT  11168H, 81-176 
and encapsulated S. pneumoniae,  serotype FI9.  Un-treated Caco-2  cells,  deficient in 
NOD2, were included as control. 24h post-infection, IL-8 protein levels in cell-culture 
supernatants  were  analysed  by  ELISA.  Data  is  expressed  as  fold-induction  of IL-8 
protein levels compared to respective (+/-NOD2) uninfected control Caco-2 cells.  Error 
bars indicate +/-SEM of 2 independent experiments performed in duplicates.
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5.3.7  Intestinal  epithelial  NODI  engagement  mediates  antimicrobial  defence 
against C. jejuni
The biological consequence of NODI-mediated antimicrobial activity on C. jejuni was 
also investigated. For this purpose, bacterial co-culture studies with WT strain 81-176 
were performed over 20h on control untransfected,  siNEG,  siNODla,  siNODlb  and 
NOD2 transfected Caco-2 cells. This time period was chosen to allow sufficient time 
for  bacterial  adhesion/invasion,  host  sensing  and  initiation  of  innate  antimicrobial 
response. Following bacterial co-culture, cells were washed and subjected to a standard 
gentamicin  protection  assay.  Lysed  cell  suspensions  were  diluted  and  viable 
intracellular bacteria enumerated by CFU counts on blood agar plates. Duplicates from 
a representative experiment are shown in Figure 5.12a (columns A & B). Data of two 
similar experiments is schematically shown in Figure 5.12b. At the same serial dilution 
status, no bacteria were detected in control cells,  similarly,  siNEG cells also  showed 
minimal presence of live intracellular C. jejuni.  Most importantly, the specific knock­
down  of NODI  (siNODl  a &  b)  during  infection  greatly  enhanced  the  number  of 
intracellular C. jejuni cells. In contrast, the additional presence of NOD2 did not appear 
to  modulate  the  number  of  intracellular  bacteria  when  compared  to  control 
untransfected cells.
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Figure  5.12a  and  b:  Effect  of  IEC  NODI  expression  on  the  presence  of 
intracellular  C. jejuni  cells  following  20h  co-culture.  Caco-2  cells  were  reverse 
transfected with  siRNA  (sequences  a  &  b)  targeting  NODI,  siNEG  or  with plasmid 
expressing NOD2.  Non-treated  Caco-2  cells  served  as  control.  48h  post-transfection, 
cells were co-cultured with live WT C. jejuni 81-176 for 20h prior to enumeration of 
intracellular bacteria. Duplicates (columns A & B) from a representative experiment are 
shown (a).  Statistical  analysis of two to three  independent experiments performed  in 
triplicates  is  also  shown  (b).  Data  represents  average  percentage  CFU  obtained  in 
treated versus untreated Caco-2 cells (the latter set as 100%). **, P<0.001 vs.  untreated 
Caco-2 cells.
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5.4  Discussion
Despite  increasing  knowledge  about  activation  of  several  IEC  signal  transduction 
pathways  by  C. jejuni,  little  is  known  about the  mechanism(s)  by  which  C. jejuni 
triggers  host  responses.  Specifically,  to  date  no  pattern  recognition  receptor  (PRR) 
implicated in bacterial  sensing and initiating intestinal  epithelial host response to  C. 
jejuni has been identified.
Adhesion  to  and  invasion  of IECs  is  a  well  established  early  event  in  C.  jejuni 
pathogenesis.  Several  studies  have  demonstrated  activation  of  multiple  signal 
transduction pathways by C. jejuni, in particular IL-8 production has been shown to be 
intimately  linked  with  these  early  cellular  events  (Konkel  and  Cieplak,  1992; 
Oelschlaeger et al,  1993; Kopecko et al., 2001b; Biswas et al, 2003; Mooney et al, 
2003; Hu and Hickey, 2005; Watson and Galan, 2005).  Despite the lack of complete 
correlation between the degree of C. jejuni invasion and IEC IL-8 protein induction, the 
process  of  ‘invasion’  itself is  a  crucial  event  involved  in  eliciting  innate  immune 
responses.  Experiments  conducted  in  the  presence  of  PFA  fixed  bacteria  showed 
marked absence of intracellular C. jejuni cells (Figure 5.3) and correspondingly, IECs 
exhibited  weak  IL-8  gene  (Figure  5.1)  and  protein  expression  (Figure  5.2),  thus 
highlighting  the  requirement  for  C.  jejuni  cell  components  to  be  within  the  IEC 
cytoplasm for optimal host detection and response.
Unlike Salmonella which engages host TLR5, C. jejuni flagellin has been found to have 
weak  immune-stimulatory  properties  with  minimal  interaction  with  IEC  TLR5 
(Andersen-Nissen et al., 2005; Watson and Galan, 2005; Johanesen and Dwinell, 2006). 
Armed with the information that bacterial invasion is crucial for IEC immunity, coupled 
with minimal involvement of TLR5 led us to hypothesize that the family of intracellular 
NOD receptors could be likely PRR(s) for C. jejuni.
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Firstly  we  investigated  if C. jejuni  infection  could  modulate  the  expression  of the 
potential PRR(s). Utilizing Caco-2 and HT -29 cell lines and two bacterial WT strains in 
co-culture experiments, we found no significant modulation of NODI expression in the 
24h infection period (Caco-2: Figure 5.4a and b, HT-29: Figure 5.5a and b; top panel). 
This was an important observation as it suggests that the bacterium does not directly 
modulate NODI expression as an early immune evasion strategy. However, due to the 
limitations of an in vitro  cell line model of infection,  one cannot rule  out bacterial- 
driven  changes  in NODI  expression  and  function  in  an  ongoing  infection  in  vivo. 
Cytokines such as IFNy are known to augment NODI  expression (Hisamatsu et al, 
2003a) suggesting greater complexity to  C. ye/wm/epithelial NODI  interactions in an 
on-going inflammatory episode are likely. In contrast, NOD2 gene expression was not 
detected in control Caco-2 or HT-29 cells (Figure 5.4 and 5.5; third panel) and infection 
with either C. jejuni strain did not result in NOD2 induction, suggesting that it is NODI 
and not NOD2 that maybe a potential PRR for C. jejuni in our model system.  In the 
same experiments, we confirmed appropriate infectivity by following the expression of 
hBD-2,  a peptide whose  expression  is NODI  activation  dependent  (Boughan et al., 
2006).  Induction  of hBD-2  in the  absence  of NOD2  clearly  implicated NODI  as  a 
potential intracellular sensor for C. jejuni.
Next, we sought evidence for a functional role for NODI in C. jejuni infection. For this 
purpose we transiently transfected two NODI  siRNA sequences prior to exposure of 
cells to  C. jejuni.  We observed marked reduction of C. jejuni IL-8 and hBD-2 gene 
expression in cells treated with  siNODla  and b,  while treatment with non-targeting 
siNEG  did  not  have  any  effect  (Figure  5.6a  and  b).  Similarly,  siNODl  caused 
significant  reduction  of IL-8  protein  levels  induced  by  C. jejuni  (Figure  5.7).  This 
specific inhibitory effect of siNODl  was confirmed at the transcriptional level using 
luciferase promoter assays (Figure 5.9a and b). Importantly, despite the marked knock­
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down of the NODI  gene expression (Figure  5.6a and b) its corresponding inhibitory 
effect on IL-8 and hBD-2 gene (Figure 5.6 a and b) and promoter function (Figure 5.7a- 
f) ranged between 40 and 60%, suggesting NODI-independent signaling events are also 
involved in IEC innate immune gene regulation. Several studies have implicated MAP 
kinase  pathways  in  C.  ye/wm-mediated  IL-8  production  (MacCallum  et  al,  2005; 
Watson and Galan, 2005) and it is most likely that they are also operative in our model 
system.
Studies  by  Podolsky  and  colleagues  have  suggested  a  role  for  NOD2  in  intestinal 
epithelial defence against Salmonella infection (Hisamatsu et al, 2003b). In our study, 
over-expression of NOD2 by transient transfection did not augment innate defence gene 
expression in response to C. jejuni infection (Figure 5.10). To validate the functionality 
of transfected NOD2 in our culture system, we included live Streptococcus pneumoniae 
infection as a positive control as Optiz and co-workers have elegantly demonstrated 
NOD2 as the intracellular PRR for S. pneumoniae (Opitz et al.,  2004) (Figure 5.11). 
Why Salmonella and Campylobacter, two Gram-negative enteropathogens exhibit such 
contrasting requirement for NOD2 warrants further investigation.
Finally,  if antibacterial  immunity  is  generated  in response  to  C. jejuni infection via 
NODI  activation (e.g.  hBD-2  production),  one  can hypothesise  that  absence of this 
armory  is  likely  to  enhance  bacterial  invasion  and/or  survival.  We  followed  the 
biological consequence of NODI knock down on C. jejuni infection. We found marked 
increase  in the  number  of invasive  bacteria 20h  post-infection  in  cells treated  with 
siNODla  or  b  sequences  (Figure  5.12a &  b),  suggesting  unequivocally  that NODI 
mediated cellular events do contribute to the number of intracellular bacteria, whether 
this is due to increased invasion or increased survival or both remains a question for 
future work.
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The identification of NODI as a major sensor to enteroinvasive E. coli led Kagnoff and 
colleagues  to  propose  that  NODI  signaling  in  the  IEC  may  provide  a  backup 
mechanism for rapidly activating innate immunity during infection by highly invasive 
pathogenic Gram-negative enteropathogens (Kim et al., 2004).  Our study implicating 
NODI as a major intracellular PRR for C. jejuni, lends further support for a critical role 
for NODI  mediated immunity at the gastrointestinal mucosal surface.  Further studies 
are now required to investigate C. jejuni mediated signaling via NODI  in more detail. 
Activation of both TLRs and NOD-like receptors (NLRs) by different bacterial PAMPs 
is emerging as an important factor in mounting the hosts inflammatory response and 
priming of cells with PGN resulting in activation of NLRs has a synergistic effect on 
TLR signaling (Kufer and Sansonetti, 2007).  Insight into mechanisms involved in C. 
jejuni  PGN  delivery,  the  subsequent  recognition  by  NODI  and  possible  interplay 
between NLR and TLR signaling pathways will  shed greater light on the role of C. 
jejuni invasion in eliciting host responses.
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Ex-vivo model to study C. jejuni 
disease pathogenesis
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6.1  Introduction
Although intestinal pathology caused by C. jejuni in humans can vary, ranging from 
mild non-inflammatory watery, to severe bloody diarrhoea (Blaser, 1997), the presence 
of fresh  blood,  pus  or  mucous  suggesting  the  presence  of colorectal  inflammation 
remains a common feature of infection (Wassenaar and Blaser,  1999; Crushed et al., 
2004). Despite the clinical spectrum described, our knowledge of disease pathogenesis 
at molecular level remains limited.  One of the main reasons for this is the lack of a 
suitable animal model,  as  C. jejuni colonizes most domestic  and wild animals in an 
apparently commensal association with little or no pathology  (Shreeve  et al.,  2000). 
Furthermore,  due  to  the  generally  mild  and  self-limiting  nature  of  disease, 
hospitalization is rarely required and endoscopic examination during acute infection is 
rarely performed. Limited reports of colonoscopy  (i.e.  sigmoidoscopy)  findings have 
revealed mucosal changes in the large bowel ranging  form oedema and hyperaemia, 
petechial  haemorrhages  and  mucosal  friability  (van  Spreeuwel  et  al.,  1985;  Ketley, 
1997). These changes can sometimes be difficult to distinguish from those observed in 
patients suffering from IBD,  such as Ulcerative Colitis (van  Spreeuwel et al.,  1985; 
Siegal et al.,  2005).  Inflammation can also occur in parts of the  ileum and jejunum 
commonly  associated  with  mesenteric  adenitis  (Loss  et  al.,  1980;  Ketley,  1997; 
Wassenaar  and  Blaser,  1999).  Collectively,  data  suggest  that  C.  jejuni  can  cause 
inflammation in both the small and the large bowel. However, at present the sequence 
of adhesion and colonization, possible  cell type tropism (e.g.  Peyers Patches,  Goblet 
cells)  and early  host pathogen interactions  in-vivo  remain  largely  unknown.  Despite 
several advantages of the use of IEC lines as a reliable and reproducible in-vitro model 
to  study  C.  jejuni-Qpithelial  interactions,  limitations  of the  model  are  clear.  These 
include the absence of other cell types (i.e. Paneth cells, goblet cells), which interact in 
a complex three-dimensional manner leading to a concerted intestinal response to C.CHAPTER 6
jejuni, absence of a thick mucus layer and differences in the structural function of the 
various parts of the digestive tract.
To gain a better understanding of early C. jejuni -  intestinal interaction, in this series of 
experiments  we  initially  wished to  establish  an  ex-vivo  model  of infection.  Human 
intestinal forceps biopsy samples from small and large bowel of children undergoing 
lower endoscopy were obtained and cultured for up to 12h in the presence of C. jejuni. 
Following  infection,  the  tissue  was  fixed  and  host  pathogen  interaction  studied  by 
immunostaining and confocal microscopy.
A second major limitation of in-vitro and ex-vivo models used to study GI bacterial host 
pathogen interactions,  is that culture conditions generally favour eukaryotic  survival. 
Specifically, high oxygen levels are required to ensure host cell survival while many 
enteric  bacteria  (commensals  and  pathogens)  including  C.  jejuni  are  adapted  to 
microaerophilic/ anaerobic conditions. In the GI tract, oxygen supply for the intestinal 
epithelium  is  provided  via  the  underlying  submucosal  capillary  network,  while 
conditions  in  the  lumen  and  the  apical  epithelial  surface  are  anaerobic.  One  may 
hypothesize, that bacteria/pathogens in their natural anaerobic environment are likely to 
express  virulence  genes whose  expression may  differ  in  aerobic,  general  laboratory 
conditions. Taking these factors into account, we aimed to design a model of infection 
closely mimicking conditions in the GI tract. A vertical diffusion chamber system was 
employed  to  provide  ideal  growth  conditions  for  both  C.  jejuni  and  host  IECs. 
Following optimization, experiments were performed to test for potential differences in 
virulence according to culture conditions.
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6.2  Methods
6.2.1  In-vitro organ culture (IVOC) of intestinal biopsies
All reagents were supplied from Sigma, Poole, UK unless stated otherwise.
6.2.1.1 Preparation of IVOC medium
IVOC medium was prepared by adding 0.95g powdered NCTC-135 media and lg D- 
mannose  (to  prevent  non-specific  adherence)  to  100ml  sterile,  deionised  water. 
Following, pH was adjusted to 7.4 by adding 0.22g sodium bicarbonate. Finally, lOOmls 
of tissue culture medium (DMEM+ Glutamax) and 20mls FCS were added to lOOmls of 
filter sterilized NCTC-135 media (0.22pm filter, Millipore) to make up complete IVOC 
medium.
6.2.1.2 IVOC protocol and bacterial co-culture
This method has previously been established for the co-culture of intestinal biopsies 
with E. coli (Hicks et al., 1996). Histologically normal mucosal samples from ileum and 
colon  were  obtained  from  pediatric  patients  undergoing  endoscopic  investigation. 
Institutional ethical  approval  (ID:  BRD/06/049)  and parental  consent were  obtained. 
Immediately  after  collection,  samples  were  transferred  into  IVOC  medium  and 
transported  to  the  laboratory.  Biopsies  were  examined  for  tissue  integrity  under  a 
dissection microscope (XTL-101, GX Optical, Suffolk, UK), and mounted (mucosa side 
up) on sponge support units (autoclaved sponge rubber pieces) placed in 12 well plates 
and  soaked in  complete  IVOC  medium.  Fluid  levels  in  each well  were  adjusted to 
provide partial submersion of biopsies in IVOC medium (Figure 6.1a).
Twenty to fifty microliters of bacterial suspension containing approximately  108  CFU 
(C. jejuni  11168H)  was  applied immediately to the  apical/mucosal  surface  of tissue 
samples.  An uninoculated  specimen was  included  in  each  experiment  as  a negative 
control. Co-cultures were placed on a rocking platform/shaker and maintained at 37°C 
and 5% CO2 in a humidified incubator (Galaxy CO2 Incubator, Wolf Laboratories, UK)
154CHAPTER 6
for up to  12h  (Figure  6.1b).  Tissue culture  medium  was  changed regularly  (2-3h)  to 
maintain pH and nutrient levels and additional C. jejuni suspension applied twice. 
Following incubation period, tissue samples were washed 3 times in fresh tissue culture 
medium to remove any non-adherent bacteria, transferred into 4% PFA stored at 4°C 
until further processing.
(a)  (b)
Figure 6.1a  and  b: In-vitro  organ  culture of intestinal  forceps  biopsies.  Intestinal 
biopsies from terminal ileum and colon were mounted on sponge support units placed in 
12 well plates and soaked in IVOC medium mucosal side facing up (a). Twenty to fifty 
microliters  of C. jejuni  in  suspension  was  directly  applied  to  biopsies  and  samples 
maintained on a rocking platform at 37°C and 5% CO2 in a humidified incubator (b).
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6.2.2  C. jejuni immimo-labeling and biopsy staining
4% PFA-fixed tissue was washed three times in PBS to remove residual traces of PFA. 
Tissue was lysed by immersion in 0.2% Triton X  100/PBS  solution for 5min at RT. 
Non-specific binding was blocked by incubating tissue  samples in  1% BSA/PBS  for 
45min. C. jejuni was labeled using primary unconjugated goat anti-C. jejuni antibodies 
(KPL, Maryland,  USA) at a concentration of 5pg/ml  for 60min at RT,  followed by 
incubation with  FITC-conjugated rabbit anti-goat IgG  (0.5jig/ml,  Molecular Probes, 
Eugene,  Oregon,  USA)  for  30min.  Cell nuclei  were  counterstained  with TO-PRO-3 
(Molecular Probes,  Eugene,  Oregon,  USA)  for 30min.  Following  immuno-labeling, 
actin  cytoskeleton  was  stained  with  1  Unit/ml  rhodamine  phalloidin  in  PBS/BSA 
solution (Invitrogen Ltd, Paisley, UK) for 45min. After each step, cells were washed 3 
times  with  PBS.  Finally,  whole  biopsies  were  mounted  in  Vectashield  (Vector 
Laboratories Ltd.,  Peterborough, UK)  and visualized with a Radiance 2100  confocal 
laser scanning microscope equipped with an Argon-Krypton laser and a red diode (Bio- 
Rad Laboratories, Hemel Hempstead, UK).
6.2.3  Tight junction staining of Caco-2 cell monolayers
Occludin  is  an  integral  transmembrane  protein,  associated  with  epithelial  tight 
junctions  (Kimura  et  al,  1997).  In  order  to  monitor  tight junction  formation  and 
monolayer integrity,  Caco-2  cells  grown on  snapwell  inserts  (diameter:  12mm, pore 
size: 0.4 pm; Fisher Scientific, Leicestershire, UK) were stained for occludin. Briefly, 
approximately 4 x  105  cells were placed into each snapwell insert and grown over a 
minimum of 21d to allow for polarization and tight junction formation.  Inserts were 
placed into vertical diffusion chamber devices and incubated for 20h in either CO2 or 
VAIN incubator (will be described in 6.3.2).  Post-incubation, cells were fixed in 4% 
PFA and lysed for 5min at RT in 0.2% Triton X 100/PBS. Following blocking of non­
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specific binding sites in BSA,  cells were incubated in  10p,g/ml unlabeled polyclonal 
rabbit anti-occludin antibody (ZYMED Laboratories,  San Francisco,  USA) for  lh at 
RT.  FITC  labelling was performed by incubation in  secondary  anti-rabbit antibody 
(0.5pg/ml)  for 30min at RT (Molecular probes,  Eugene,  Oregon,  USA).  Cell nuclei 
were counterstained with TO-PRO-3 (Molecular probes, Eugene, Oregon, USA).
6.3  Results
6.3.1  C. jejuni interactions with human intestine
Prior to investigating C. jejuni cross-talk, tissue  survival in the organ culture system 
over a period of up to  12h was studied. As shown in Figure 6.2, uninfected samples 
from both small (terminal ileum) and large bowel (colon) remained structurally intact 
with the outline of small intestinal villi (Figure 6.2a) and colonic crypts (Figure 6.2b) 
visible. Following demonstration of tissue survival/integrity, co-culture experiments of 
intestinal  biopsies  with  WT  C.  jejuni  11168H  were  performed  and  host-pathogen 
interactions analyzed by immuno-labelling of C. jejuni and confocal microscopy. 
Although the majority of C. jejuni organisms were found in the mucus layer covering 
the epithelial surface in the terminal ileum (Figure 6.3a and b), close contact between C. 
jejuni and the intestinal epithelium was also observed at several sites in the same biopsy 
(Figure 6.3c and d). This was a reproducible and regular finding in biopsies infected 
with C. jejuni 11168H for more than 8h. Interestingly, despite the close contact between 
C. jejuni and the epithelium, the brush border appeared to remain intact with no visible 
actin rearrangements (Figure  6.3c and d).  An intriguing finding was the presence of 
small clusters of C. jejuni that appeared to associate with single cells of the terminal 
ileum (6.4a and b). These findings have been noted in only one sample.  In contrast to 
our observations in small bowel, to date similar C. jejuni localisation in the colon has 
not been found.
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Figure  6.2a  and  b:  Integrity  of intestinal  biopsies  following  12h  ex-vivo  culture. 
Intestinal forceps biopsies of terminal ileum (a) and colon (b) were incubated in IVOC 
media over  12h.  Following  fixation in 4%  PFA,  actin cytoskeleton was  stained with 
rhodamine  phalloidin  (red)  and  nuclei  counterstained  with  T0-PR03  (blue).  Intact 
small intestinal villi (a) and colonic crypts (b) as observed by confocal microscopy.
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(a)  (b)
Figure 6.3a to d: Co-culture of G jejuni with human small bowel biopsies. Human 
intestinal biopsies from the terminal ileum were co-cultured for 12h with WT C. jejuni 
11168H.  Post-infection,  bacteria  (green)  and  actin  filaments  including  apical  brush 
border (red) were visualized. T0-PR03  (blue) allowed nuclear staining.  Whole tissue 
samples were mounted on glass slides and examined by confocal microscopy.
159CHAPTER 6
(a) (b)
Figure  6.4a  and  b:  Small  clusters  of  C.  jejuni  associated  with  small  bowel 
epithelium. Intestinal biopsies from the terminal ileum were co-cultured with C. jejuni 
11168H  for  12h and bacteria visualized by  immunolabelling  (green).  Actin  filaments 
were stained with rhodamine phalloidin (red). Biopsies were mounted on coverslips and 
examined by confocal microscopy.
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6.3.2  The asymmetrical vertical diffusion chamber system
The diffusion cell-system, derived from an Ussing chamber, was originally developed 
by Grass and Sweetana to study the transport of substances across membranes (Grass 
and Sweetana, 1988). In the present study, a vertical diffusion chamber system (Harvard 
Apparatus Ltd, Kent, UK) was utilised to provide optimal growth conditions for both C. 
jejuni and Caco-2 cells (Figure 6.5).
Caco-2 cells were grown on snapwell filters over a minimum of 21  days to allow for 
polarization  and  tight  junction  formation.  This  was  established  by  measuring 
transepithelial  electrical  resistance  (TEER)  prior to  experiments  using  a  DVC-1000 
voltage  clamp  (details  below;  World  Precision  Instruments,  Hertfordshire,  UK).  A 
TEER  of >200  ohm  x  cm2  was  indicative  of formation  of a  tight,  polarized  cell 
monolayer.
6.3.2.1  Set up of the vertical diffusion chamber system
The vertical diffusion chamber was set up as outlined in Figure 6.5. Polarized Caco-2 
cell  monolayers  on  snapwell  inserts  were placed  into  the  diffusion  chamber  device 
creating an apical and basolateral compartment, which were filled with tissue culture 
medium. Several chambers could be mounted serially allowing for inclusion of control 
and duplicate samples. The chambers were placed into a variable atmosphere incubator 
(VAIN, Don Whitley Scientific Ltd, Shipley, UK) containing 90% N2, 5% O2 and 10% 
CO2  at 37°C and hence providing ideal growth conditions for  C. jejuni.  The apical 
compartment was left open  and exposed to  the  microaerobic  atmosphere within the 
VAIN, whilst the basolateral compartment was closed with airtight caps.  Basolateral 
oxygen  supply  for  Caco-2  cells  was  provided  by  constant  administration  of a  gas 
mixture  containing  5%  CO2  and  95%  O2.  The  gas  mixture  flow  rate  was  set  to 
approximately  5-10mls/min  (30-40  gas  bubbles/min)  with  an  outlet  tube  preventing 
accumulation of pressure.
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(a)
(b)
Figure 6.5:  Asymmetrical, vertical diffusion  chamber system.  A vertical  diffusion 
chamber system was set up as illustrated schematically (a) and in the laboratory (b), to 
provide optimal culture conditions for both C. jejuni and  Caco-2  cells.  Differentiated 
Caco-2  cell monolayers  grown on  snapwell  inserts were placed  in the  diffusion cell, 
creating an apical and basolateral compartment. With the apical compartment left open, 
the chamber was placed in a VAIN incubator containing 10% C02, 5% 0 2 and 90% N2. 
The basolateral compartment was closed with an airtight cap and continuously gassed 
with a mixture containing 5% C02 and 95% 0 2. A gas outlet tube, leading out of the 
VAIN incubator, prevented accumulation of gas pressure.
'outlet Chamber in VAIN incubator airtight cap
5% CO, + 95% O.
I   10% CO, + 5% O, + 90% N,
inlet
Transwell/Snapwell 
Caco-2 monolayer
Apical compartment: 
C jejuni in MHB/DMEM
Basolateral compartment: 
DMEM medium
airtight cap
G as outlet
b aso lateral
Chamber in VAIN incubator 
(10% C 02 + 5% 0 2  + 90% N2)
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6.3.2.2  Assessment of monolayer integrity in VAIN incubator
In order to prove functionality of our system we firstly aimed to demonstrate survival of 
Caco-2  cell  monolayer  and  hence  physical  separation  of  apical  and  basolateral 
compartment in the  low  oxygen environment of the  VAIN  incubator.  We therefore 
monitored the TEER throughout the experiment and visualized tight junction integrity 
by staining for occludin following a 20h incubation period.
a)  TEER measurements 
TEER across a cell monolayer is a reliable parameter to monitor tissue integrity and was 
performed in our diffusion chamber system as shown in Figure 6.6a and b. Two silver 
chloride (AgCl) electrodes (Harvard Apparatus Ltd, Kent, UK) were inserted in each 
compartment of the diffusion chamber. Voltage sensing electrodes (Vi  and V2) were 
placed in close proximity of the cell monolayer, while current passing electrodes (Ii and 
I2) were placed further away form the tissue (Figure 6.6a). An empty snapwell insert 
(without Caco-2 cells) was used to auto zero and compensate for fluid resistance prior 
to  the  insertion  of a  snapwell  containing  the  cell  monolayer.  At  the  start  of the 
experiment and at regular time intervals an electrical current (180fxA) was passed via Ii 
and I2 and voltage read-out on the voltage clamp recorded. Resistance was calculated 
according to Ohm’s law: R (in I2)=V / 1  and monolayer TEER (in Hem2) calculated by 
multiplying  resistance  with the  surface  area of the  snapwell  insert  (1.12  cm2).  As 
shown in Figure 6.6c, TEER in cells maintained in the VAIN incubator over a 20h time 
period remained above 200 Hem2, suggesting integrity of cell monolayer.
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Figure 6.6a to c: Measurement of TEER in the vertical diffusion chamber system.
Two AgCl electrodes were placed in each compartment, with voltage sensing electrodes 
placed in close proximity to the cell monolayer (Vi and V2). Electrodes were connected 
to the voltage clamp as outlined in (a). A current of 180pA was passed via Ii and I2 and 
voltage  read-out  recorded.  Resistance  was  calculated  according  to  Ohm’s  law  and 
TEER (in 12 cm ) obtained by multiplication with the surface area of snapwell inserts 
(1.12 cm2), (c) TEER measurements of Caco-2 monolayer maintained in VAIN for 20h. 
Arrow bars indicate mean +/- SEM of one experiment performed in duplicates.
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b)  Assessment of monolayer integrity by tight junction staining 
Integrity  of cell  monolayers  maintained  in  VAIN  for  20h  was  further  assessed  by 
staining for the tight junction protein occludin. As shown in Figure 6.7a, tight junctions 
remained present and evenly distributed between the cell borders, with occludin staining 
pattern similar to cells maintained in air containing CO2 tissue culture incubator (b).
(a)  (b)
Figure 6.7a and  b:  Assessment of tissue integrity by staining for tight junctions.
Caco-2 cell monolayers maintained in the vertical  diffusion chamber system for 20h. 
Tissue integrity was assessed by staining for the tight junction protein occludin (green) 
and distribution of tight junctions in VAIN (a) compared to cells maintained in a CO2 
incubator (b). Cell nuclei were counterstained with TO-PRO-3 (blue).
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6.3.2.3  Bacterial growth, adhesion and invasion in VAIN, preliminary results 
Following  demonstration  of  Caco-2  survival  and  monolayer  integrity,  C.  jejuni 
virulence  in  low  oxygen  condition  was  investigated  by  assessing  bacterial  growth, 
adhesion and invasion using a gentamicin protection assay. Approximately 3 x 106 CFU 
of C. jejuni WT 11168H were added to the apical compartment of the diffusion chamber 
and placed either in the VAIN or CO2 incubator.  Following  3.5h incubation period, 
bacterial  growth  and  adhesion  were  assessed  by  plating  out  serial  dilutions  of 
supernatants and cells lysates respectively on blood agar plates. In a second chamber, 
media in both compartments was replaced with media containing 150pg/ml gentamicin 
and cells incubated for 60min.  Bacterial invasion was assessed by plating out serial 
dilutions of cell lysates on blood agar plates followed by counting of CFU three days 
later. As shown in Figure 6.8, we observed higher rates for bacterial growth, adhesion 
and invasion for C. jejuni 11168H kept in low oxygen VAIN for 3.5h when compared 
to normal oxygen CO2 incubator. However, this is data from one experiment only and 
requires confirmation.
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Figure 6.8a and b: C. jejuni 11168H growth, adhesion and invasion in VAIN versus 
CO2 incubator. Approximately 3 x 106  CFU of WT C. jejuni 11168H were placed in 
the  apical  compartment  of  the  vertical  diffusion  chamber  containing  Caco-2  cell 
monolayers. Two diffusion chambers each were placed in VAIN and CO2 incubator for 
3.5h. Following, bacterial growth/survival (a), adhesion and invasion (b) were assessed 
using a standard gentamicin protection assay.
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6.4  Discussion
Our knowledge about early host pathogen interactions between C. jejuni and the human 
intestinal mucosa in-vivo remain limited. Reasons include the lack of a suitable animal 
model  and  the  generally  mild,  self-limiting  nature  of  human  intestinal  disease. 
Additionally, several major limitations of cell-line models currently available underline 
the need for novel infection models to study C. jejuni disease pathogenesis.
For  data  presented  in  this  chapter,  we  used  paediatric  intestinal  forceps  biopsies 
obtained from healthy  children as an ex-vivo model  of infection to  investigate early 
host-C. jejuni interactions.  Since the distribution and pattern of intestinal colonization 
by C. jejuni is unknown, we aimed to shed further light on which part of the digestive 
tract is initially targeted by the bacterium. Co-culture studies on both the small (terminal 
ileum) and large bowel (colon) with WT C. jejuni 11168H were performed.
Unlike in cell line models (i.e. Caco-2 cells), where bacteria have direct access to the 
epithelium allowing for adhesion and invasion to occur, the intestinal tissue is covered 
in a thick mucus layer. As an important initial observation, we found the majority of C. 
jejuni to be localized within the mucus film overlaying the intestinal epithelium of small 
bowel tissue (Figure 6.3a and b). These findings are consistent with studies by Grant 
and colleagues, suggesting that C. jejuni preferentially associates with mucus overlying 
tissue  of duodenal  biopsies  (Grant  et  al.,  2006).  Furthermore,  several  studies  have 
provided evidence that  C. jejun  is chemotactic  towards mucin  and may  explain the 
localisation of majority of C. jejuni found in our study (Figure 6.3a and b). Taking into 
account that ingestion of only a few hundred C. jejuni organisms can cause disease in 
humans  (Black et al,  1988),  one  may  hypothesise  that the  bacterium  colonizes the 
mucus  layer,  allowing  for multiplication and  expression  of virulence  genes prior to 
further progression and interaction with the intestinal epithelium.
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As a consistent finding, we observed C. jejuni in close association with the small bowel 
epithelium (Figure 6.3c and d). Importantly, these areas were commonly overlaid by C. 
jejuni containing mucus, lending further support for the hypothesis that the bacterium 
colonizes the mucus layer prior to adhesion and invasion of the IEC. However, despite 
the close contact of C. jejuni with the epithelial layer, the brush boarder remained intact 
with  no  visible  actin  rearrangements.  Furthermore,  in  contrast  to  well-established 
findings in cell line models, we were unable to demonstrate bacterial invasion in our ex- 
vivo system.  However, this might be due to the relatively  short incubation period of 
12h, which might not be sufficient for bacterial invasion to occur.
We observed several clusters of C. jejuni associated with single cells within the small 
bowel epithelial layer in one biopsy sample (Figure 6.4a and b).  Unfortunately we were 
unable to verify the cell type and potential cell topism remains speculative. However, 
similar findings were observed in the duodenum by  Grant and colleagues suggesting 
that these cells might be mucus producing goblet cells (Grant et al, 2006). Experiments 
are currently in progress to address these questions.
In contrast to  our findings in  small bowel biopsies,  we  were  unable to  demonstrate 
similar  close  association  of  C.  jejuni  with  the  intestinal  epithelium  in  the  colon. 
Whether this is due to limitations of our IVOC model and imaging techniques or a true 
reflection of in-vivo events remains unanswered. However, if this was a true event, this 
finding stands in some contrast to observations from human infection, stating that the 
major  inflammatory  changes  occur  in  the  colon  (Blaser,  1997).  One  possible 
explanation  would  be  that  C.  jejuni  might  initially  target  the  small  bowel  before 
colonizing the  large  intestine.  This process can be  expected to  take  longer than the 
studied  12h period and therefore might help  to  explain the  absence  of C. jejuni  in 
colonic tissue samples in our system. However, limitations of the IVOC system have to 
be considered when interpreting these results. Most importantly, culture conditions in
169CHAPTER 6
the CO2 tissue culture incubator (high oxygen), were suboptimal for C. jejuni and in 
favour of the eukaryotic cell.  With C. jejuni requiring microaerophilic conditions for 
ideal growth, high oxygen might prevent the bacterium from exhibiting its full virulence 
and  hence  mask  important  events  occurring  in-vivo.  To  address  this  problem,  we 
utilised a vertical diffusion chamber system to provide ideal growth conditions for both 
C. jejuni and intestinal epithelial Caco-2 cells (Figure 6.5).
Optimization of system set-up included demonstrating survival of Caco-2 cells in low 
oxygen within the  VAIN.  This was  important  as  integrity  of the  cell  monolayer  is 
mandatory to ensure the physical separation of apical and basolateral compartments and 
hence separation of both gas environments. We therefore monitored monolayer integrity 
over a 20h incubation period by measuring TEER throughout the experiment (Figure 
6.6) and visualized tight junction integrity by staining for occludin (6.7).  With TEER 
remaining above 200 'Q cm2 (Figure 6.6c) and staining for the tight junction protein 
occludin suggesting their integrity (Figure 6.7a), we were able to provide good evidence 
not  only  for tissue  survival  but  also  successful  separation  of apical  and  basolateral 
compartments.  Unfortunately,  due  to  technical  limitations  and  lack  of facilities  (i.e. 
blood gas analyzer) we were unable to measure exact oxygen concentrations in apical 
and basolateral compartments, however, the constant measurement and adjustment of 
CO2 and O2 levels to set values by the VAIN incubator, provides further evidence for 
the functionality of our system.
In 2002, Cottet and colleagues published their findings on the use of a similar vertical 
diffusion chamber system to study H. pylori virulence in low oxygen conditions (Cottet 
et al., 2002). They were able to demonstrate not only increased survival of H. pylori in 
5% O2 as compared to normal air, but also showed a significant increase in adherence to 
and  invasion  of Caco-2  cells.  Following  optimization  of our  system,  we  aimed to 
investigate differences in virulence of C. jejuni according to the gas environment. We
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therefore  performed  gentamicin  protection  assays  and  analyzed  bacterial  survival, 
adhesion  and  invasion.  Preliminary  results  obtained  were  promising,  demonstrating 
slightly increased survival, adhesion and invasion in low oxygen conditions after 3.5h 
(Figure 6.8). However, these experiments were performed only once and require further 
confirmation. With set-up now completed, longer time periods can be investigated and 
parameters  such  as  MOI,  bacterial  strain  and  infection  media  used  in  the  apical 
compartment (i.e. tissue culture medium vs. MH broth) explored. Furthermore, we aim 
to  replace  Caco-2  cells  with  intestinal  biopsies  allowing  to  combine  both  infection 
models and create a novel system closely reflecting human in-vivo conditions.
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Since its discovery a century ago, the Gram-negative bacterium C. jejuni has emerged 
as  the  worlds  leading  cause  of bacterial  mediated  diarrhoea.  In  several  developed 
countries the  number  of reported  C. jejuni  enteritis  cases  currently  exceeds  80  per
100.000 people (Friedman et al., 2000), while the true incidence including un-reported 
cases are likely to be much higher with estimates suggested in the region of 1.000 to
2.000  cases per  100,000  people  (Samuel  et al.,  2004).  Numbers  are  even higher in 
developing countries where infection is endemic, reaching estimated 40,000 to 60,000 
cases per 100,000 (Oberhelman and Taylor, 2000). Mainly young children under the age 
of 5 years are affected and with dehydration occurring rapidly in this age group, even 
mild watery diarrhoea can turn into a live threatening event if adequate treatment is 
delayed. Further, it is now well established that C. jejuni infection is associated with a 
wide  range  of intestinal  and  extra-intestinal  complications.  A  prime  example  is  the 
frequently  occurring  GBS  (1  in  1000  cases  of  C.  jejuni  enteritis),  an  acute  post- 
infectious ascending paralysis that can affect peripheral and cranial nerves, in severe 
cases  requiring  artificial  ventilation  (Douglas  and  Winer,  2006;  Kuwabara,  2007). 
Despite this significant health burden caused by C. jejuni our knowledge about disease 
pathogenesis remains ill defined. However, elucidation of the genome sequence of C. 
jejuni  strain NCTC11168  in recent years has  accelerated research  in  Campylobacter 
genetics, microbiology and pathogenesis  (Parkhill et al.,  2000a).  Significant findings 
include the discovery of both an O- and A-linked glycosylation system allowing post 
translational modification of several surface structure (Szymanski and Wren, 2005), one 
of which is a previously un-noted capsular polysaccharide (Karlyshev and Wren, 2001). 
These and other features of C. jejuni are likely to not only modulate bacterial virulence 
and survival, but also influence host-pathogen interactions and disease outcome. With 
the possibility of creating knock out mutants now available, exciting opportunities have 
opened to unravel molecular events involved in C. yeywm'-associated disease.
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The variable  clinical picture of C. jejuni enteritis and lack of direct correlation with 
strain virulence underlines the crucial role of host immune response(s) in determining 
disease severity and outcome. Furthermore, given the generally self-limiting nature of 
infection,  insight  into  immune  defence  mechanisms  that  allow  successful  bacterial 
clearance are essential to further our understanding of C. jejuni disease pathogenesis. As 
the first site of host-pathogen interaction, the epithelial lining of the GI tract not only 
provides a crucial physical barrier, protecting the underlying mucosa from the external 
environment  but  also  actively  participates  in  microbial  sensing  and  mounting 
appropriate innate immune responses by the production of chemokines, cytokines and 
AMPs (Kagnoff and Eckmann, 1997; Eckmann, 2005). Members of the latter group are 
p-defensins, evolutionary conserved small cationic peptides (Pazgier et al, 2006). The 
now  well  established  unique  role  in  host  defence  results  from  their  antimicrobial 
properties  against  a  wide  range  of microbes  (including  bacteria,  fungi,  yeast  and 
viruses)  combined  with  their  ability  to  act  as  multieffector  molecules  capable  of 
enhancing innate immune response as well as activating cells of the adaptive immune 
system (Selsted and Ouellette, 2005; de Leeuw and Lu, 2007).
Several  studies  have  demonstrated  how  defensins  and  their  modulation  in-vivo  can 
influence both susceptibility to infection (Goldman et al.,  1997; Schroder and Harder, 
1999) or conversely provide protection for the host (Salzman et al., 2003). The first aim 
of this study was therefore to  investigate the role  and regulation of hBDs during  C. 
jejuni infection. To date the most extensively studied p-defensins are hBD-1, -2 and -3. 
While  hBD-1  is  expressed  constitutively  in  IEC  of the  GI  tract,  hBD-2  and -3  are 
inducible during infection and inflammation (O'Neil et al.,  1999; Ogushi et al., 2001; 
Wehkamp  et al,  2003b).  We  firstly  examined the  modulation  of hBD-1,  -2  and -3 
during C. jejuni infection in two frequently used intestinal epithelial cell lines Caco-2 
and HT-29. We found expression of hBD-1 to remain constitutive during infection with
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two virulent WT C. jejuni strains tested 11168H and 81-176 (Figure 3.1). This was an 
important finding, particularly in the light of other studies that have demonstrated up- 
and  down-regulation  of  hBD-1  expression  during  infection  with  H  pylori  and 
Cryptosporidiumparvum respectively (Bajaj-Elliott et al., 2002; Zaalouk et al., 2004). 
Unlike these enteropathogens, C. jejuni does not seem to regulate expression of hBD-1 
highlighting  the  distinct  differences  amongst  microbes  in  modulating  innate  host 
defence. In contrast to hBD-1, we were the first to demonstrate induction of hBD-2 and 
hBD-3  by WT C. jejuni (Figure 3.1)  suggesting a potential role of these peptides in 
disease pathogenesis. Additionally, several studies have demonstrated induction of the 
potent neutrophil attractant IL-8 in response to C. jejuni (Hickey et al., 1999; Hickey et 
al., 2000; MacCallum et al., 2005; Watson and Galan, 2005). This cytokine is thought 
to be involved in disease pathogenesis by initiating a local inflammatory process in the 
affected  intestinal  mucosa,  contributing  to  bacterial  clearance  in-vivo  (Watson  and 
Galan,  2005).  We  were  able  to  confirm  and  further  extend  these  findings  by 
demonstrating  induction of IL-8  by  C. jejuni  11168H  and  81-176  in both cell lines 
tested  (Figure  3.1).  Interestingly,  kinetics  and  magnitude  of  IL-8  gene  expression 
followed a similar pattern as hBD-2 and hBD-3 with up-regulation occurring at 6h post 
infection and levels remaining elevated throughout the tested 24h time interval (Figure 
3.1). These findings suggest common signaling pathway(s) involved in the regulation of 
several innate defence genes.
Despite lack of significance, we found a reproducible difference in innate defence gene 
modulation, depending on WT strain and cell line utilized. Specifically, we consistently 
observed slightly higher levels of P-defensin and IL-8 induction by WT strain 81-176. 
These differences are not surprising, considering the large genetic and microbiological 
diversity of C. jejuni strains, which is likely to influence their virulence and hence host 
response. In fact several studies have demonstrated differences in the ability of various
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C. jejuni strains to induce IL-8  secretion (Hu and Hickey,  2005;  Watson and Galan, 
2005).  Regarding the two  WT strains used in this study,  81-176 is considered to be 
more invasive and harbors a plasmid (pVir) that has been shown to be associated with 
virulence (Bacon et al, 2000). Experiments to compare the invasive potential of strain 
11168H and 81-176 are underway (Mr. A. Elmi, LSHTM), and might provide further 
explanation  for  our  findings.  Additionally,  differences  in  host  response  are  also 
expected  to  vary  according  to  host  cells  used  (MacCallum  et  al.,  2006).  We  have 
observed a consistently lower induction of hBD-3 mRNA levels in HT-29 cells when 
compared  to  Caco-2  (Figure  3.1).  This  was  again  the  case  for  both  WT  strains, 
highlighting the importance to take differences in cell line models into account when 
investigating bacterial host pathogen interactions. Western Blot analysis of Caco-2 cells 
infected with WT C. jejuni 11168H confirmed correlation between elevated hBD-2 and 
-3  mRNA with protein levels  (Figure  3.2).  An additional  important finding was the 
presence  of hBD-2  peptide  in  infected  cell  supernatants,  while  hBD-3  was  mainly 
extracted from the cell lysate.  It is tempting to  speculate that these findings indicate 
compartmentalization of defensin expression (secretory versus intracellular) providing 
several  levels  of host defence.  Specifically,  given the  suggested  secretory  nature  of 
hBD-2, this peptide might target extra cellular, adhering pathogens, while hBD-3 may 
attack bacteria that have managed to invade the host cell. Additionally, hBD-3 might be 
released  upon  apoptosis  of IEC  or  during  the  inflammatory  process  providing  an 
additional extracellular line of defence.
Utilizing  luciferase reporter gene  assays,  we  aimed to  investigate the transcriptional 
regulation of innate  defence  genes  in response to  C. jejuni.  In  addition to  promoter 
constructs for IL-8, hBD-2, -3 we also investigated transcriptional regulation of NF-kB. 
The transcription factor is well established as a central player in regulating innate gene 
transcription and has been implicated in C. jejuni mediated host defence (Fox et al.,
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2004; Hu and Hickey, 2005). For all innate genes tested, we observed a two to three 
fold  induction  in  response  to  both  WT  strains  11168H  and  81-176  (Figure  3.4). 
Compared  to  other  stimuli,  such as  IL-lp,  this  could  be  considered  as  a relatively 
moderate  induction.  However,  it is  likely  that  C. jejuni  has  developed  strategies to 
evade host recognition for example by phase variation of surface structures, and hence 
causes  a considerably moderate  immune response.  Similar to  our RT-PCR findings, 
there was  a reproducible,  yet not  statistically  significant trend  of 81-176  leading to 
slightly higher levels of promoter activity (Figure 3.4).  Findings at that stage clearly 
demonstrated dynamic cross talk between C. jejuni and the IEC leading to the induction 
of hBD-2 and hBD-3.  However,  in order for these peptides to play a role in disease 
pathogenesis they must exhibit antimicrobial activity against the bacterium. This could 
not be taken for granted as the antimicrobial activity of hBDs varies greatly according 
to peptide and organism tested (Pazgier et al., 2006). Additionally, several mechanisms 
have been reported that allow bacteria to become resistant to cationic peptides (Peschel 
and Sahl, 2006). We therefore investigated the bactericidal activity of hBD-1, -2 and -3 
against WT C. jejuni 11168H and found inducible hBD-2 and -3 to be highly potent and 
fast acting bactericidal agents against C. jejuni, further highlighting their potential role 
in C. jejuni disease pathogenesis (Figure 4.1). In contrast to hBD-2 and -3, bactericidal 
activity of hBD-1  was found to be significantly lower and more variable (Figure 4.1). 
However, the observed synergistic or at least additive bactericidal effects of hBD-1 with 
lysozyme indicated how AMPs from different families might combine forces and hence 
enhance their individual properties (Figure 4.6). Although the exact concentration of 
hBDs at the GI mucosal surface remains unknown, killing capacity of defensins in the 
10* M range observed in the present study is comparable to those reported for other 
Gram-negative bacteria (Lee et al, 2004).  Speculating about a potential role of these 
peptides in-vivo, one has to take the salt sensitive nature of defensins into consideration.
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Higher  salt  concentrations  in  the  GI  tract,  might  inhibit  bactericidal  activity  and 
therefore  be  considerably  lower  than  in  the  more  favorable  low  salt  experimental 
conditions. However, regardless of in-vivo salt concentrations, given the observed fast 
acting  bactericidal  effect  of hBD-2  and  -3,  close  contact  to  the  host  cell  or  even 
intracellular presence of C. jejuni could allow defensin mediated killing to take place in 
a “microenvironment” where high peptide concentrations can be achieved and hence 
salt concentrations may become less relevant.  Further  studies are needed to  support 
these speculations.
The exact mechanism of how defensins mediate  their  antimicrobial  activity remains 
unknown,  however  increasing  evidence  suggest  structural  changes  to  the  bacterial 
membrane  leading  to  pore  formation  as  one  of the  a  major  mechanisms  involved 
(Jenssen  et al.,  2006).  We were able to  demonstrate  structural  changes  in  C. jejuni 
bacterial  cell  membrane  following  incubation with recombinant hBD-3  (Figure  4.9). 
Using SEM we observed thinning out of membranes with evidence of pore formation 
and  leakage  of intracellular  contents,  suggesting  that the  bacterial  membrane  might 
indeed  be  a  prime  target  for  hBD-3  (Figure  4.9).  More  recently,  several  other 
mechanisms for defensin mediated bactericidal activity have been suggested including 
interference with mRNA, DNA or protein synthesis as well as induction of proteolytic 
enzymes (Sahl et al.,  2005;  Jenssen et al.,  2006).  It is more than likely that one or 
several  of these  mechanisms  are  also  operative  and  either  enhance  or  compliment 
killing of C. jejuni leading to the observed high potency of these peptides against the 
bacterium.  In light of the increasing resistance of C. jejuni to commercial antibiotics 
used  as  first  line  treatment  for  human  infections  (i.e.  Fluroquinolones,  Macrolides) 
(Padungton  and  Kaneene,  2003;  Andersen  et al.,  2006),  defensins  may  represent  a 
promising candidate for future therapeutic intervention.
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Since its recent discovery, C. jejuni CPS has been investigated intensively and evidence 
is accumulating that this structure might play a major role in disease pathogenesis in 
several ways including mediating bacterial adhesion and invasion (Bacon et al., 2001), 
serum resistance and last but not least by undergoing phase variation (Karlyshev et al., 
2005b). The latter mechanisms, causing constant variation/change of surface structures 
might allow C. jejuni to avoid recognition and evade host defence.  Using a capsule 
deficient  isogenic  mutant  strain  of  C.  jejuni  11168H,  kpsM,  we  investigated  the 
potential role of CPS  in modulating  intestinal  innate  host defence.  Interestingly,  we 
were unable to detect any significant differences in innate host defence gene expression 
including hBD-1, -2, -3 and IL-8 (Figure 3.3) and transcriptional regulation (Figure 3.4) 
between mutant and parental WT strain, suggesting that the presence of this structure 
does not seem to be required for the host to recognize the presence of C. jejuni and 
mount innate immune defence. However, despite its limited role in host cell recognition, 
we hypothesized that the  capsule might provide  protection  for  C. jejuni  against the 
bactericidal activity of defensins as this has been shown to be the case for other Gram- 
negative bacteria (Campos et al., 2004). In order to address this question, we performed 
bactericidal assays, comparing susceptibility of kpsM and parental WT strain towards 
hBDs.  Surprisingly, we did not observe a significant difference in killing activity for 
either hBD-2 or hBD-3  suggesting that CPS  does not protect C. jejuni against these 
peptides (Figure 4.7). However, a statistically not significant but yet reproducible trend 
of kpsM mutant to be more susceptible to hBD-1 and lysozyme was noted (Figure 4.7). 
If  true  then  this  data  suggests  that  the  capsule  provides  added  resistance  of 
constitutively expressed AMPs, a property that may assist the bacterium in overcoming 
the initial line of host defence and hence allow adhesion and invasion to occur in-vivo 
(Figure 4.7).
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Prior to the induction of host innate defence in response to microbes, it is essential for 
the host to sense the presence of a potential pathogen. An ancient, universal strategy 
host microbial  sensing  is  the  interaction  of PAMPs  with  corresponding  host  PRRs 
(Akira, 2006; Franchi et al., 2006). In the GI tract the constant exposure to the diverse 
commensal flora causes selective pathogen recognition to be of paramount importance. 
In  order  to  tolerate  the  presence  of commensal  bacteria  while  ensuring  protection 
against pathogens the GI epithelium as the frontline of defence has developed several 
mechanisms.  Expression of luminal surface PRRs is reduced (i.e.  TLR4) (Cario and 
Podolsky, 2000; Abreu et al, 2001) and/or mainly restricted to the basoloateral surface 
(i.e. TLR5) (Gewirtz et al, 2001a). Additionally, signaling of TLRs is tightly regulated 
for  example  via  co-expression  of the  TLR-signaling  suppressor  Tollip  maintaining 
relative  hyporesponsiveness  to  luminal  bacteria  and  their  products  (Melmed  et  al., 
2003).
Recent  studies  investigating  host  sensing  of C.  jejuni  via  TLR5  demonstrated  that 
unlike Salmonella which engages host TLR5 (Gewirtz et al., 2001a), C. jejuni flagellin 
was found to have weak immune-stimulatory properties towards IEC TLR5 (Andersen- 
Nissen  et al.,  2005;  Watson  and  Galan,  2005;  Johanesen  and  Dwinell,  2006).  The 
information that bacterial invasion is crucial for IEC immunity, coupled with minimal 
involvement of TLR5 led us to hypothesize that the intracellularly located NOD family 
could be likely PRR(s) for C. jejuni.
Firstly, we confirmed the association between the intracellular presence of C. jejuni (or 
at least C. jejuni components) and induction of innate host defence by  showing that 
infection  of  Caco-2  cells  with  PFA-fixed  bacteria  led  to  a  significantly  reduced 
induction of IL-8 and hBD-2 (Figure 5.1). Immuno-staining of C. jejuni in Caco-2 co­
cultures was performed to  demonstrate that inactivated bacteria were  indeed located 
mainly  on  the  extracellular  surface,  while  a  significant  proportion  of live  bacteria
180CHAPTER 7
invaded the host cell within the 5h infection period (Figure 5.3). These findings further 
supported  our  hypothesis  that  bacterial  sensing  might  take  place  intracellularly.  In 
recent years, NOD-like  receptors  have  emerged  as  family  of cytoplasmic receptors, 
responsible  for  the  sensing  PGN  of  Gram-positive  and  Gram-negative  bacteria 
ultimately leading to activation of NF-kB and transcription of several innate defence 
genes including IL-8  and hBD-2 (Inohara et al,  2002;  Philpott and  Girardin,  2004; 
Franchi et al, 2006; Fritz et al, 2006; Strober et al, 2006). Two members of the NOD 
receptor  family  found  to  be  expressed  in  the  GI  tract  are  NODI  and  NOD2.  We 
investigated  expression  of both  receptors  in  our  cell  line  model  during  C.  jejuni 
infection. NODI  was found to be expressed constitutively both in Caco-2 and HT-29 
cells, with no further modulation of mRNA levels occurring over a 24h infection period 
with WT C. jejuni strain 11168H and 81-176 (Figure 5.4). In contrast, we were unable 
to detect expression of NOD2 in unstimulated IEC and mRNA levels remained absent 
during C. jejuni infection regardless of WT strain tested or cell line utilized (Figure 5.4 
and 5.5). In the same experiments, we confirmed appropriate infectivity by following 
expression  of  hBD-2,  a  peptide  whose  induction  has  been  shown  to  depend  on 
activation of NODI (Boughan et al, 2006). Induction of hBD2 in the absence of NOD2 
further highlighted NODI as a potential intracellular sensor for C. jejuni (Figure 5.4 and 
5.5).  Si RNA, specifically targeting NODI  (siNODl) allowed us to reduce expression 
of this  receptor  in  our  model  cell  line  system  and  we  were  able  to  demonstrate  a 
significant decrease in C. jejuni mediated IL-8 and hBD-2 expression in siRNA treated 
cells (Figure 5.6). Significant reduction was confirmed with two C. jejuni WT strains on 
IL-8 and hBD-2 (Figure 5.6), transcriptional activity (Figure 5.7 and 5.9) and also the 
IL-8 protein level (Figure 5.8) unequivocally highlighting IEC NODI  as a major PRR 
for mediating host innate defence against C. jejuni. However, although marked knock­
down of the NODI  gene was observed (Figure 5.6) its corresponding inhibitory effect
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on IL-8 and hBD2 gene and promoter function (Figure 5.6, 5.7 and 5.9) ranged between 
40 and 60%, suggesting NODI-independent signaling events are also involved in IEC 
innate immune gene regulation. Several studies have implicated MAP kinase pathways 
in  C. yeyww-mediated IL-8  production (MacCallum et al,  2005;  Watson and  Galan,
2005)  and it is most likely that they are also operative in our model system.
Despite undetectable levels of NOD2 in Caco-2 cells, expression can be induced under 
inflammatory conditions in-vivo, which led us to investigate the potential role for this 
PRR in epithelial sensing of C. jejuni. Interestingly, NOD2 did not enhance C. jejuni 
mediated IL-8 or hBD-2 (Figure 5.10 and 5.11).  Importantly, functionality of NOD2 
was confirmed by using S. pneumoniae, known to activate the receptor, suggesting that 
NOD2 plays a minor role in sensing C. jejuni in IEC (Figure 5.11). However, this might 
not be the case in other innate immune cells such as DCs, which express NOD2 and 
differ in their ability to uptake C. jejuni (Ogura et al., 2001).  Unlike IECs, DCs are 
phagocytic in nature and therefore may lead to differential immune responses.
Taken together,  we  demonstrated NODI  and not NOD2  involvement in sensing the 
intracellular presence of C. jejuni leading to the induction of IL-8 and hBD-2. Reduced 
expression of NODI  should lead to an impaired antimicrobial host response (including 
reduced hBD-2)  allowing  for increased bacterial adhesion  and  invasion to  occur.  In 
order to investigate this hypothesis we performed invasion assays on cells transfected 
with either siNODl, siNEG, NOD2 overexpression plasmid and untreated control cells. 
Following 20h incubation time, allowing for bacterial invasion and activation of innate 
defence including secretion of hBD-2 to occur, the number of live intracellular C. jejuni 
81-176 organisms was evaluated using a gentamicin protection assay. Bacterial invasion 
was observed in untreated control Caco-2 cells and numbers obtained were similar to 
those  from  cells  treated  with  negative  control  siRNA  (siNEG)  as  well  as  NOD2 
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intracellular C. jejuni in cells treated with either of the siRNA sequences specific for 
NODI  (Figure 5.12) suggesting that NODI-mediated cellular events do  contribute to 
the  number  of intracellular  bacteria.  Whether  this  is  due  to  increased  invasion  or 
survival or due to decrease in bacterial transcytosis remains a question for future work 
(McKay et al, 2007).
There are major limitations to the use of cell lines as in-vitro models, which include the 
absence of several cell types (e.g. Paneth cells, goblet cells) and structural organization 
(villi and crypts) of the GI mucosa in-vivo. Further, C. jejuni is a commensal in most 
wild and domestic animals; hence studies of disease pathogenesis in animal models to 
date have been limited. In order to establish an improved model of C. jejuni infection 
addressing some of these limitations, we used intestinal forceps biopsies to study host- 
C. jejuni  interactions.  Following optimization  allowing  the  in-vitro  culture  of tissue 
samples of small and large bowel for up to  12h, co-culture experiments with WT  C. 
jejuni were preformed and samples examined for the presence of the bacterium at the 
epithelial  surface.  The  major  differences  to  cell  lines  became  immediately  evident, 
when most C. jejuni were found to be trapped within the thick mucus layer covering the 
IEC (Figure 6.3). To date only few studies have reported on the interaction of C. jejuni 
with human intestinal biopsies in an ex-vivo model. Similar to our findings, a study by 
Grant and colleagues also  demonstrated the association of C. jejuni in large clusters 
within the mucus overlaying the epithelium of duodenal tissue  samples (Grant et al,
2006). Although the majority of bacteria were found in the mucus layer of the small 
bowel, it was particularly in those areas where we observed close contact of C. jejuni 
with the  intestinal  epithelium possibly  representing  true  adhesion  (Figure  6.3).  It  is 
tempting to speculate that C. jejuni might use the potentially protected environment of 
the  mucus  to  multiply  prior  to  attacking  the  epithelium  layer.  The  suggested 
chemotactic  properties  of  mucus  towards  C.  jejuni  lend  further  support  for  this
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hypothesis (Hendrixson et al, 2001). In comparison to findings in the small bowel (i.e. 
terminal ileum), we were unable to detect close bacterial contact to the epithelium layer 
in the colon, the reason for which remains unknown. One possible explanation might be 
that culture conditions were suboptimal for C. jejuni and in favour for the eukaryotic 
cell.  With C. jejuni requiring microaerophilic  conditions  for ideal  growth, relatively 
high oxygen levels might prevent the bacterium from exhibiting its full virulence and 
hence mask important events occurring in-vivo.  In order to address this problem and 
further  optimize  existing  in-vitro  models,  we  utilised  a  vertical  diffusion  chamber 
system attempting to provide ideal growth conditions for both  C. jejuni and Caco-2 
cells.  Preliminary results provided promising data,  suggesting that  C. jejuni exhibits 
greater  virulence  when  exposed  to  microaerophilic  conditions  (Figure  6.7a  and  b). 
However, further experiments are needed to confirm and extend these data.
In future work, we aim to combine both models by placing intestinal biopsies in the 
vertical diffusion chamber system, creating a close to in-vivo setting. This would open 
exciting opportunities to study C. jejuni disease pathogenesis in health and disease. For 
example,  access to  tissue from children  suffering  from  chronic  inflammatory bowel 
diseases (i.e.  Crohn’s Disease and Ulcerative Colitis), known to have defects in their 
innate  defence  set up  (i.e.  impaired defensins  expression,  NOD  mutations)  will  add 
further to the strength of this novel system.
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In conclusion, this study highlights the important role of intestinal epithelial innate host 
defence in C. jejuni disease pathogenesis. We identified hBD-2 and hBD-3  as AMPs 
that are not only induced during C. jejuni infection but also exhibit a highly potent and 
fast acting bactericidal activity against the bacterium. They are therefore likely to play a 
major role  in  disease  pathogenesis possibly  via  enhanced bacterial  clearance  in the 
healthy  host.  Furthermore,  with the increase  of antibiotic  resistant  C. jejuni  strains, 
hBDs represent promising candidates for developing novel treatment strategies in the 
future. With the identification of IEC NODI as the first PRR involved in the sensing of
C.  jejuni and mediating host bactericidal response, several new questions arise that can 
now  be  investigated,  such  as  the  role  of  bacterial  invasion  and  or  intracellular 
processing of C. jejuni PGN leading to activation of NODI.
However, despite the discovery of these important host defence mechanisms C. jejuni 
causes disease in otherwise healthy individuals. It is therefore likely that the bacterium 
has evolved several mechanisms allowing evasion of initial host recognition leading to 
the observed spectrum of disease. Likely mechanisms to be involved include the N- and 
O-linked glycosylation system, phase variability of surface structures such as CPS and 
LOS as well as changes in the flagellin locus avoiding stimulation of TLR5. Further 
studies are needed to explore both bacterial and host mechanisms in order to complete 
our understanding of C. jejuni disease pathogenesis. The development of novel ex-vivo 
systems to study C. jejuni disease pathogenesis has therefore great potential to provide 
us with previously unavailable opportunities to unravel some of the secrets behind this 
major human pathogen.
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